This invention relates to new compounds, in particular ethyne derivatives, to processes for preparing such compounds, to their use as inhibitors of acetyl-CoA carboxylases, to methods for their therapeutic use, in particular in diseases and conditions mediated by the inhibition of acetyl-CoA carboxylase enzyme(s), and to pharmaceutical compositions comprising them.

Background of the invention

Obesity is a major public health issue not only for the EU, USA, Japan but also for the world in general. It is associated with a number of serious diseases including diabetes, dyslipidemia, hypertension, cardiovascular and cerebrovascular diseases. Although the underlying mechanisms are not yet fully understood, the impairement of insulin action in target tissues by accumulation of excess lipids is generally regarded as a key mechanism linking obesity to secondary pathologies (G. Wolf, Nutrition Reviews Vol. 66(10):597-600; DB Savage, KF Petersen, Gl Shulman, Physiol Rev. 2007;87:507-520). Therefore, understanding of cellular lipid metabolism in insulin target tissues is crucial in order to elucidate the development of diseases associated with obesity.

A central event in lipid metabolism is the generation of malonyl-CoA via carboxylation of acetyl-CoA by the two mammalian ACC isoforms ACC1 (ACC-alpha, also termed ACCA) and ACC2 (ACC-beta, also designated ACCB) (D Saggerson, Annu Rev Nutr. 2008;28:253-72). The malonyl-CoA generated is used for de novo fatty acid synthesis and acts as inhibitor of CPT-1 , thereby regulating mitochondrial fatty acid oxidation. Furthermore, malonyl-CoA is also described to act centrally to control food intake, and may play an important role in controlling insulin secretion from the pancreas (GD Lopaschuk, JR Ussher, JS Jaswal. Pharmacol Rev. 2010;62(2):237- 64; D Saggerson Annu Rev Nutr. 2008;28:253-72), further coordinating the regulation of intermediary metabolism.

Therefore ACC1 and ACC2 have been shown to be major regulators of fatty acid metabolism and are presently considered as an attractive target to regulate the human diseases of obesity, diabetes and cardiovascular complications (SJ Wakil and LA Abu-Elheiga, J. Lipid Res. 2009. 50: S1 38-S143; L. Tong, HJ Harwood Jr. Journal of Cellular Biochemistry 99: 1476-1488, 2006).

As a result of its unique position in intermediary metabolism, inhibition of ACC offers the ability to inhibit de novo fatty acid production in lipogenic tissues (liver and adipose) while at the same time stimulating fatty acid oxidation in oxidative tissues (liver, heart, and skeletal muscle) and therefore offers an attractive modality for favorably affecting, in a concerted manner, a multitude of cardiovascular risk factors associated with obesity, diabetes, insulin resistance, nonalcoholic steatohepatitis (NASH) and the metabolic syndrome (L. Tong, HJ Harwood Jr., Journal of Cellular Biochemistry 99: 1476-1488, 2006; JW Corbett, J H J r. Harwood, Recent Pat Cardiovasc Drug Discov. 2007 Nov;2(3): 162-80).

Furthermore recent data show that cellular toxicity mediated by lipids (lipotoxicity) is implicated in the susceptibitlity to diabetes associated nephropathy (for review see M Murea, Bl Freedmann, JS Parks, PA Antinozzi, SC Elbein, LM Ma; Clin J Am Soc Nephrol. 2010; 5:2373-9). A large-scale genome-wide association study in japanese patients identified single nucleotide polymorphism in the ACC2 gene (ACACB) associated with diabetic nephropathy risk which was replicated in nine independent cohorts. In the kidney, dysregulation of fatty acid metabolism leading to increased fatty acid levels is believed to lead to glomerular and tubular dysfunction (M Murea, Bl Freedmann, JS Parks, PA Antinozzi, SC Elbein, LM Ma; Clin J Am Soc Nephrol. 2010; 5:2373-9). Therefore inhibitors targeting ACC as key molecule involved in lipid oxidation have the potential to be beneficial for favorably affecting diabetic nephropathy.

Additionally, insulin resistance, deregulated lipid metabolism, lipotoxicity and increased intramuscular lipids have also been described to play a role in type 1 diabetes (IE Schauer, JK Snell-Bergeon, BC Bergman, DM Maahs, A Kretowski, RH Eckel, M Rewers Diabetes 201 1 ;60:306-14; P Ebeling, B Essen-Gustavsson, JA Tuominen and VA Koivisto Diabetologia 41 : 1 1 1 -1 15; KJ Nadeau, JG Regensteiner, TA Bauer, MS Brown, JL Dorosz, A Hull, P Zeitler, B Draznin, JEB. Reusch J Clin Endocrinol Metab, 2010, 95:513-521 ). Therefore ACC inhibitors are also considered as interesting drugs for the treatment of type 1 diabetes.

In addition ACC inhibitors also have the potential to intervene in the progression of diseases that result from the rapid growth of malignant cells or invading organisms that are dependent on endogenous lipid synthesis to sustain their rapid proliferation. De novo lipogenesis is known to be required for growth of many tumor cells and ACC up-regulation has been recognized in multiple human cancers, promoting lipogenesis to meet the need of cancer cells for rapid growth and proliferation (C Wang, S Rajput, K Watabe, DF Liao, D Cao Front Biosci 2010; 2:515-26). This is further demonstrated in studies using ACC inhibitors which induced growth arrest and selective cytotoxicity in cancer cells and by RNA interference-mediated knock-down of ACC which inh ibited growth and induced apoptosis in different types of cancer cel ls. Furthermore, ACC1 associates with and is regulated by the breast cancer susceptibility gene 1 (BRCA1 ). Commonly occurring BRCA1 mutations lead to ACC1 activation and breast cancer susceptibility (C Wang, S Rajput, K Watabe, DF Liao, D Cao Front Biosci 2010; 2:515-26)

Furthermore in central nervous system disorders including but not lim ited to Alzheimer's disease, Parkinson disease and epilepsy, impairements in neuronal energy metabolism have been described (Ogawa M , Fukuyama H , Ouchi Y, Yamauchi H, Kimura J, J Neurol Sci. 1996; 139(1 ):78-82). Interventions targeting this metabolic defect may prove beneficial to the patients. One promising intervention is therefore to provide the glucose-compromised neuronscerebral brain neurons with ketone bodies as an alternative substrate (ST Henderson Neurotherapeutics, 2008, 5:470-480; LC Costantini, LJ Barr, JL Vogel, ST Henderson BMC Neurosci. 2008, 9 Suppl 2:S16; KW Baranano, AL Hartman. Curr Treat Options Neurol. 2008; 10:410- 9). ACC inhibition leading to increased fatty acid oxidation may thereby result in increases in the blood levels of ketone bodies thereby providing an alternative energy substrate for the brain.

Preclinical and clinical evidence indicates that ketone bodies can provide

neuroprotective effects in models of Parkinson's disease, AD, hypoxia, ischemia, amyotrophic lateral sclerosis and glioma (LC Costantini, LJ Barr, JL Vogel, ST

Henderson BMC Neurosci. 2008, 9 Suppl 2:S16) and improved cognitive scores in Alzheimers Diseases patients (MA Reger, ST Henderson, C Hale, B Cholerton, LD Baker, GS Watson, K Hydea, D Chapmana, S Craft Neurobiology of Aging 25 (2004) 31 1-314). The end result of increased ketone levels is an improvement in

mitochondrial efficiency and reduction in the generation of reactive oxygen species (for reviews see LC Costantini, LJ Barr, JL Vogel, ST Henderson BMC Neurosci. 2008, 9 Suppl 2:S16; KW Baranano, AL Hartman. Curr Treat Options Neurol.

2008; 10:410-9). Furthermore, the potential of ACC inhibitors as antifungal agents and as antibacterial agents is well documented (L. Tong, HJ Harwood Jr. Journal of Cellular Biochemistry 99: 1476-1488, 2006). In addition, ACC inhibitors can be used to combat viral infections. It was discovered recently that viruses rely on the metabolic network of their cellular hosts to provide energy and building blocks for viral replication (Munger J, BD Bennett, A Parikh, XJ Feng, J McArdle, HA Rabitz, T Shenk, JD Rabinowitz. Nat Biotechnol. 2008;26: 1 179-86). A flux measurement approach to quantify changes in metabolic activity induced by human cytomegalovirus (HCMV) elucidated that infection with HCMV markedly changed fluxes through much of the central carbon metabolism, including glycolysis, tricarboxylic acid cycle and fatty acid biosynthesis. Pharmacological inhibition of fatty acid biosynthesis suppressed the replication of two divergent enveloped viruses (HCMV and influenza A) indicating that fatty acid synthesis is essential for the replication. These examples show that acetyl- CoA fluxes and de novo fatty acid biosynthesis are critical to viral survival and propagation as the newly synthesized fatty acids and phospholipids are important for formation of viral envelopes. Changing the metabolic flux influences the absolute quantity of phospholipid available, the chemical composition and physical properties of the envelope negatively affect viral growth and replication. Hence, ACC inhibitors acting on key enzymes in the fatty acid metabolism, have the potential to be antiviral drugs.

Aim of the present invention

The aim of the present invention is to provide new compounds, in particular new ethyne derivatives, which are active with regard to acetyl-CoA carboxylase

enzyme(s).

Another aim of the present invention is to provide new compounds, in particular new ethyne derivatives, which are active with regard to ACC2.

A further aim of the present invention is to provide new compounds, in particular new ethyne derivatives, which have an inhibitory effect on the enzyme acetyl-CoA carboxylase enzyme(s) in vitro and/or in vivo and possess suitable pharmacological and pharmacokinetic properties to use them as medicaments. A further aim of the present invention is to provide new compounds, in particular new ethyne derivatives, which have an inhibitory effect on the enzyme ACC2 in vitro and/or in vivo and possess suitable pharmacological and pharmacokinetic properties to use them as medicaments.

A further aim of the present invention is to provide effective ACC inhibitors, in particular for the treatment of metabolic disorders, for example of obesity and/or diabetes.

A further aim of the present invention is to provide methods for treating a disease or condition mediated by the inhibition of acetyl-CoA carboxylase enzyme(s) in a patient.

A further aim of the present invention is to provide a pharmaceutical composition comprising at least one compound according to the invention.

A further aim of the present invention is to provide a combination of at least one compound according to the invention with one or more additional therapeutic agents.

A further aim of the present invention is to provide methods for the synthesis of the new compounds, in particular ethyne derivatives.

A further aim of the present invention is to provide starting and/or intermediate compounds suitable in methods for the synthesis of the new compounds.

Further aims of the present invention become apparent to the one skilled in the art by the description hereinbefore and in the following and by the examples.

Object of the Invention

Within the scope of the present invention it has now surprisingly been found that the new compounds of general formula (I) as described hereinafter exhibit an inhibiting activity with regard to enzyme(s) of acetyl-CoA carboxylases. According to another aspect of the present invention it has been found that the new compounds of general formula (I) as described hereinafter exhibit an inhibiting activity with regard to ACC2.

Therefore, in a first aspect the present invention provides a compound of general formula (I)

wherein

Ar ¹ is selected from the group Ar ¹ -G1 consisting of aryl and heteroaryl all of

which may be optionally substituted with one or more substituents R ^A , wherein two substituents R ^A linked to adjacent C-atoms of Ar ¹ may be connected with each other and together form a C3-5-alkylene bridging group in which 1 , 2 or 3 -CH ₂ -groups may be replaced by 0, C(=0), S, S(=0), S(=0)2, NH or N(Ci- ₄ -alkyl)-, wherein the alkylene bridge may optionally be substituted by one or two d-3-alkyl groups; and

R ^A is selected from the group R ^A -G1 consisting of H, F, CI, Br, I, CN, OH, -NO ₂ , C-i-6-alkyl, C _2- 6-alkenyl, C _2- 6-alkynyl, C3-io-carbocyclyl, C3-io-carbocyclyl-Ci-3- alkyl, C-i-6-alkyl-O-, C3-6-alkenyl-O-, C3-6-alkynyl-O-, C3-io-carbocyclyl-O-, C3- io-carbocyclyl-Ci _-3 -alkyl-O-, Ci _-6 -alkyl-S-, Ci _-6 -alkyl-S(=O)-, Ci _-6 -alkyl-S(=O) ₂ -, C3-io-carbocyclyl-S-, C3-io-carbocyclyl-Ci-3-alkyl-S-, C3-10- carbocyclyl-C(=O)-, R ^N1 R ^N2 N-, R ^N1 R ^N2 N-C ₂ - ₃ -alkyl-O-, R ^N1 R ^N2 N-C(=O)-, Ci _-6 -alkyl- HO-C(=O)-, Ci _-6 -alkyl-O-C(=O)-, heterocyclyl, heterocyclyl-O-, heterocyclyl-C-i-3-alkyl, heterocyclyl-Ci-3-alkyl-O-,

heterocyclyl-C(=O)-, aryl, aryl-Ci-3-alkyl, aryl-O-, aryl-Ci-3-alkyl-O-, heteroaryl, heteroaryl-Ci-3-alkyl, heteroaryl-O- and heteroaryl-C-i-3-alkyl-O-, wherein in each carbocyclyl and heterocyclyl a -CH ₂ -group may optionally be replaced by -C(=0)- or -C(=CR ^Alk ₂ )-, and wherein each carbocyclyl and heterocyclyl may be optionally substituted with one or more Ci- ₄ -alkyl, which may be optionally substituted with one or more substituents R ^c , and wherein each alkyl, carbocyclyl and heterocyclyl may be optionally

substituted with one or more substituents R ^c , and wherein each heterocyclyl may be optionally substituted with aryl or heteroaryl, and wherein each aryl and heteroaryl group may be optionally substituted with one or more substituents L,

R ^c is selected from the group R ^c -G1 consisting of F, CI, Br, CN, OH, Ci- -alkyl- O-, C ₃ -7-cycloalkyl-O-, C ₃ -7-cycloalkyl-Ci _-3 -alkyl-O-, H ₂ N-, (Ci- -alkyl)NH-, (Ci_ 4-alkyl) ₂ N-, HO-C(=O)- and Ci- -alkyl-O- C(=O)-, wherein each alkyl or cycloalkyl may be optionally substituted with one or more substituents selected from F and OH; and

R ^N1 is selected from the group R ^N1 -G1 consisting of H, d-6-alkyl, C3-10- carbocyclyl, C3-io-carbocyclyl-Ci-3-alkyl, C3-6-alkenyl, C3-6-alkynyl,

heterocyclyl, heterocyclyl-C-i-3-alkyl, aryl, aryl-C-i-3-alkyl, heteroaryl and heteroaryl-C-i-3-alkyl,

wherein each carbocyclyl and heterocyclyl may be optionally substituted with one or more Ci _-4 -alkyl, and wherein in each carbocyclyl and heterocyclyl a -CH ₂ -group may optionally be replaced by -C(=O)-, and wherein each alkyl, carbocyclyl and heterocyclyl may be optionally

substituted with one or more substituents R ^c , and wherein each aryl and heteroaryl group may be optionally substituted with one or more substituents L, is selected from the group R ^N2 -G1 consisting of H and d-6-alkyl; and is selected from the group R ^Alk -G1 consisting of H and C-i-6-alkyl which may be substituted with one or more F atoms; and is selected from the group Ar ² -G1 consisting of phenyl and a 5- or 6- membered monocyclic aromatic carbocyclic ring system containing 1 , 2 or 3 heteroatoms selected from N, 0, or S, wherein all of the before mentioned groups may be optionally substituted with one or more substituents L; and is selected from the group L-G1 consisting of F, CI, Br, CN, OH, Ci _-4 -alkyl-, Ci-4-alkyl-O-, Ci _-4 -alkyl-S-, H ₂ N- (Ci- -alkyl)NH-, (Ci- - alkyl) ₂ N- and heterocyclyl, wherein each alkyl may be optionally substituted with one or more F-atoms and/ or with a substituent selected from OH, C1-3- alkyl-O- and CN; and wherein two substituents L attached to an aryl or heteroaryl group may be linked to each other and form a C2-5-alkylene bridging group in which 1 or 2 -CH ₂ -groups may be replaced by a group independently of each other selected from O, S, NH and N(Ci _-4 -alkyl)-, wherein the C2-5-alkylene bridging group is optionally be substituted by 1 or 2 C-i-3-alkyl groups; and is selected from the group X-G1 consisting of a straight chain C-i-3-alkylene group which may be optionally substituted with one or more groups selected from C-i-3-alkyl and Ci-3-alkyl-O-Ci-3-alkyl, and wherein two alkyl substituents may be connected with each other and together form a C-i-5-alkylene bridging group in which 1 or 2 -CH ₂ -groups may be replaced by a group

independently of each other selected from O, S, NH or N(Ci _-4 -alkyl)-, wherein the C-i-5-alkylene bridging group may be optionally substituted by 1 or 2 C1-3- alkyl groups; and is selected from the group Y-G1 consisting of -C(=O)- and -S(=O)2-; R is selected from the group R -G1 consisting of H and d-3-alkyl;

T is selected from the group T-G1 consisting of C-i-6-alkyl, C ₂ -6-alkenyl, C ₂ -6- alkynyl, C3-io-carbocyclyl, C3-io-carbocyclyl-Ci-3-alkyl, Ci-6-alkyl-O-, C3-10- carbocyclyl-O-, C3-io-carbocyclyl-Ci-3-alkyl-0-, C-i-6-alkyl-S-, C3-io-carbocyclyl- S-, C ₃ -io-carbocyclyl-Ci.3-alkyl-S-,

1 RN2_ _N _ _R I _R N2_ _N _ _{C I 3} _ _A | _KY |_

alkyl, heterocyclyl, aryl and heteroaryl, wherein in each carbocyclyl and heterocyclyl a -CH ₂ -group may optionally be replaced by -C(=0)-, and wherein each carbocyclyl and heterocyclyl may be optionally substituted with one or more Ci _-4 -alkyl, which may be optionally substituted with one or more substituents R ^C , and wherein each alkyl, carbocyclyl and heterocyclyl may be optionally

substituted with one or more substituents R ^C , and wherein each aryl and heteroaryl group may be optionally substituted with one or more substituents L, or the groups T and R ^N may be connected with each other and together form a group which is selected from the group T-R ^N -G1 consisting of C ₂ -5-alkylene which may be optionally substituted with one or more substituents selected from F, CI, Br, OH, CN, Ci _-4 -alkyl, C3-io-carbocyclyl, C3-io-carbocyclyl-Ci-3- alkyl, Ci _-4 -alkyl-O-, C3-7-cycloalkyl-O-, C3-io-carbocyclyl-Ci-3-alkyl-O-, H ₂ N-, (Ci- -alkyl)NH-, (Ci- -alkyl) ₂ N-, HO- C(=O)- and Ci _-4 -alkyl-O-C(=O)-, wherein each alkyl or carbocyclyl may be optionally substituted with one or more substituents selected from R ^C , including any tautomers and stereoisomers thereof, or a salt thereof or a solvate or hydrate thereof.

In a further aspect the present invention relates to processes for preparing a compound of general formula (I) and to new intermediate compounds in these processes.

A further aspect of the invention relates to a salt of the compounds of general formula (I) according to this invention, in particular to a pharmaceutically acceptable salt thereof.

In a further aspect this invention relates to a pharmaceutical composition, comprising one or more compounds of general formula (I) or one or more pharmaceutically acceptable salts thereof according to the invention, optionally together with one or more inert carriers and/or diluents.

In a further aspect this invention relates to a method for treating diseases or conditions which are mediated by inhibiting the activity of acetyl-CoA carboxylase enzyme(s) in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.

According to another aspect of the invention, there is provided a method for treating a metabolic disease or disorder in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.

According to another aspect of the invention, there is provided a method for treating a cardiovascular disease or disorder in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient. According to another aspect of the invention, there is provided a method for treating a neurodegenerative disease or disorder or for treating a disease or disorder of the central nervous system in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.

According to another aspect of the invention, there is provided a method for treating a cancer, a malignant disorder or a neoplasia in a patient in need thereof

characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.

According to another aspect of the invention, there is provided the use of a

compound of the general formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for a therapeutic method as described

hereinbefore and hereinafter.

According to another aspect of the invention, there is provided a compound of the general formula (I) or a pharmaceutically acceptable salt thereof for a therapeutic method as described hereinbefore and hereinafter.

In a further aspect this invention relates to a method for treating a disease or condition mediated by the inhibition of acetyl-CoA carboxylase enzyme(s) in a patient that includes the step of administering to the patient in need of such treatment a therapeutically effective amount of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of one or more additional therapeutic agents.

In a further aspect this invention relates to a use of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof in combination with one or more additional therapeutic agents for the treatment or prevention of diseases or conditions which are mediated by the inhibition of the enzyme(s) acetyl-CoA carboxylase. In a further aspect this invention relates to a pharmaceutical composition which comprises a compound according to general formula (I) or a pharmaceutically acceptable salt thereof and one or more additional therapeutic agents, optionally together with one or more inert carriers and/or diluents.

Other aspects of the invention become apparent to the one skilled in the art from the specification and the experimental part as described hereinbefore and hereinafter.

Detailed Description

Unless otherwise stated, the groups, residues, and substituents, particularly Ar ¹ , Ar ² , X, Y, R ^N , T, R ^A , R ^c , R ^N1 , R ^N2 , R ^Alk , L, T, are defined as above and hereinafter. If residues, substituents, or groups occur several times in a compound, as for example R ^c , R ^N1 , R ^N2 or L, they may have the same or different meanings. Some preferred meanings of individual groups and substituents of the compounds according to the invention will be given hereinafter. Any and each of these definitions may be combined with each other.

Ar ¹ :

Ar -G1 :

The group Ar ¹ is preferably selected from the group Ar ¹ -G1 as defined hereinbefore and hereinafter.

Ar -G2:

In one embodiment the group Ar ¹ is selected from the group Ar ¹ -G2 consisting of phenyl, dihydronaphthyl, tetrahydronaphthyl, naphthyl and a 5- or 6-membered monocyclic or 9- or 10-membered bicyclic-ring system containing 1 , 2, 3 or 4 heteroatoms selected from N, O, S, or S(O) _r with r = 1 or 2 wherein at least one of the heteroatoms is part of an aromatic ring, and wherein all of the before mentioned groups may be optionally substituted with one or more substituents R ^A , particularly wherein all of the before mentioned groups may be optionally substituted with a substituent R ^A and optionally one or more substituents L, and wherein two

substituents R ^A linked to adjacent C-atoms of Ar ¹ may be connected with each other and together form a C3-5-alkylene bridging group in which 1 , 2 or 3 CH ₂ -groups may be replaced by O, C(=O), S, S(=O), S(=O) ₂ , NH or N(Ci _-4 -alkyl)-, wherein the alkylene bridging group may optionally be substituted by one or two d-3-alkyl groups. Ar -G3:

In another embodiment the group Ar ¹ is selected from the group Ar ¹ -G3 consisting of phenyl, naphthyl, pyridyl, 2H-pyridin-2-onyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, pyrazolyl, thiazolyl, quinolinyl, isoquinolinyl, indolyl, benzofuranyl, benzoimidazolyl, benzooxazolyl, benzotriazolyl, 2,3-dihydrobenzofuranyl, benzo[1 ,3]dioxolyl, 2,3-dihydro- benzo[1 ,4]dioxinyl and 3,4-dihydro-2H-benzo[b][1 ,4]dioxepinyl wherein the before mentioned bicyclic groups preferably are linked to the -C≡C- group of the core structure of the formula (I) via an aromatic or heteroaromatic ring of the bicyclic group, and wherein all of the before mentioned mono- and bicyclic groups may be optionally substituted with one or more substituents R ^A , particularly wherein all of the before mentioned mono- or bicyclic groups may be optionally substituted with a substituent R ^A and optionally one or more substituents L.

Ar -G4:

In another embodiment the group Ar ¹ is selected from the group Ar ¹ -G4 consisting of phenyl, naphthyl, pyridyl, 2H-pyridin-2-onyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, thiazolyl, quinolinyl, indolyl, benzofuranyl, 2,3- dihydrobenzofuranyl, benzo[1 ,3]dioxolyl, 2,3-dihydro-benzo[1 ,4]dioxinyl and 3,4- dihydro-2H-benzo[b][1 ,4]dioxepinyl, wherein the before mentioned bicyclic groups preferably are linked to the -C≡C- group of the core structure of the formula (I) via an aromatic or heteroaromatic ring of the bicyclic group, and wherein all of the before mentioned mono- and bicyclic groups may be optionally substituted with one or more substituents R ^A , particularly wherein all of the before mentioned mono- or bicyclic groups may be optionally substituted with a substituent R ^A and optionally one or more substituents L.

Ar -G5: - 14-

wherein the asterisk to the right side of each cyclic group indicates the bond which is connected to the -C≡C- group of the core structure of the formula (I), and if existing the asterisk to the left side of each cyclic group indicates the bond which is

connected to a substituent R ^A or H, and in addition each of the before mentioned cyclic groups is optionally substituted with one or more further substituents R ^A , in particular one or more substituents L, and the substituent R ^N is defined as

hereinbefore and hereinafter.

Ar -G6:

In another embodiment the roup Ar ¹ is selected from the group Ar ¹ -G6 consisting of: , wherein the asterisk to the right side of the cyclic group indicates the bond which is connected to the -C≡C- group of the core structure of the formula (I), and the asterisk to the left side of the cyclic group indicates the bond which is connected to a substituent R ^A or H, and in addition the before mentioned cyclic group is optionally substituted with one or more further substituents R ^A , in particular one or more substituents L.

Examples of members of the group Ar ¹ -G6 are without being limited to it:

Ar -G7:

In another embodiment the group Ar ¹ is selected from the group Ar ¹ -G7 consisting of 6-membered aromatic rings containing 1 or 2 N-atoms, wherein said rings may be optionally substituted with one or more substituents R ^A , particularly wherein said rings may be optionally substituted with a substituent R ^A and optionally one or more substituents L. Exam les of members of the group Ar ¹ -G7 are:

cyclic group indicates the bond which is connected to the -C≡C- group of the core structure of the formula (I), and the asterisk to the left side of each cyclic group indicates the bond which is connected to a substituent R ^A , and in addition each of the before mentioned cyclic groups is optionally substituted with one or more further substituents R ^A , in particular one or more substituents L.

Preferred examples of members of the group Ar ¹ -G7 are without being limited to it: R ^A -G1 :

The group R ^A is preferably selected from the group R ^A -G1 as defined hereinbefore and hereinafter,

R ^A -G2:

In another embodiment the group R ^A is selected from the group R ^A -G2 consisting of H, F, CI, Br, I, CN, OH, NO ₂ , Ci _-6 -alkyl, C ₃ -io-carbocyclyl, C ₃ -io-carbocyclyl-Ci _-3 -alkyl, Ci-6-alkyl-O-, C3-6-alkenyl-O- C3-6-alkynyl-O-, C3-io-carbocyclyl-O-, C3-io-carbocyclyl- Ci-3-alkyl-O-, Ci-6-alkyl-S-, C3-io-carbocyclyl-S-, C3-io-carbocyclyl-Ci-3-alkyl-S-, C-i _-4 - alkyl-C(=O)-, R ^N1 R ^N2 N-, R ^N1 R ^N2 N-C ₂ - ₃ -alkyl-O- R ^N1 R ^N2 N-C(=O)-, HO-C(=O)-, Ci _-6 - alkyl-O-C(=O)-, heterocyclyl, heterocyclyl-O-, heterocyclyl-Ci-3-alkyl, heterocyclyl-C-i- 3-alkyl-O-, heterocyclyl-C(=O)-, aryl, aryl-Ci-3-alkyl, aryl-O-, aryl-Ci-3-alkyl-O-, heteroaryl, heteroaryl-d-3-alkyl, heteroaryl-O- and heteroaryl-Ci-3-alkyl-O-; wherein heterocyclyl is defined as hereinbefore and hereinafter, or alternatively each heterocyclyl is selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-Ci _-4 -alkyl-piperazin-1 -yl, N-Ci _-4 -alkylsulfonyl-piperazin-1 -yl, morpholinyl, dihydroquinolinyl, dihydroisoquinolinyl, dihydroindolyl, dihydroisoindolyl, oxetan l, tetrahydrofuranyl and tetrahydropyranyl, or from the group consisting of

wherein carbocyclyl is defined as hereinbefore and hereinafter, or each carbocyclyl is preferably selected from C3-7-cycloalkyl, indanyl and tetrahydronaphthyl; and wherein heteroaryl is defined as hereinbefore and hereinafter, or each heteroaryl is preferably selected from the group consisting of pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, thiazolyl, triazolyl, tetrazolyl, benzofuranyl, indolyl, quinolinyl and indazolyl; and wherein in each heterocyclyl and carbocydyl a -CH ₂ -group may optionally be replaced by -C(=0)- or -C(=CR ^Alk ₂ )-; and wherein each carbocydyl and heterocyclyl may be optionally substituted with one or more d-3-alkyl, which may be substituted as defined hereinafter, and wherein each alkyl, carbocydyl and heterocyclyl may be optionally substituted with one or more F atoms; and wherein each alkyl, carbocydyl and heterocyclyl may be optionally substituted with 1 , 2 or 3 substituents R ^c , which are independently of each other selected from the group R ^c -G1 , R ^c -G2 or R ^c -G3 as defined hereinbefore and hereinafter; even more preferably R ^c is selected from CI, Br, CN, OH, Ci _-3 -alkyl-O-, C ₃ - ₆ -cycloalkyl-O-, HO- Ci _-3 -alkyl-O-, H ₂ N-, (Ci _-3 -alkyl)NH- and (Ci _-3 -alkyl) ₂ N-, HO-C(=O)- and Ci- -alkyl-O- C(=O)-; and wherein each R ^N1 is selected from the group R ^N1 -G1 , R ^N1 -G2 or R ^N1 -G3 as defined hereinbefore and hereinafter; and each R ^N2 is selected from the group R ^N2 -G1 or R ^N2 -G2 as defined hereinbefore and hereinafter; and wherein each carbocydyl or heterocyclyl may be optionally substituted with an aryl or heteroaryl group, in particular with phenyl or pyridyl, and wherein each aryl and heteroaryl group may be optionally substituted with one or more substituents L, wherein L is selected from the groups L-G1 , L-G2 or L-G3 as defined hereinbefore and hereinafter.

R ^A -G2a:

In another embodiment the group R ^A is selected from the group R ^A -G2a consisting of C-i-6-alkyl-O-, C3-6-alkenyl-O- C3-6-alkynyl-O-, C3-io-carbocyclyl-O-, C3-io-carbocyclyl- C-i-3-alkyl-O-, C-i-6-alkyl-S-, C3-io-carbocyclyl-S-, C3-io-carbocyclyl-Ci-3-alkyl-S-, heterocyclyl-O- and heterocyclyl-C-i-3-alkyl-O-; wherein heterocyclyl is defined as hereinbefore and hereinafter, or each heterocyclyl is preferably selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-Ci _-4 -alkyl-piperazin-1 -yl, N-Ci _-4 -alkylsulfonyl-piperazin-1 -yl,

morpholinyl, dihydroquinolinyl, dihydroisoquinolinyl, dihydroindolyl, dihydroisoindolyl, oxetan l, tetrahydrofuranyl and tetrahydropyranyl, or from the group consisting of

wherein carbocyclyl is defined as hereinbefore and hereinafter, or each carbocyclyl is preferably selected from C3-7-cycloalkyl, indanyl and tetrahydronaphthyl; and wherein in each heterocyclyl and carbocyclyl a CH ₂ -group may optionally be replaced by -C(=0)- or -C(=CR ^Alk ₂ )-; and wherein each carbocyclyl and heterocyclyl may be optionally substituted with one or more d-3-alkyl, which may be substituted as defined hereinafter; and wherein each alkyl, carbocyclyl and heterocyclyl may be optionally substituted with one or more substituents selected from F; and wherein each alkyl, carbocyclyl and heterocyclyl may be optionally substituted with 1 , 2 or 3 substituents R ^c , which are selected from the group R ^c -G1 , R ^c -G2 or R ^c -G3 as defined hereinbefore and hereinafter; even more preferably R ^c is selected from CI, Br, CN, OH, Ci-3-alkyl-O-, C ₃ - ₆ -cycloalkyl-O-, HO-Ci _-3 -alkyl-O-, H ₂ N-, (Ci _-3 -alkyl)NH- and (Ci _-3 -alkyl) ₂ N-, HO-C(=O)- and

R ^A -G2b:

In another embodiment the group R ^A is selected from the group R ^A -G2b consisting of C-i-6-alkyl, C3-io-carbocyclyl, C3-io-carbocyclyl-Ci-3-alkyl, heterocyclyl, heterocyclyl-C-i- 3-alkyl, aryl, aryl-C-i-3-alkyl, heteroaryl and heteroaryl-C-i-3-alkyl; wherein heterocyclyl is defined as hereinbefore and hereinafter, or each heterocyclyl is preferably selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-Ci _-4 -alkyl-piperazin-1 -yl, N-Ci _-4 -alkylsulfonyl-piperazin-1 -yl,

morpholinyl, dihydroquinolinyl, dihydroisoquinolinyl, dihydroindolyl, dihydroisoindolyl, oxetan l, tetrahydrofuranyl and tetrahydropyranyl, or from the group consisting of

wherein carbocyclyl is defined as hereinbefore and hereinafter, or each carbocyclyl is preferably selected from C3-7-cycloalkyl, indanyl and tetrahydronaphthyl; and wherein heteroaryl is defined as hereinbefore and hereinafter, or each heteroaryl is preferably selected from the group consisting of pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, thiazolyl, triazolyl, tetrazolyl, benzofuranyl, indolyl, quinolinyl and indazolyl; and wherein in each heterocyclyl and carbocyclyl a CH ₂ -group may optionally be replaced by -C(=0)- or -C(=CR ^Alk ₂ )-; and wherein each carbocyclyl and heterocyclyl may be optionally substituted with one or more d-3-alkyl, which may be substituted as defined hereinafter; and wherein each alkyl, carbocyclyl and heterocyclyl may be optionally substituted with one or more substituents selected from F; and wherein each alkyl, carbocyclyl and heterocyclyl may be optionally substituted with 1 , 2 or 3 substituents R ^c , which are selected from the group R ^c -G1 , R ^c -G2 or R ^c -G3 as defined hereinbefore and hereinafter; even more preferably R ^c is selected from CI, Br, CN, OH, Ci-3-alkyl-O-, C ₃ - ₆ -cycloalkyl-O-, HO-Ci _-3 -alkyl-O-, H ₂ N-, (Ci _-3 -alkyl)NH- and (Ci- ₃ -alkyl) ₂ N-, HO-C(=O)- and and wherein each carbocyclyl or heterocyclyl may be optionally substituted with an aryl or heteroaryl group, in particular with phenyl or pyridyl; and wherein each aryl and heteroaryl group may be optionally substituted with one or more substituents L, wherein L is selected from the groups L-G1 , L-G2 or L-G3 as defined hereinbefore and hereinafter.

R ^A -G3:

In another embodiment the group R ^A is selected from the group R ^A -G3 consisting of F, CI, Br, I, CN, NO2, C-i-6-alkyl, C3-io-carbocyclyl-, C3-io-carbocyclyl-Ci-3-alkyl, C-i-6- alkyl-O-, C3-6-alkenyl-0-, C3-6-alkynyl-0-, d-4-alkyl-S-, C3-io-carbocyclyl-0-, C3-10- carbocyclyl-Ci-3-alkyl-O-, R ^N1 R ^N2 N-, R ^N1 R ^N2 N-C ₂ - ₃ -alkyl-0-, R ^N1 heterocyclyl, heterocyclyl-Ci _-3 - alkyl, heterocyclyl-O-, heterocyclyl-Ci-3-alkyl-O-, heterocyclyl-C(=0)-, phenyl, phenyl- 0-, phenyl-C-i-3-alkyl-, phenyl-Ci-3-alkyl-O-, heteroaryl, heteroaryl-Ci-3-alkyl, heteroaryl-O- and heteroaryl-Ci-3-alkyl-O-; wherein each heterocyclyl is selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-Ci _-4 -alkyl-piperazin-1 -yl, N-Ci _-4 -alkylsulfonyl- piperazin-1 -yl, morpholinyl, dihydroisoindolyl, oxetanyl, tetrahydrofuranyl and tetrahydropyranyl, or from the group consisting of

wherein carbocyclyl is defined as hereinbefore and hereinafter, or each carbocyclyl is preferably selected from C3-6-cycloalkyl, indanyl and tetrahydronaphthyl; most preferably carbocyclyl denotes C3-6-cycloalkyl; and wherein in each carbocyclyl, pyrrolidinyl and piperidinyl a CH ₂ -group may optionally be replaced by -C(=0)- or -C(=CR ^Alk ₂ )-; and wherein each heteroaryl is selected from the group consisting of pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, thiazolyl, triazolyl, tetrazolyl, indazolyl, benzofuranyl, indolyl and quinolinyl; and wherein each carbocydyl or heterocyclyl may be optionally substituted with one or more d-3-alkyl, which may be substituted as defined hereinafter; and wherein each alkyl, carbocydyl and heterocyclyl may be optionally substituted with one or more substituents selected from F; and wherein each alkyl, carbocydyl and heterocyclyl may be optionally substituted with one or two substituents R ^c , which are selected from the group R ^c -G1 , R ^c -G2 or R ^c - G3 as defined hereinbefore and hereinafter; even more preferably R ^c is selected from CI, Br, CN, OH, Ci _-3 -alkyl-O-, C ₃ - ₆ -cycloalkyl-O-, HO-Ci _-3 -alkyl-O-, H ₂ N-, (C ₁ -3- alkyl)NH- (Ci _-3 -alkyl) ₂ N-, HO-C(=O)- and and wherein each R ^N1 is selected from the group R ^N1 -G1 , R ^N1 -G2 or R ^N1 -G3; and each R ^N2 is selected from the group R ^N2 -G1 or R ^N2 -G2 as defined hereinbefore and hereinafter; and wherein each carbocydyl and heterocyclyl may be optionally substituted with an aryl or heteroaryl group, in particular with phenyl or pyridyl; and wherein each phenyl and heteroaryl group may be optionally substituted with one or more substituents L, wherein L is selected from the groups L-G1 , L-G2 or L-G3 as defined hereinbefore and hereinafter.

R ^A -G4:

In another embodiment the group R ^A is selected from the group R ^A -G4 consisting of F, CI, Br, I, CN, NO ₂ , C-i-6-alkyl, C _3- io-carbocyclyl-, C ₃ -io-carbocyclyl-Ci _-3 -alkyl, C ₁ -5- alkyl-O-, C _3- 5-alkenyl-O-, C _3- 5-alkynyl-O-, C _3- io-carbocyclyl-O-, C ₃ -io-carbocyclyl-Ci _-3 - alkyl-O-, R ^N1 R ^N2 N-, R ^N1 R ^N2 N-C(=O)-, heterocyclyl, heterocyclyl-Ci _-3 -alkyl,

heterocyclyl-O-, heterocyclyl-Ci _-3 -alkyl-O-, heterocyclyl-C(=O)-, phenyl, phenyl-O- phenyl-Ci-3-alkyl-, phenyl-d-3-alkyl-O-, heteroaryl, heteroaryl-Ci-3-alkyl, heteroaryl-O- and heteroaryl-C-i-3-alkyl-O-; wherein carbocyclyl is defined as hereinbefore and hereinafter, or each carbocyclyl is preferably selected from C3-6-cycloalkyl, indanyl and tetrahydronaphthyl; most preferably carbocyclyl denotes C3-6-cycloalkyl; and wherein each heterocyclyl is selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-Ci- ₄ -alkyl-piperazin-1 -yl, N-Ci _-4 -alkylsulfonyl- piperazin-1 -yl, morpholinyl, dihydroisoindolyl, oxetanyl, tetrahydrofuranyl and tetrah dropyranyl, or from the group consisting of

wherein in each carbocyclyl and heterocyclyl a CH ₂ -group may optionally be replaced by -C(=0)- or -C(=CR ^Alk ₂ )-; and wherein each heteroaryl is selected from the group consisting of pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, thiazolyl, triazolyl, tetrazolyl, indazolyl, benzofuranyl, indolyl, and quinolinyl; and wherein each carbocyclyl and heterocyclyl may be optionally substituted with one or more C-i-3-alkyl, which may be substituted as defined hereinafter; and wherein each alkyl, carbocyclyl and heterocyclyl may be optionally substituted with one or more substituents selected from F; and wherein each alkyl, carbocyclyl and heterocyclyl may be optionally substituted with one or two substituents R ^c , which are selected from the group R ^c -G1 , R ^c -G2 or R ^c - G3 as defined hereinbefore and hereinafter; even more preferably R ^c is selected from CI, Br, CN, OH, Ci _-3 -alkyl-O-, C ₃ - ₆ -cycloalkyl-O-, HO-Ci _-3 -alkyl-O-, H ₂ N-, (Ci _-3 - alkyl)NH- (Ci _-3 -alkyl) ₂ N-, HO-C(=0)- and and wherein each R ^m is selected from the group R -G1 , R -G2 or R -G3; and each R ^N2 is selected from the group R ^N2 -G1 or R ^N2 -G2 as defined hereinbefore and hereinafter; and wherein each carbocydyl and heterocyclyl may be optionally substituted with an aryl or heteroaryl group, in particular with phenyl or pyridyl; and wherein each phenyl and heteroaryl group may be optionally substituted with one or more substituents L, wherein L is selected from the groups L-G1 , L-G2 or L-G3 as defined hereinbefore and hereinafter.

R ^A -G5:

In another embodiment the group R ^A is selected from the group R ^A -G5 consisting of F, CI, Br, I, CN, Ci _-5 -alkyl, C ₃ - ₆ -cycloalkyl, Ci _-5 -alkyl-0-, C ₃ - ₆ -cycloalkyl-0-, C _3-6 - cycloalkyl-Ci- ₃ -alkyl-0-, R ^N1 R ^N2 N-, phenyl, phenyl-O-, phenyl-CH ₂ -O- heteroaryl, heteroaryl-O- and heteroaryl-CH ₂ -0-; and wherein each cycloalkyl may be optionally substituted with one or more Ci _-3 -alkyl, which may be substituted as defined hereinafter; and wherein each alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from F; and wherein in each cycloalkyl group a CH ₂ -group may optionally be replaced by -0-; and wherein each alkyl and cycloalkyl may be optionally substituted with one or two substituents R ^c , wherein R ^c is defined as hereinbefore and hereinafter; preferably R ^c is selected from the group consisting of CI, Br, CN, OH, Ci _-3 -alkyl-O-, C _3- 6-cycloalkyl- O-, HO-Ci _-3 -alkyl-O-, H ₂ N-, (Ci _-3 -alkyl)NH-, (Ci _-3 -alkyl) ₂ N-, HO-C(=O)- and Ci _-3 -alkyl- O-C(=O)-; and wherein each R ^N1 is selected from the group R ^N1 -G1 , R ^N1 -G2 or R ^N1 -G3 as defined hereinbefore and hereinafter; preferably R ^N1 is selected from the group consisting of H, C-i-6-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-CH ₂ - and phenyl-CH ₂ -, wherein each cycloalkyi may be optionally substituted with one or more Ci- ₄ -alkyl, and wherein each alkyl and cycloalkyi may be optionally substituted with one or more substituents selected from F, and wherein each alkyl and cycloalkyi may be optionally substituted with a substituent selected from OH, d-3-alkyl-O- and H ₂ N-; and wherein each R ^N2 is selected from the group R ^N2 -G1 or R ^N2 -G2 as defined

hereinbefore and hereinafter; and wherein heteroaryl is defined as hereinbefore and hereinafter; preferably heteroaryl is selected from the group consisting of pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, thiazolyl, benzofuranyl, indolyl and quinolinyl; and wherein each phenyl and heteroaryl group may be optionally substituted with one or more substituents L, wherein L is selected from the groups L-G1 , L-G2 or L-G3 as defined hereinbefore and hereinafter.

R ^A -G5a:

In another embodiment the group R ^A is selected from the group R ^A -G5a consisting of C-i-5-alkyl-O-, C3-5-alkenyl-O- C3-5-alkynyl-O-, C3-6-cycloalkyl-O- and C3-6-cycloalkyl- Ci-3-alkyl-O-; wherein each cycloalkyi may be optionally substituted with one or more C-i-3-alkyl, which may be substituted as defined hereinafter; and wherein each alkyl and cycloalkyi may be optionally substituted with one or more substituents selected from F; and wherein in each cycloalkyi group a CH ₂ -group may optionally be replaced by -O-; and wherein each alkyl and cycloalkyi may be optionally substituted with one or two substituents R ^c , wherein R ^c is defined as hereinbefore and hereinafter; preferably R ^c is selected from the group consisting of CI, Br, CN, OH, d-3-alkyl-O-, C3-6-cycloalkyl- O-, HO-Ci _-3 -alkyl-O-, H ₂ N- (Ci _-3 -alkyl)NH-, (Ci _-3 -alkyl) ₂ N-, HO-C(=O)- and Ci _-3 -alkyl- O-C(=O)-.

R ^A -G5b:

In another embodiment the group R ^A is selected from the group R ^A -G5b consisting of C-i-5-alkyl, C3-6-cycloalkyl, phenyl and heteroaryl; wherein each cycloalkyl may be optionally substituted with one or more C-i-3-alkyl, which may be substituted as defined hereinafter; and wherein each alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from F; and wherein in each cycloalkyl group a CH ₂ -group may optionally be replaced by -O-; and wherein each alkyl and cycloalkyl may be optionally substituted with one or two substituents R ^c , wherein R ^c is defined as hereinbefore and hereinafter; preferably R ^c is selected from the group consisting of CI, Br, CN, OH, C-i-3-alkyl-O-, C3-6-cycloalkyl- O-, HO-Ci-3-alkyl-O-, H ₂ N-, (Ci _-3 -alkyl)NH-, (Ci _-3 -alkyl) ₂ N-, HO-C(=O)- and Ci _-3 -alkyl- O-C(=O)-; and wherein heteroaryl is defined as hereinbefore and hereinafter; preferably heteroaryl is selected from the group consisting of pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, thiazolyl, benzofuranyl, indolyl and quinolinyl; and wherein each phenyl and heteroaryl group may be optionally substituted with one or more substituents L, wherein L is selected from the groups L-G1 , L-G2 or L-G3 as defined hereinbefore and hereinafter.

In the embodiments with regard to R ^A as described hereinbefore and hereinafter it is to be understood that the double or triple bond in the groups C3 _-n -alkenyl-O- and C3 _-n - alkynyl-O- (with n being an integer) is preferably not conjugated with the O-atom of that group.

R ^A -G6:

In another embodiment the group R ^A is selected from the group R ^A -G6 consisting of F, CI, Br, I, CN, methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, F ₃ C-, HO-CH ₂ CH ₂ -,

-28-

-31 -

-32 -

wherein each alkyl group and each cycloalkyi and heterocydyl ring may be optionally substituted with one or more F atoms; and wherein each phenyl and heteroaryl ring may be optionally substituted with one or more substituents L.

R ^A -G7:

In another preferred embodiment the group R ^A is selected from the group R ^A -G7 consisting of

wherein each alkyl or cycloalkyi group may optionally be substituted with one or more F atoms. e

R ^c -G1 :

The group R ^c is preferably selected from the group R ^c -G1 as defined hereinbefore and hereinafter.

R ^c -G2:

In another embodiment the group R ^c is selected from the group R ^c -G2 consisting of F, CI, Br, CN, OH, Ci _-4 -alkyl-O-, C ₃ - ₆ -cycloalkyl-O-, C ₃ -6-cycloalkyl-CH ₂ -O-, H ₂ N-, (Ci_ 3-alkyl)NH-, (Ci _-3 -alkyl) ₂ N-, Ci _-3 -alkyl-C(=O)-, Ci _-3 -alkyl-S(=O) ₂ -, HO-C(=O)- and Ci- - alkyl-O-C(=O)-, wherein each alkyl or cycloalkyi may be optionally substituted with one or more substituents selected from F and OH.

R ^c -G3:

In another embodiment the group R ^c is selected from the group R ^c -G3 consisting of F, CI, Br, CN, OH, Ci _-3 -alkyl-O-, C _3-6 -cycloalkyl-O-, H ₂ N-, (Ci _-3 -alkyl)NH-, (Ci _-3 - alkyl) ₂ N-, Ci _-3 -alkyl-C(=O)-, Ci _-3 -alkyl-S(=O) ₂ -, HO-C(=O)- and Ci _-3 -alkyl-O-C(=O)-, wherein each alkyl may be optionally substituted with one or more F-atoms and/or may be substituted with OH.

R^

R ^N -G1 :

The group R ^N1 is preferably selected from the group R ^N1 -G1 as defined hereinbefore and hereinafter. In another embodiment the group R is selected from the group R -G2 consisting of H, C-i-6-alkyl, C3-io-carbocyclyl, C3-io-carbocyclyl-Ci-3-alkyl, C3-6-alkynyl, heterocyclyl, heterocyclyl-Ci-3-alkyl, phenyl, phenyl-d-3-alkyl, heteroaryl and heteroaryl-Ci-3-alkyl; wherein carbocyclyl is defined as hereinbefore and hereinafter, or each carbocyclyl is preferably selected from C3-7-cycloalkyl, indanyl and tetrahydrofuranyl; and wherein heterocyclyl is defined as hereinbefore and hereinafter, or each heterocyclyl is preferably selected from tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl; and wherein heteroaryl is defined as hereinbefore and hereinafter, or heteroaryl preferably denotes pyridyl, pyrimidinyl, pyrazolyl and oxazolyl; and wherein each carbocyclyl and heterocyclyl, may be optionally substituted with one or more Ci _-4 -alkyl; and wherein each alkyl, carbocyclyl, heterocyclyl, including piperazinyl and morpholinyl, may be optionally substituted with one or more substituents selected from F; and wherein each alkyl, carbocyclyl, heterocyclyl, including piperazinyl and morpholinyl, may be optionally substituted with a substituent selected from OH, C-i-3-alkyl-O-, H ₂ N- wherein each phenyl and heteroaryl may be optionally substituted with one or more substituents L.

With regard to an alkenyl or alkynyl group, for example R ^N1 , attached to the N-atom of an amino-group it is to be understood that the double or triple bond is preferably not conjugated with the N-atom. R ^N -G3:

In another embodiment the group R ^N1 is selected from the group R ^N1 -G3 consisting of H, C-i-6-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-CH ₂ -, heterocydyl, heterocyclyl-CH ₂ -, phenyl, phenyl-CH ₂ -, pyridyl, pyridyl-CH ₂ - and oxazolyl-CH ₂ -; wherein heterocydyl is defined as hereinbefore and hereinafter, or each heterocydyl is preferably selected from tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl and piperidinyl; and wherein each cydoalkyi and heterocydyl may be optionally substituted with one or more Ci _-4 -alkyl; and wherein each alkyl, cydoalkyi and heterocydyl may be optionally substituted with one or more substituents selected from F; and wherein each alkyl, cydoalkyi and heterocydyl may be optionally substituted with a substituent selected from OH, Ci _-3 -alkyl-O-, H ₂ N-, HO-C(=O)- and Ci- -alkyl-O- C(=O)-; and wherein each phenyl and heteroaryl, including pyridyl, pyrazolyl and oxazolyl, may be optionally substituted with one or more substituents L.

With regard to an alkenyl or alkynyl group, for example R , attached to the N-atom of an amino-group it is to be understood that the double or triple bond is preferably not conjugated with the N-atom.

R ^N2 -G1 :

The group R ^N2 is preferably selected from the group R ^N2 -G1 as defined hereinbefore and hereinafter.

R ^N2 -G2:

In another embodiment the group R ^N2 is selected from the group R ^N2 -G2 consisting of H and Ci _-4 -alkyl. R ^Alk :

R ^Alk -G1 :

The group R ^Alk is preferably selected from the group R ^Alk -G1 as defined hereinbefore and hereinafter.

R ^Alk -G2:

In another embodiment the group R ^Alk is selected from the group R ^Alk -G2 consisting of H and d-3-alkyl which may be substituted with one or more F atoms.

Ar ² :

Ar ² -G1 :

The group Ar ² is preferably selected from the group Ar ² -G1 as defined hereinbefore and hereinafter.

Ar ² -G2:

In another embodiment the group Ar ² is selected from the group Ar ² -G2 consisting of phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, pyrazolyl and thiazolyl, wherein all of the before mentioned groups may be optionally substituted with one or more substituents L .

Ar ² -G3:

In another embodiment the group Ar ² is selected from the group Ar ² -G3 consisting of phenyl and pyridyl, wherein all of the before mentioned groups may be optionally substituted with one or more substituents L.

Ar ² -G4:

In another embodiment the group Ar ² is selected from the group Ar ² -G4 consisting of:

wherein the before mentioned group may be optionally substituted with one or more substituents L. L:

L-G1 :

The group L is preferably selected from the group L-G1 as defined hereinbefore and hereinafter.

L-G2:

In another embodiment the group L is selected from the group L-G2 consisting of F, CI, Br, CN, OH, Ci _-3 -alkyl-, Ci _-3 -alkyl-O-, Ci _-3 -alkyl-S-, H ₂ N-, (Ci _-3 -alkyl)NH-, (Ci _-3 - alkyl) ₂ N- and heterocyclyl; wherein each alkyl may be optionally substituted with one or more F-atoms and/or a substituent selected from OH, Ci _-3 -alkyl-O- and CN; and wherein heterocyclyl is defined as hereinbefore and hereinafter, or heterocyclyl preferably denotes a C _3- 6-cycloalkyl ring wherein one or two -CH ₂ -groups are replaced by a group selected from -O-, -NH-, -N(Ci _-3 -alkyl)-; and wherein two substituents L attached to an aryl or heteroaryl group may be linked to each other and form a C2-5-alkylene bridging group in which 1 or 2 -CH ₂ -groups may be replaced by a group independently of each other selected from O, NH and N(Ci _-4 - alkyl)-, wherein the C2-5-alkylene bridging group is optionally be substituted by 1 or 2 Ci-3-alkyl groups.

L-G3:

In another embodiment the group L is selected from the group L-G3 consisting of F, CI, CN, OH, Ci _-3 -alkyl-, Ci _-3 -alkyl-O-, Ci _-3 -alkyl-S-, H ₂ N-, (Ci _-3 -alkyl)NH-, (Ci _-3 - alkyl) ₂ N- and heterocyclyl; wherein each alkyl may be optionally substituted with one or more F-atoms and/or a substituent selected from OH, CH ₃ -O- and CN; and wherein heterocyclyl is defined as hereinbefore and hereinafter or heterocyclyl preferably denotes a C _3- 6-cycloalkyl ring wherein one or two -CH ₂ -groups are replaced by a group selected from -O-, -NH-, -N(Ci _-3 -alkyl)-; and wherein two substituents L attached to adjacent C-atoms of an aryl or heteroaryl group may be linked to each other and form a -CH2-CH2-O-, -O-CH2-CH2-O- or -0- CH2-O- bridging group which is optionally substituted by 1 or 2 CH ₃ - groups.

*1

X-G1 :

The group X is preferably selected from the group X-G1 as defined hereinbefore and hereinafter, in particular from a group consisting of a straight chain d-3-alkylene group which may be optionally substituted with 1 , 2 or 3 groups selected from C1-3- alkyl and Ci-3-alkyl-0-Ci-3-alkyl; even more preferably optionally substituted with 1 or 2 groups independently selected from methyl, ethyl or methoxy methyl; and wherein two alkyl substituents may be connected with each other and together form a C1-5- alkylene bridging group in which 1 or 2 -CH ₂ -groups may be replaced by 0, S, NH or N(Ci- ₄ -alkyl)-, wherein the C-i-5-alkylene bridging group may optionally be substituted by one or two C-i-3-alkyl groups.

X-G2:

In another embodiment the roup X is selected from the group X-G2 consisting of:

even more preferably selected from the group X-G3 consisting of:

X-GC1 :

According an embodiment X-GC1 the group X is -CH ₂ - which may be optionally substituted with one or two d-3-alkyl groups, preferably with one or two groups independently selected from methyl and ethyl, and wherein two alkyl substituents may be connected with each other and together form a C2-5-alkylene bridging group in which 1 or 2 -CH ₂ -groups may be replaced by 0, S, NH or N(Ci _-4 -alkyl)-, wherein the C-i-5-alkylene bridging group may optionally be substituted by one or two C-i-3-alkyl groups.

Examples of this embodiment are:

X-GC1a:

According an embodiment X-GC1 a the group X is and

_* X _{* * *}

A preferred example of the group X-GC1 a is

X-GC2:

According to another embodiment X-GC2 the group X is -CH ₂ -CH ₂ - which may be optionally substituted with one or more C-i-3-alkyl groups, preferably with one or two groups independently selected from methyl and ethyl, and wherein two alkyl substituents may be connected with each other and together form a d-5-alkylene bridging group in which 1 or 2 -CH ₂ -groups may be replaced by 0, S, NH or N(Ci _-4 - alkyl)-, wherein the d-5-alkylene bridging group may optionally be substituted by one or two C-i-3-alkyl groups.

Examples of this embodiment are:

Preferred examples are:

X-GC2a:

Accordin an embodiment X-GC2a the group X is embracing and A preferred example of the group X-GC2a is

X-GC3:

According another embodiment X-GC3 the group X is -CH ₂ -CH ₂ -CH ₂ - which may be optionally substituted with one or more C-i-3-alkyl groups, preferably with one or two groups independently selected from methyl and ethyl, and wherein two alkyl substituents may be connected with each other and together form a C-i-5-alkylene bridging group in which 1 or 2 -CH ₂ -groups may be replaced by 0, S, NH or N(C-i _-4 - alkyl)-, wherein the d-5-alkylene bridging group may optionally be substituted by one or two C-i-3-alkyl groups.

Examples of this embodiment are:

!i

Y-G1 :

The group Y is preferably selected from the group Y-G1 as defined hereinbefore and hereinafter.

Y-G2:

In another embodiment the group Y is selected from the group Y-G2 consisting of -C(=0)-.

Y-G3:

In another embodiment the group Y is selected from the group Y-G3 consisting of -S(=0) ₂ -.

R^:

R ^N -G1 :

The group R ^N is preferably selected from the group R ^N -G1 as defined hereinbefore and hereinafter.

R ^N -G2:

In another embodiment the group R ^N is selected from the group R ^N -G2 consisting of H, methyl and ethyl.

T:

T-G1 :

The group T is preferably selected from the group T-G1 as defined hereinbefore and hereinafter. T-G2:

In another embodiment the group T is selected from the group T-G2 consisting of C-i- 6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-Ci-3-alkyl, d-6-alkyl- 0-, C3-7-cycloalkyl-0-, C3-7-cycloalkyl-Ci-3-alkyl-0-, Ci-6-alkyl-S-, C3-7-cycloalkyl-S-, C ₃ -7-cycloalkyl-Ci _-3 -alkyl-S-, R ^T1 R ^T2 -N-, R ^T1 R ^T2 - N-Ci _-3 -alkyl-, R ^T1 R ^T2 -N-CO-, Ci- -alkyl-C(=0)-R ^T2 N-Ci _-3 -alkyl, heterocydyl, phenyl and heteroaryl; wherein in each cydoalkyi and heterocydyl a -CH ₂ -group may optionally be replaced by -C(=0)-; and wherein each cydoalkyi and heterocydyl may be optionally substituted with one or more Ci _-4 -alkyl, which may be optionally substituted with one or more substituents R ^c : and wherein each alkyl, cydoalkyi and heterocydyl may be optionally substituted with one or more substituents R ^c ; and wherein R ^c is selected from the group consisting of R ^c -G1 , R ^c -G2 or R ^c -G3 as defined hereinbefore and hereinafter, wherein R ^T1 is selected from the group R ^T1 -G1 or R ^T1 -G2 as defined as hereinbefore and hereinafter; and wherein R ^T2 is selected from the group R ^T2 -G1 or R ^T2 -G2 as defined as hereinbefore and hereinafter; and wherein heterocydyl is defined as hereinbefore and hereinafter; preferably

heterocydyl is azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl, tetrahydrofuranyl or tetrahydropyranyl; and wherein heteroaryl is selected from the group consisting of phenyl, pyridyl,

pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl and thiazolyl; and wherein each aryl and heteroaryl group may be optionally substituted with one or more substituents L.

T-G3:

In another embodiment the group T is selected from the group T-G3 consisting of C-i- 4-alkyl, C3-6-cycloalkyl, Ci- ₄ -alkyl-0-, R ^T1 R ^T2 -N-, heterocyclyl, phenyl and heteroaryl, wherein in each cycloalkyi and heterocyclyl a CH ₂ -group may optionally be replaced by -C(=0)-; and wherein each cycloalkyi and heterocyclyl may be optionally substituted with one or more Ci _-4 -alkyl, which may be optionally substituted with one or more substituents R ^c ; and wherein each alkyl, cycloalkyi and heterocyclyl may be optionally substituted with one or more substituents R ^c ; and wherein R ^c is selected from the group consisting of R ^c -G1 , R ^c -G2 or R ^c -G3 as defined hereinbefore and hereinafter; and wherein R ^T1 is selected from the group R ^T1 -G1 or R ^T1 -G2 as defined as hereinbefore and hereinafter; preferably R ^T1 denotes H, Ci _-4 -alkyl, C3-6-cycloalkyl or C3-6- cycloalkyl-C-i-3-alkyl; and wherein R ^T2 is selected from the group R ^T2 -G1 or R ^T2 -G2 as defined as hereinbefore and hereinafter; preferably R ^T2 denotes H or Ci _-4 -alkyl; and wherein heterocyclyl is defined as hereinbefore and hereinafter, preferably

heterocyclyl is selected from the group consisting of

wherein heteroaryl is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl and thiazolyl; and wherein each heteroaryl group may be optionally substituted with one or more substituents L.

T-G4:

In another embodiment the group T is selected from the group T-G4 consisting of C-i- 3-alkyl, C ₃ - ₅ -cycloalkyl, Ci _-3 -alkyl-0- and R ^T1 R ^T2 -N-; wherein each cycloalkyl may be optionally substituted with one or more d-3-alkyl; and wherein R ^T1 and R ^T2 are independently of each other selected from H and d-3-alkyl. Preferred examples of the group T-G4 are H ₃ C-,

H3C-O-, (H ₃ C) ₂ N-, and

T-G5:

In another embodiment the group T is selected from the group T-G5 consisting of H3C-, H2FC-, HF2C-, NC-CH2-, F3C-CH2-, (H ₃ C) ₂ CF-, H5C2-, n-propyl, i-propyl, n- butyl, i-butyl, H ₃ C-(H ₃ CO)CH-, H ₃ C-(HO)CH-, NC-CH ₂ -, NC-CH ₂ -CH ₂ -,

cyclopropyl, cyclobutyl, cyclopropyl-CH ₂ -,

H ₂ C=CH-, H ₃ C-CH=CH-, (H ₃ C) ₂ C=CH-, H ₂ C=CH-CH ₂ -,HO-CH ₂ -, HO-CH ₂ -CH ₂ -, (CH ₃ ) ₂ CH-(HO)CH-, H ₃ C-(HO)CH-,

H ₃ C-O-CH ₂ -, H ₃ C-O-CH ₂ -CH ₂ -,

H ₃ C-O-,

H ₃ C-CH ₂ -CO-, H ₃ C-SO ₂ -CH ₂ -,

T-G6:

In another preferred embodiment the group T is preferably selected from the group T-G6 consisting of H ₃ C-, H ₂ FC-, HF ₂ C-, NC-CH ₂ -, F ₃ C-CH ₂ -, (H ₃ C) ₂ CF-, H ₅ C ₂ -, n- propyl, i-propyl, n-butyl, i-butyl, H ₃ C-(H ₃ CO)CH-, H ₃ C-(HO)CH-, NC-CH ₂ -, NC-CH ₂ - CH ₂ -,

cyclopropyl, cyclobutyl, cyclopropyl-CH ₂ -,

H ₃ C-0-, T- R -G1 :

In an embodiment the groups T and R ^N are connected with each other and together form a group which is preferably selected from the group T-R ^N -G1 as defined hereinbefore and hereinafter.

T-R -G2:

In another embodiment the groups T and R ^N are connected with each other such that the group is selected from the group T-R ^N -G2 consisting

all of which may be optionally substituted with one or more substituents selected from F, CI, Br, OH, CN, Ci _-4 -alkyl, C ₃ - ₆ -cycloalkyl, C ₃ -6-cycloalkyl-Ci _-3 -alkyl, Ci- -alkyl-O-, C ₃ -6-cycloalkyl-O-, C _3-6 -cycloalkyl-Ci _-3 -alkyl-O- H ₂ N-, (Ci- -alkyl)NH-, (Ci- -alkyl) ₂ N-, wherein each alkyl or cycloalkyl may be optionally substituted with one or more substituents selected from F, and wherein each alkyl or cycloalkyl may be optionally substituted with a substituent selected from CI, Br, OH, CN, Ci _-3 -alkyl-O-, C _3- 6-cycloalkyl-O-, C _3- 6- cycloalkyl-Ci _-3 -alkyl-O-, H ₂ N-, (Ci _-3 -alkyl)NH-, (Ci _-3 -alkyl) ₂ N-, Ci- - alkyl-S(=O) ₂ -, HO-C(=O)- and

T-R ^N -G3:

In another embodiment the groups T and R ^N are connected with each other such that the group is selected from the group T-R ^N -G3 consisting of: , all of which may be substituted with one or more F atoms and/or Ci _-3 -alkyl. R ^T -G1 :

The group R ^T1 is preferably selected from the group R ^T1 -G1 consisting of H, C-i-6- alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-Ci-3-alkyl, phenyl and pyridyl,

wherein each cycloalkyi may be optionally substituted with one or more Ci- ₄ -alkyl, and

wherein each alkyl and cycloalkyi may be optionally substituted with one or more F atoms, and

wherein each alkyl and cycloalkyi may be optionally substituted with a substituent selected from OH, Ci _-3 -alkyl-O-, Ci _-3 -alkyl-C(=O)-, HO-C(=O)- and Ci- -alkyl-O- C(=O)-; and wherein each phenyl and pyridyl group may be optionally substituted with one or more substituents L.

R ^T -G2:

In another embodiment the group R ^T1 is selected from the group R ^T1 -G2 consisting of methyl, ethyl, n-propyl, isopropyl, HOOC-CH ₂ -, H3C-CO-, phenyl and pyridinyl, wherein the groups phenyl and pyridyl may be substituted with one or more substituents L. eZ

R ^T2 -G1 :

The group R ^T2 is preferably selected from the group R ^T2 -G1 consisting of H and Ci _-4 - alkyl.

R ^T2 -G2:

In another embodiment the group R ^T2 is selected from the group R ^T2 -G2 consisting of H, methyl, ethyl, n-propyl and isopropyl.

Examples of preferred subgeneric embodiments according to the present invention are set forth in the following table, wherein each substituent group of each embodiment is defined according to the definitions set forth hereinbefore and wherein all other substituents of the formula (I) are defined according to the definitions set forth hereinbefore:

The following preferred embodiments of compounds of the formula (I) are described using generic formulas (1.1 a) to (l.1f) and (1.1 ) to (1.5), wherein any tautomers and stereoisomers, solvates, hydrates and salts thereof, in particular the pharmaceutically acceptable salts thereof, are encompassed. -52 -

wherein in each of the above formulas (1.1 a) to (l.1f) and (1.1 ) to (1.5), the groups R ,

L, X and T are defined as hereinbefore and hereinafter; and

P is N or CH, wherein CH may be optionally substituted by L as defined; and

Q is N or CH, wherein CH may be optionally substituted by L as defined; and r is 0, 1 or 2; and

s is 0, 1 or 2.

Preferred embodiments of the above formulas (1.1 a) to (l.1f) and (1.1 ) to (1.5) according to the present invention are set forth in the following table, wherein each group R ^A , X, T, L of each embodiment is defined according to the definitions set forth hereinbefore and wherein all other substituents of the formula (I) are defined according to the definitions set forth hereinbefore and P, Q, r and s are defined as hereinbefore: Embodiment Formula R ^A X T L

E-A (1.1 ) RA-G2 X-G1 T-G2 L-G2

E-B (1.1 ) RA-G4 X-G2 T-G3 L-G2

E-C (1.1 a) RA-G2 X-G1 T-G2 L-G2

E-D (1.1 a) RA-G4 X-G2 T-G3 L-G2

E-E (1.1 b) RA-G2 X-G1 T-G2 L-G2

E-F (1.1 b) RA-G4 X-G2 T-G3 L-G2

E-G (1.1 c) RA-G2 X-G1 T-G2 L-G2

E-H (1.1 c) RA-G4 X-G2 T-G3 L-G2

E-l (1.1 d) RA-G2 X-G1 T-G2 L-G2

E-J (1.1 d) RA-G4 X-G2 T-G3 L-G2

E-K (l.1 e) RA-G2 X-G1 T-G2 L-G2

E-L (l.1 e) RA-G4 X-G2 T-G3 L-G2

E-M (l.1f) RA-G2 X-G1 T-G2 L-G2

E-N (l.1f) RA-G4 X-G2 T-G3 L-G2

E-0 (I.2) RA-G2 X-G1 T-G2 L-G2

E-P (I.2) RA-G4 X-G2 T-G3 L-G2

E-Q (I.3) RA-G2 X-G1 T-G2 L-G2

E-R (I.3) RA-G4 X-G2 T-G3 L-G2

E-S (I.4) RA-G2 X-G1 T-G2 L-G2

E-T (I.4) RA-G4 X-G2 T-G3 L-G2

E-U (I.5) RA-G2 X-G1 T-G2 L-G2

E-V (I.5) RA-G4 X-G2 T-G3 L-G2 including any tautomers and stereoisomers, solvates, hydrates and salts thereof, in particular the pharmaceutically acceptable salts thereof.

Particularly preferred compounds, including their tautomers and stereoisomers, the salts thereof, or any solvates or hydrates thereof, are described in the experimental section hereinafter.

The compounds according to the invention may be obtained using methods of synthesis which are known to the one skilled in the art and described in the literature of organic synthesis. Preferably the compounds are obtained analogously to the methods of preparation explained more fully hereinafter, in particular as described in the experimental section.

Compounds of the general formula (I) can be prepared by the following methods: Ar ¹ — C≡C-H + Z-Ar ² -X-I\l ,- ^T *~ Ar ¹ — C≡C-Ar-X-|

(ii) (ill) (I)

Compounds of general formula (I) may be prepared by a palladium-catalyzed

Sonogashira reaction of alkynes (II) with aryi halogenides or aryi inflates (III) wherein Z is a leaving group which for example denotes CI, Br, I or OTf (triflate).

Ar ¹ — C≡C

(IV) (III) (I)

In an alternative approach compounds of general formula (I) may be prepared by a palladium-catalyzed decarbonylative Sonogashira reaction of propynoic acids (IV) with aryi halogenides or aryi inflates (III) wherein Z is a leaving group which for example denotes CI, Br, I or OTf (triflate).

(V) (vi) (I)

Compounds of general formula (I) may be prepared by a palladium-catalyzed

Sonogashira reaction of alkynes (VI) with aryi halogenides or aryi triflates (V) wherein Z is a leaving group which for example denotes CI, Br, I or OTf (triflate).

(VI I lb)

Compounds of general formula (la) may be prepared by amide coupling reactions of amines (VII) with either carboxylic acids (Villa) mediated by coupling reagents such as e.g. TBTU, HOBt or HATU or carboxylic acid chlorides (Vlllb).

o

H O; J I

O , O

' // -S-T

Ar— C≡C— Ar-X-N s— T Ar— C≡C— Ar-X— N

/ \

R ci R

(VII) (IX) (lb)

Compounds of general formula (lb) may be prepared by sulfonylation of amines (VII) with sulfonyl chlorides (IX).

Ar ¹ — c

(XI)

Compounds of general formula (Ic) may be prepared by urea forming reactions such as reaction of amines (VII) with carbamoyl chlorides (X) or isocyanates (XI).

(VII) (XII) (Id) Compounds of general formula (Id) may be prepared by urethane forming reactions such as reaction of amines (VII) with chloro formates (XII).

Ar ¹ — C≡C-Ar-X-

(le) (XIII) (If)

Compounds of general formula (If) may be prepared by alkylation reactions of secondary amides (le) with alkylating reagents (XIII) wherein Z denotes leaving groups such as CI, Br, I, OTf (triflate), sulfonate or sulfate.

(Vii) (XIV) (ig)

Compounds of general formula (Ig) may be prepared by ring-closing reactions of amines (VII) with double electrophiles (XIV) combining an acylating and an alkylating step in a one-pot recation. Z ¹ denotes leaving groups such as CI, Br or I, Z ² denotes leaving groups such as CI, Br, I, OTf (triflate), sulfonate or sulfate.

(XVI) (XVII) (XV)

Compounds of general formula (XV) may be prepared by amide coupling reactions of carboxylic acids (XVI) with amines (XVII) with mediated by coupling reagents such as eg TBTU, HOBt or HATU.

R-OH

1 2 / ^Y ^T ( a) 1 2 ^/Y ^T

Ar ¹ -C≡C-Ar-X-N J + Ar-C≡C-Ar-X-N

HO ^{7 + 0r} RC^

(XIX) ^ _x ^Z _b) (xviii) Compounds of general formula (XVIII) may be prepared by Mitsunobu reactions of aromatic alcohols (XIX) with alcohols (XXa) mediated by coupling reagents such as azodicarboxylates (e.g. DEAD, DIAD etc.) and phosphines (e.g. triphenylphosphine) or by a nucleophilic substitution reaction of the phenol (XIX) with electrophiles (XXb) wherein Z is a leaving group which for example denotes CI, Br, I, mesylate, tosylate or triflate in the presence of a base, such as e.g. K2CO3 or NaH.

(XXII) (XXIII) (XXI)

Compounds of general formula (XXI) may be prepared by nucleophilic aromatic substitution reactions of pyrimidines (XXI I) with nucleophiles R (XXI I I), wherein Z is a leaving group which for example denotes CI, Br, I, S(=0)CH ₃ or triflate and wherein R is a nucleophile, such as for example an alcohol or an amine and wherein the reaction may be performed with other regioisomers of pyrimidine or other hetaryls also.

Terms and definitions

Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the specification, however, unless specified to the contrary, the following terms have the meaning indicated and the following conventions are adhered to.

The terms "compound(s) according to this invention", "compound(s) of formula (I)", "compound(s) of the invention" and the like denote the compounds of the formula (I) according to the present invention including their tautomers, stereoisomers and mixtures thereof and the salts thereof, in particular the pharmaceutically acceptable salts thereof, and the solvates and hydrates of such compounds, including the solvates and hydrates of such tautomers, stereoisomers and salts thereof.

The terms "treatment" and "treating" embraces both preventative, i.e. prophylactic, or therapeutic, i.e. curative and/or palliative, treatment. Thus the terms "treatment" and "treating" comprise therapeutic treatment of patients having already developed said condition, in particular in manifest form. Therapeutic treatment may be symptomatic treatment in order to relieve the symptoms of the specific indication or causal treatment in order to reverse or partially reverse the conditions of the indication or to stop or slow down progression of the disease. Thus the compositions and methods of the present invention may be used for instance as therapeutic treatment over a period of time as well as for chronic therapy. In addition the terms "treatment" and "treating" comprise prophylactic treatment, i.e. a treatment of patients at risk to develop a condition mentioned hereinbefore, thus reducing said risk.

When this invention refers to patients requiring treatment, it relates primarily to treatment in mammals, in particular humans.

The term "therapeutically effective amount" means an amount of a compound of the present invention that (i) treats or prevents the particular disease or condition, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease or condition, or (iii) prevents or delays the onset of one or more symptoms of the particular disease or condition described herein.

The terms "modulated" or "modulating", or "modulate(s)", as used herein, unless otherwise indicated, refers to the inhibition of the Acetyl-CoA carboxylases (ACC) enzyme(s) with one or more compounds of the present invention.

The terms "mediated" or "mediating" or "mediate", as used herein, unless otherwise indicated, refers to the (i) treatment, including prevention the particular disease or condition, (ii) attenuation, amelioration, or elimination of one or more symptoms of the particular disease or condition, or (iii) prevention or delay of the onset of one or more symptoms of the particular disease or condition described herein.

The term "substituted" as used herein, means that any one or more hydrogens on the designated atom, radical or moiety is replaced with a selection from the indicated group, provided that the atom's normal valence is not exceeded, and that the substitution results in an acceptably stable compound. ln the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, d-6-alkyl means an alkyl group or radical having 1 to 6 carbon atoms. In general, for groups comprising two or more subgroups, the last named subgroup is the radical attachment point, for example, the substituent "aryl-C-i -3-alkyl-" means an aryl group which is bound to a C-i -3-alkyl- group, the latter of which is bound to the core or to the group to which the substituent is attached.

In case a compound of the present invention is depicted in form of a chemical name and as a formula in case of any discrepancy the formula shall prevail.

An asterisk is may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.

The numeration of the atoms of a substituent starts with the atom which is closest to the core or to the group to which the substituent is attached.

For example, the term "3-carboxypropyl-group" represents the following substituent:

wherein the carboxy group is attached to the third carbon atom of the propyl group. The terms "1 -methylpropyl-", "2,2-dimethylpropyl-" or "cyclopropylmethyl-" group represent the following groups:

The asterisk may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.

In a definition of a group the term "wherein each X, Y and Z group is optionally substituted with" and the like denotes that each group X, each group Y and each group Z either each as a separate group or each as part of a composed group may be substituted as defined. For example a definition "R ^ex denotes H, d-3-alkyl, C3-6- cycloalkyl, C3-6-cycloalkyl-Ci-3-alkyl or Ci-3-alkyl-O-, wherein each alkyl group is optionally substituted with one or more L ^ex ." or the like means that in each of the beforementioned groups which comprise the term alkyl, i.e. in each of the groups C-i- 3-alkyl, C3-6-cycloalkyl-Ci-3-alkyl and d-3-alkyl-O-, the alkyl moiety may be substituted with L ^ex as defined.

In the following the term bicyclic includes spirocyclic.

Unless specifically indicated, throughout the specification and the appended claims, a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc .. ) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including

pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates of the free compounds or solvates of a salt of the compound.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.

As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. For example, such salts include acetates, ascorbates, benzenesulfonates, benzoates, besylates, bicarbonates, bitartrates, bromides/hydrobromides, Ca-edetates/edetates,

camsylates, carbonates, chlorides/hydrochlorides, citrates, edisylates, ethane disulfonates, estolates esylates, fumarates, gluceptates, gluconates, glutamates, glycolates, glycollylarsnilates, hexylresorcinates, hydrabamines, hydroxymaleates, hydroxynaphthoates, iodides, isothionates, lactates, lactobionates, malates, maleates, mandelates, methanesulfonates, mesylates, methylbromides,

methylnitrates, methylsulfates, mucates, napsylates, nitrates, oxalates, pamoates, pantothenates, phenylacetates, phosphates/diphosphates, polygalacturonates, propionates, salicylates, stearates subacetates, succinates, sulfamides, sulfates, tannates, tartrates, teoclates, toluenesulfonates, triethiodides, ammonium,

benzathines, chloroprocaines, cholines, diethanolamines, ethylenediamines, meglumines and procaines. Further pharmaceutically acceptable salts can be formed with cations from metals like aluminium, calcium, lithium, magnesium, potassium, sodium, zinc and the like, (also see Pharmaceutical salts, Birge, S.M. et al., J.

Pharm. Sci., (1977), 66, 1 -19).

The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.

Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention (e.g. trifluoro acetate salts) also comprise a part of the invention.

The term halogen generally denotes fluorine, chlorine, bromine and iodine.

The term "Ci _-n -alkyl", wherein n is an integer from 1 to n, either alone or in

combination with another radical denotes an acyclic, saturated, branched or linear 7hydrocarbon radical with 1 to n C atoms. For example the term d-5-alkyl embraces the radicals H ₃ C-, H3C-CH2-, H ₃ C-CH ₂ -CH ₂ -, H ₃ C-CH(CH ₃ )-, H ₃ C-CH2-CH ₂ -CH ₂ -, H ₃ C-CH ₂ -CH(CH ₃ )-, H ₃ C-CH(CH ₃ )-CH ₂ -, H ₃ C-C(CH ₃ ) ₂ -, H ₃ C-CH ₂ -CH ₂ -CH ₂ -CH ₂ -, H ₃ C-CH ₂ -CH ₂ -CH(CH ₃ )-, H ₃ C-CH ₂ -CH(CH ₃ )-CH ₂ -, H ₃ C-CH(CH ₃ )-CH ₂ -CH ₂ -, H ₃ C- CH ₂ -C(CH ₃ ) ₂ -, H ₃ C-C(CH ₃ ) ₂ -CH ₂ -, H ₃ C-CH(CH ₃ )-CH(CH ₃ )- and H ₃ C-CH ₂ - CH(CH ₂ CH ₃ )-. The term "Ci _-n -alkylene" wherein n is an integer 1 to n, either alone or in combination with another radical, denotes an acyclic, straight or branched chain divalent alkyl radical containing from 1 to n carbon atoms. For example the term Ci _-4 -alkylene includes -(CH ₂ )-, -(CH ₂ -CH ₂ )-, -(CH(CH ₃ ))-, -(CH ₂ -CH ₂ -CH ₂ )-, -(C(CH ₃ ) ₂ )-, - (CH(CH ₂ CH ₃ ))-, -(CH(CH ₃ )-CH ₂ )-, -(CH ₂ -CH(CH ₃ ))-, -(CH ₂ -CH ₂ -CH ₂ -CH ₂ )-, -(CH ₂ - CH ₂ -CH(CH ₃ ))-, -(CH(CH ₃ )-CH ₂ -CH ₂ )-, -(CH ₂ -CH(CH ₃ )-CH ₂ )-, -(CH ₂ -C(CH ₃ ) ₂ )-, -(C (CH ₃ ) ₂ -CH ₂ )-, -(CH(CH ₃ )-CH(CH ₃ ))-, -(CH ₂ -CH(CH ₂ CH ₃ ))-, -(CH(CH ₂ CH ₃ )-CH ₂ )-, -(CH(CH ₂ CH ₂ CH ₃ ))- , -(CHCH(CH ₃ ) ₂ )- and -C(CH ₃ )(CH ₂ CH ₃ )-.

The term "C ₂ - _n -alkenyl", is used for a group as defined in the definition for "Ci _-n -alkyl" with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond. For example the term C _2-3 -alkenyl includes -CH=CH ₂ , -CH=CH-CH ₃ , -CH ₂ -CH=CH ₂ .

The term "C _2-n -alkenylene" is used for a group as defined in the definition for

"C-i-n-alkylene" with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond. For example the term C _2-3 - alkenylene includes -CH=CH-, -CH=CH-CH ₂ -, -CH ₂ -CH=CH-.

The term "C ₂ - _n -alkynyl", is used for a group as defined in the definition for "Ci _-n -alkyl" with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a triple bond. For example the term C _2-3 -alkynyl includes -C≡CH, -C≡C-CH ₃ , -CH ₂ -C≡CH.

The term "C _2-n -alkynylene" is used for a group as defined in the definition for

"C-i-n-alkylene" with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a triple bond. For example the term C _2-3 - alkynylene includes -C≡C-, -C≡C-CH ₂ -, -CH ₂ -C≡C-.

The term "C ₃ - _n -carbocyclyl" as used either alone or in combination with another radical, denotes a monocyclic, bicyclic or tricyclic, saturated or unsaturated hydrocarbon radical with 3 to n C atoms. The hydrocarbon radical is preferably nonaromatic. Preferably the 3 to n C atoms form one or two rings. In case of a bicyclic or tricyclic ring system the rings may be attached to each other via a single bond or may be fused or may form a spirocydic or bridged ring system. For example the term C3-io-carbocyclyl includes C3-io-cylcoalkyl, C3-io-cycloalkenyl,

octahydropentalenyl, octahydroindenyl, decahydronaphthyl, indanyl,

tetrahydronaphthyl. Most preferably the term C3 _-n -carbocyclyl denotes C3 _-n -cylcoalkyl, in particular C3-7-cycloalkyl.

The term "C3- _n -cycloalkyl", wherein n is an integer 4 to n, either alone or in

combination with another radical denotes a cyclic, saturated, unbranched

hydrocarbon radical with 3 to n C atoms. The cyclic group may be mono-, bi-, tri- or spirocydic, most preferably monocyclic. Examples of such cycloalkyi groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo[3.2.1 .]octyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, adamantyl, etc.

The term "C3- _n -cycloalkenyl", wherein n is an integer 3 to n, either alone or in combination with another radical, denotes a cyclic, unsaturated but nonaromatic, unbranched hydrocarbon radical with 3 to n C atoms, at least two of which are bonded to each other by a double bond. For example the term C3-7-cycloalkenyl includes cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl and cycloheptatrienyl.

The term "aryl" as used herein, either alone or in combination with another radical, denotes a carbocyclic aromatic monocyclic group containing 6 carbon atoms which may be further fused to a second 5- or 6-membered carbocyclic group which may be aromatic, saturated or unsaturated. Aryl includes, but is not limited to, phenyl, indanyl, indenyl, naphthyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl and dihydronaphthyl. More preferably the term "aryl" as used herein, either alone or in combination with another radical, denotes phenyl or naphthyl, most preferably phenyl.

The term "heterocyclyl" means a saturated or unsaturated mono-, bi-, tri- or spirocarbocyclic, preferably mono-, bi- or spirocyclic-ring system containing one or more heteroatoms selected from N, 0 or S(0) _r with r=0, 1 or 2, which in addition may have a carbonyl group. More preferably the term "heterocyclyl" as used herein, either alone or in combination with another radical, means a saturated or unsaturated, even more preferably a saturated mono-, bi- or spirocyclic-ring system containing 1 , 2, 3 or 4 heteroatoms selected from N, 0 or S(0) _r with r=0, 1 or 2 which in addition may have a carbonyl group. The term "heterocyclyl is intended to include all the possible isomeric forms. Examples of such groups include aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, azepanyl, piperazinyl, morpholinyl, tetrahydrofuranonyl, tetrahydropyranonyl, pyrrolidinonyl, piperidinonyl, piperazinonyl, morpholinonyl.

Thus, the term "heterocyclyl" includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:

-66-

The term "heteroaryl" means a mono- or polycyclic, preferably mono- or bicyclic-ring system containing one or more heteroatoms selected from N, 0 or S(0) _r with r=0, 1 or 2 wherein at least one of the heteroatoms is part of an aromatic ring, and wherein said ring system may have a carbonyl group. More preferably the term "heteroaryl" as used herein, either alone or in combination with another radical, means a mono- or bicyclic-ring system containing 1 , 2, 3 or 4 heteroatoms selected from N, 0 or S(0) _r with r=0, 1 or 2 wherein at least one of the heteroatoms is part of an aromatic ring, and wherein said ring system may have a carbonyl group. The term "heteroaryl" is intended to include all the possible isomeric forms. Thus, the term "heteroaryl" includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:

Many of the terms given above may be used repeatedly in the definition of a formula or group and in each case have one of the meanings given above, independently of one another.

Pharmacological Activity

The activity of the compounds of the invention may be demonstrated using the following ACC2 assay:

Spectrophotometric 384 well assay

Malonyl CoA formation by acetyl CoA carboxylases is stoichometrically linked to the consumption of ATP. ACC2 activity is measured in a NADH-linked kinetic method measuring ADP generated during the ACC reaction using a coupled lactate dehydrogenase / pyruvate kinase reaction.

For biological testing, a human ACC2 construct which lacks the 128 amino acids at the N-terminus for increased solubility (nt 385-6966 in Genbank entry AJ575592) is cloned. The protein is then expressed in insect cells using a baculoviral expression system. Protein purification is performed by anion exchange.

All compounds are dissolved in dimethyl sulfoxide (DMSO) to a concentration of 10 mM.

Assay reactions are then carried out in 384-well plates, with hACC2 in an appropriate dilution and at final assay concentrations (f.c.) of 100 mM Tris (pH 7.5), 10 mM trisodium citrate, 25 mM KHCO ₃ , 10 mM MgCI ₂ , 0.5 mg/mL BSA, 3.75 mM reduced L-glutathione, 15 U/mL lactate dehydrogenase, 0.5 mM phosphoenolpyruvate, 15 U/mL pyruvate kinase, compounds at different concentrations at final DMSO concentrations of 1 %.

The enzymatic reaction is then started by addition of a mixture of NADH, acetyl Coenzyme A (both 200μΜ f.c.) and ATP (500 uM f.c). The decrease of the optical density (slope S) is then determined at 25°C at a wavelength of 340 nm over 1 5 minutes in a spectrophotometric reader.

Each assay microtiter plate contains wells with vehicle instead of compound as controls for the non-inhibited enzyme (100% CTL; 'HIGH') and wells without acetyl- CoA as controls for non-specific NADH degradation (0% CTL; 'LOW'). The slope S is used for calculation of %CTL= (S(compound)-S('LOW))/(S('HIGH')- S('LOW')) ^* 100. Compounds will give values between 100%CTL (no inhibition) and 0%CTL (complete inhibition).

For IC50 value determination, the sample slope in the presence of the test compound after subtraction of the low controls (S(compound)-S('LOW)) are used.

An IC50 value is derived from the compound slopes at different dosages after subtraction of the low controls (S(compound)-S('LOW)) by non-linear regression curve fitting (equation y = (A+((B-A)/(1 +((C/x) ^A D))))).

The compounds of general formula (I) according to the invention for example have IC ₅ o values below 30000 nM, particularly below 1000 nM, preferably below 300 nM.

In the following table the activity expressed as IC50 (μΜ) of compounds according to the invention is presented wherein the IC50 values are determined in the ACC2 assay as described hereinbefore. The term "Ex." refers to the example numbers according to the following experimental section.

IC50 IC50 IC50 IC50

Ex. Ex. Ex. Ex.

[μΜ] [μΜ] [μΜ] [μΜ]

1 .1 0.53 4.1 1 1 .4 9.34 6.4 13.39 0.64

1 .2 0.81 4.12 0.56 9.35 0.66 13.40 2.2

1 .3 0.69 4.13 0.68 9.36 0.42 13.41 2.4

1 .4 2.0 4.14 1 .2 9.37 0.52 13.42 4.5

1 .5 2.4 4.15 0.78 9.38 2.6 13.43 0.58

1 .6 0.88 4.16 1 .6 9.39 0.18 13.44 0.32

1 .7 4.9 4.17 0.47 9.40 0.05 13.45 0.91

1 .8 0.20 4.18 0.46 9.41 0.50 13.46 2.7

1 .9 8.4 4.19 2.8 9.42 0.63 13.47 0.60

1 .10 5.5 4.20 0.18 10.1 0.19 13.48 1 .3

1 .1 1 1 .7 4.21 0.14 10.2 1 .2 13.49 2.6

1 .12 2.3 4.22 0.93 10.3 1 .8 13.50 1 .5

1 .13 1 .1 4.23 0.31 1 1 .1 1 .2 13.51 2.2

1 .14 0.20 4.24 1 .0 1 1 .2 30.0 13.52 5.2 1.15 1.8 4.25 0.54 11.3 2.3 13.53 5.2

1.16 0.12 4.26 0.23 11.4 0.53 13.54 0.20

1.17 0.39 4.27 13.3 11.5 7.2 13.55 0.13

1.18 0.99 4.28 0.79 11.6 0.93 13.56 0.97

1.19 1.5 4.29 2.7 11.7 12.7 13.57 0.22

1.20 0.61 4.30 1.7 11.8 0.75 13.58 1.2

1.21 0.40 4.31 0.41 11.9 4.0 13.59 0.36

1.22 0.29 4.32 0.44 11.10 16.7 13.60 0.25

1.23 1.0 4.33 0.49 11.11 0.26 13.61 3.8

1.24 1.1 4.34 0.60 11.12 5.6 13.62 0.33

1.25 5.1 4.35 0.38 11.13 1.9 13.63 0.20

1.26 0.32 4.36 0.86 11.14 13.8 13.64 0.80

1.27 0.55 4.37 0.90 11.15 0.33 13.65 1.6

1.28 0.12 4.38 0.17 11.16 0.68 13.66 0.15

1.29 0.25 4.39 0.71 11.17 1.7 13.67 0.66

1.30 2.1 4.40 3.7 11.18 0.51 13.68 0.23

1.31 0.45 4.41 2.0 11.19 5.9 13.69 5.0

1.32 16.9 4.42 - 11.20 9.9 13.70 6.8

2.1 0.46 4.43 11.0 11.21 0.25 13.71 0.21

2.2 0.39 4.44 1.5 11.22 8.1 13.72 0.19

2.3 1.4 4.45 0.53 11.23 0.37 13.73 0.28

2.4 3.3 4.46 8.5 11.24 0.39 13.74 1.7

2.5 0.82 4.47 2.7 11.25 1.8 13.75 0.17

2.6 1.4 4.48 3.9 11.26 0.43 13.76 0.60

2.7 0.76 4.49 8.7 11.27 0.40 13.77 0.22

2.8 0.73 4.50 6.3 11.28 0.38 13.78 0.13

2.9 1.5 4.51 0.51 11.29 4.5 13.79 0.11

2.10 7.5 4.52 5.1 11.30 0.48 13.80 0.48

2.11 0.27 4.53 0.37 11.31 2.0 13.81 0.33

2.12 6.7 4.54 30.0 11.32 0.35 13.82 1.2

2.13 5.3 4.55 0.33 11.33 0.68 13.83 0.19

2.14 0.13 4.56 5.6 11.34 13.9 13.84 1.0 2.15 0.56 4.57 0.99 11.35 2.4 13.85 0.08

2.16 0.12 4.58 0.68 11.36 0.69 13.86 0.12

2.17 0.11 4.59 0.11 11.37 14.3 13.87 1.0

2.18 2.2 4.60 24.7 11.38 0.43 13.88 3.1

2.19 3.6 4.61 10.1 11.39 0.72 13.89 1.0

2.20 0.30 4.62 3.7 11.40 1.1 13.90 0.96

2.21 0.24 4.63 0.92 11.41 2.7 13.91 2.9

2.22 0.72 4.64 5.1 11.42 0.62 13.92 7.3

2.23 0.32 4.65 1.1 11.43 0.93 13.93 0.27

2.24 0.76 4.66 4.7 11.44 1.3 13.94 3.6

2.25 0.17 4.67 0.07 11.45 0.53 13.95 2.8

2.26 0.93 4.68 0.45 11.46 0.29 14.1 1.2

2.27 0.28 4.69 0.07 11.47 7.4 14.2 5.9

2.28 0.27 4.70 1.3 11.48 10.3 14.3 0.45

2.29 1.6 4.71 0.43 11.49 0.46 14.4 1.5

2.30 0.33 4.72 0.94 12.1 8.5 14.5 4.1

2.31 0.28 4.73 19.2 12.2 4.3 14.6 0.12

2.32 0.16 4.74 2.8 12.3 1.3 14.7 0.07

2.33 0.27 4.75 15.4 12.4 0.98 14.8 1.3

2.34 0.18 4.76 0.66 12.5 1.6 14.9 0.18

2.35 0.13 4.77 0.46 12.6 1.1 14.10 0.10

2.36 0.14 4.78 0.29 12.7 3.6 14.11 0.13

2.37 0.10 4.79 0.16 12.8 2.2 14.12 0.17

2.38 10.1 4.80 7.7 12.9 2.1 14.13 0.22

2.39 21.6 5.1 0.25 12.10 0.63 14.14 0.16

2.40 11.8 5.2 7.2 12.11 0.67 14.15 0.14

2.41 25.0 5.3 1.2 12.12 0.09 14.16 0.12

2.42 24.6 5.4 0.33 12.13 0.43 14.17 0.51

2.43 0.45 6.1 30.0 12.14 2.5 14.18 0.14

2.44 0.42 6.2 2.2 12.15 0.23 14.19 0.19

2.45 0.25 6.3 0.23 12.16 0.17 14.20 0.51

2.46 0.41 6.4 9.6 12.17 0.38 14.21 3.1 2.47 0.36 7.1 0.62 12.18 7.1 14.22 13.4

2.48 0.26 7.2 0.19 12.19 1.2 14.23 0.14

2.49 0.25 7.3 0.36 12.20 0.53 14.24 0.20

2.50 0.90 8.1 0.50 12.21 0.38 14.25 1.8

2.51 1.3 8.2 5.6 12.22 0.64 14.26 0.14

2.52 0.19 8.3 13.0 12.23 1.1 14.27 3.7

2.53 0.12 8.4 1.6 12.24 0.59 14.28 3.4

2.54 1.2 8.5 - 12.25 2.4 14.29 0.68

2.55 0.07 8.6 1.5 12.26 1.0 14.30 0.15

2.56 0.96 8.7 26.3 12.27 0.86 14.31 0.09

2.57 0.57 8.8 4.2 12.28 1.1 14.32 0.71

2.58 3.7 8.9 3.7 12.29 0.07 14.33 1.6

2.59 2.1 8.10 1.1 12.30 0.19 14.34 0.60

2.60 0.69 8.11 16.6 12.31 1.1 14.35 0.73

2.61 2.0 8.12 1.5 12.32 0.32 14.36 2.3

2.62 0.74 8.13 2.4 12.33 0.32 14.37 0.17

2.63 0.46 8.14 11.5 12.34 0.28 14.38 1.4

2.64 2.8 8.15 2.2 12.35 2.3 14.39 1.1

2.65 0.48 8.16 1.9 12.36 1.5 14.40 0.08

2.66 0.23 8.17 4.4 12.37 1.1 14.41 0.44

2.67 7.2 8.18 7.7 12.38 0.26 14.42 0.83

2.68 0.25 8.19 4.6 12.39 3.2 14.43 0.36

2.69 2.0 8.20 4.4 12.40 0.63 14.44 0.36

2.70 0.80 8.21 1.4 12.41 0.52 14.45 1.0

2.71 3.4 8.22 6.5 12.42 0.35 14.46 0.21

2.72 0.91 8.23 10.9 12.43 2.6 14.47 0.08

2.73 0.64 8.24 30.0 12.44 1.0 14.48 0.58

2.74 1.1 8.25 2.4 12.45 0.18 14.49 0.32

2.75 0.10 8.26 1.5 12.46 1.0 14.50 1.5

2.76 5.8 8.27 11.1 12.47 0.13 14.51 0.40

2.77 1.5 8.28 5.0 12.48 0.32 14.52 3.8

2.78 0.75 8.29 4.5 12.49 0.23 14.53 0.28 2.79 0.45 8.30 2.8 12.50 0.53 14.54 0.24

2.80 0.74 8.31 14.5 12.51 1.5 14.55 0.12

2.81 4.0 8.32 2.1 12.52 0.43 15.1 0.16

2.82 1.6 8.33 2.0 12.53 9.0 16.1 1.1

2.83 17.7 8.34 1.2 12.54 0.23 16.2 3.2

2.84 5.8 8.35 2.4 12.55 0.17 16.3 0.43

2.85 1.1 8.36 2.1 12.56 4.9 17.1 1.9

2.86 0.93 8.37 1.6 12.57 1.8 18.1 13.7

2.87 12.9 8.38 14.3 12.58 4.5 18.2 4.4

2.88 0.88 8.39 13.4 12.59 1.6 19.1 1.8

2.89 16.4 8.40 6.7 12.60 0.54 20.1 0.98

2.90 5.2 8.41 23.3 12.61 0.79 20.2 0.60

2.91 0.40 8.42 30.0 12.62 0.24 21.1 0.13

2.92 0.17 8.43 3.9 12.63 1.1 22.1 1.6

2.93 0.08 8.44 22.1 12.64 0.55 23.1 0.23

2.94 0.26 8.45 1.4 12.65 0.45 23.2 0.13

2.95 0.11 8.46 11.3 12.66 2.1 23.3 0.40

2.96 0.13 8.47 12.1 12.67 3.9 23.4 0.09

2.97 0.14 8.48 6.2 12.68 0.98 23.5 0.08

2.98 0.15 8.49 22.0 12.69 2.6 23.6 0.07

2.99 7.4 8.50 - 13.1 3.2 23.7 1.6

2.100 0.12 8.51 30.0 13.2 0.21 23.8 0.18

2.101 0.35 8.52 - 13.3 1.0 23.9 0.14

2.102 0.58 8.53 - 13.4 0.17 23.10 0.22

2.103 0.50 8.54 25.1 13.5 1.4 23.11 1.4

2.104 1.5 9.1 0.22 13.6 0.10 23.12 0.65

2.105 0.93 9.2 0.10 13.7 0.26 23.13 0.45

2.106 8.2 9.3 0.09 13.8 0.22 23.14 0.65

2.107 4.9 9.4 0.61 13.9 0.81 23.15 21.5

2.108 0.30 9.5 22.1 13.10 0.45 24.1 0.07

2.109 0.79 9.6 9.4 13.11 0.23 24.2 0.08

3.1 0.40 9.7 1.9 13.12 0.11 24.3 0.17 3.2 0.27 9.8 0.81 13.13 0.23 25.1 0.14

3.3 1 .3 9.9 9.2 13.14 1 .9 26.1 7.2

3.4 0.56 9.10 12.2 13.15 0.16 27.1 0.20

3.5 0.66 9.1 1 0.18 13.16 0.19 27.2 1 .2

3.6 2.3 9.12 0.16 13.17 0.18 27.3 0.15

3.7 10.6 9.13 0.63 13.18 0.13 28.1 24.4

3.8 0.69 9.14 1 .6 13.19 0.67 29.1 13.1

3.9 0.26 9.15 2.1 13.20 0.26 29.2 0.31

3.10 4.5 9.16 0.26 13.21 0.21 30.1 0.33

3.1 1 4.3 9.17 0.61 13.22 0.73 31 .1 1 .7

3.12 1 .2 9.18 14.9 13.23 1 .2 31 .2 0.20

3.13 1 .7 9.19 0.28 13.24 0.20 32.1 0.07

3.14 0.22 9.20 0.08 13.25 0.22 32.2 0.20

3.15 0.35 9.21 0.06 13.26 0.20 32.3 0.07

3.16 4.7 9.22 0.24 13.27 0.12 32.4 0.81

3.17 0.88 9.23 0.40 13.28 3.4 33.1 0.16

4.1 0.21 9.24 0.20 13.29 0.61 33.2 0.13

4.2 0.19 9.25 2.5 13.30 0.36 33.3 2.3

4.3 0.22 9.26 0.25 13.31 0.50 33.4 0.52

4.4 0.15 9.27 0.64 13.32 0.41 34.1 0.17

4.5 1 .5 9.28 0.69 13.33 1 .8 35.1 0.07

4.6 0.97 9.29 0.19 13.34 4.7 35.2 0.33

4.7 0.12 9.30 0.23 13.35 0.29 35.3 26.9

4.8 0.46 9.31 0.55 13.36 1 .6

4.9 0.40 9.32 0.10 13.37 2.6

4.10 1 .1 9.33 0.34 13.38 0.69

In view of their ability to inhibit the enzyme(s) acetyl-CoA carboxylase, the compounds of general formula (I) according to the invention and the corresponding salts thereof are theoretically suitable for the treatment, including preventative treatment of all those diseases or conditions which may be affected or which are mediated by the inhibition of the enzyme(s) acetyl-CoA carboxylase, in particular ACC2, activity. Accordingly, the present invention relates to a compound of general formula (I) as a medicament.

Furthermore, the present invention relates to the use of a compound of general formula (I) for the treatment and/or prevention of diseases or conditions which are mediated by the inhibition of acetyl-CoA carboxylase enzyme(s), in particular ACC2, in a patient, preferably in a human.

In yet another aspect the present invention relates a method for treating, including preventing a disease or condition mediated by the inhibition of acetyl-CoA

carboxylase enzyme(s) in a mammal that includes the step of administering to a patient, preferably a human, in need of such treatment a therapeutically effective amount of a compound of the present invention, or a pharmaceutical composition thereof.

Diseases and conditions mediated by inhibitors of acetyl-CoA carboxylases embrace metabolic and/or cardiovascular and/or neurodegenerative diseases or conditions.

According to one aspect the compounds of the present invention are particularly suitable for treating diabetes mellitus, in particular Type 2 diabetes, Type 1 diabetes, and diabetes-related diseases, such as ishyperglycemia, metabolic syndrome, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, dyslipidemia, hypertension, hyperinsulinemia, and insulin resistance syndrome, hepatic insulin resistance, including complications such as macro- and microvascular disorders, including thromboses, hypercoagulable and prothrombotic states (arterial and venous), high blood pressure, coronary artery disease and heart failure, increased abdominal girth, hypercoagulability, hyperuricemia, micro- albuminemia.

According to another aspect the compounds of the present invention are particularly suitable for treating overweight, obesity, including visceral (abdominal) obesity, nonalcoholic fatty liver disease (NAFLD) and obesity related disorders, such as for example weight gain or weight maintenance Obesity and overweight are generally defined by body mass index (BMI), which is correlated with total body fat and estimates the relative risk of disease. BMI is calculated by weight in kilograms divided by height in meters squared (kg/m ² ). Overweight is typically defined as a BMI of 25-29.9 kg/m ² , and obesity is typically defined as a BMI of 30 kg/m ² or greater.

According to another aspect the compounds of the present invention are particularly suitable for treating, inclduing preventing, or delaying the progression or onset of diabetes or diabetes-related disorders including Type 1 (insulin-dependent diabetes mellitus, also referred to as "IDDM") and Type 2 (noninsulin-dependent diabetes mellitus, also referred to as "NIDDM") diabetes, impaired glucose tolerance, insulin resistance, hyperglycemia, pancreatic beta cell degeneration and diabetic

complications (such as macro- and microvascular disorders, atherosclerosis, coronary heart disease, stroke, peripheral vascular disease, nephropathy,

hypertension, neuropathy, and retinopathy).

In addition the compounds of the present invention are suitable for treating

dyslipidemias in general and more specifically elevated lipid concentrations in the blood and in tissues, dysregulation of LDL, HDL and VLDL, in particular high plasma triglyceride concentrations, high postprandial plasma triglyceride concentrations, low HDL cholesterol concentration, low apoA lipoprotein concentrations, high LDL cholesterol concentrations, high apoB lipoprotein concentrations, including

atherosclerosis, coronary heart disease, cerebrovascular disorders, diabetes mellitus, metabolic syndrome, obesity, insulin resistance and/or cardiovascular disorders.

ACC inhibition may lead to a centrally stimulating effect on food intake. Therefore compounds of the present invention may be suitable for treating eating disorders such as anorexia nervosa.

In addition the compounds of the present invention may provide neuroprotective effects in patients with Parkinson's disease, Alzheimer's disease, hypoxia, ischemia, amyotrophic lateral sclerosis or glioma and may improve cognitive scores in

Alzheimer's diseases patients. Further diseases and conditions mediated by inhibitors of acetyl-CoA carboxylases embrace but are not limited to:

A. disorders of fatty acid metabolism and glucose utilization disorders; disorders in which insulin resistance is involved;

B. hepatic disorders and conditions related thereto, including:

fatty liver, hepatic steatosis, non-alcoholic hepatitis, non-alcoholic

steatohepatitis (NASH), alcoholic hepatitis, acute fatty liver, fatty liver of pregnancy, drug-induced hepatitis, iron storage diseases, hepatic fibrosis, hepatic cirrhosis, hepatoma, viral hepatitis;

C. skin disorders and conditions and those associated with polyunsaturated fatty acids, such as

- eczema, acne, sebaceous gland diseases, psoriasis, keloid scar formation or prevention, other diseases releated to mucous membrane fatty acid

composition;

D. primary hypertriglyceridemia or secondary hypertriglyceridemias following

familial histiocytic reticulosis, lipoprotein lipase deficiency, hyperlipoproteinemias, apolipoprotein deficiency (e.g. apoCII or apoE deficiency);

E. diseases or conditions related to neoplastic cellular proliferation, for example benign or malignant tumors, cancer, neoplasias, metastases, carcinogenesis;

F. diseases or conditions related to neurological, psychiatric or immune disorders or conditions;

G. other diseases or conditions in which inflammatory reactions, cell differentiation and/or other ACC-mediated aspects may for example be involved are:

- atherosclerosis such as, for example (but not restricted thereto), coronary sclerosis including angina pectoris or myocardial infarction, stroke, ischemic, stroke and transient ischemic attack (TIA), - peripheral occlusive disease,

- vascular restenosis or reocclusion,

- chronic inflammatory bowel diseases such as, for example, Crohn's disease and ulcerative colitis,

- pancreatitis,

- sinusitis,

- retinopathy, ischemic retinopathy,

- adipose cell tumors,

- lipomatous carcinomas such as, for example, liposarcomas,

- solid tumors and neoplasms such as, for example (but not restricted thereto), carcinomas of the gastrointestinal tract, of the liver, of the biliary tract and of the pancreas, endocrine tumors, carcinomas of the lungs, of the kidneys and the urinary tract, of the genital tract, prostate carcinomas, breast cancer (in particular breast cancer with BRCA1 mutations), etc.,

- tumors in which ACC is up regulated,

- acute and chronic myeloproliferative disorders and lymphomas, angiogenesis

- neurodegenerative disorders including Alzheimer's disease, multiple sclerosis, Parkinson's disease, epilepsy,

- erythemato-squamous dermatoses such as, for example, psoriasis,

- acne vulgaris,

- other skin disorders and dermatological conditions which are modulated by PPAR,

- eczemas and neurodermatitis,

- dermatitis such as, for example, seborrheic dermatitis or photodermatitis,

- keratitis and keratoses such as, for example, seborrheic keratoses, senile keratoses, actinic keratoses, photo-induced keratoses or keratosis follicularis,

- keloids and keloid prophylaxis,

- bacterial infections,

- fungal infections,

- warts, including condylomata or condylomata acuminata

- viral infections such as, for example, human hepatitis B virus (HBV), hepatitis C virus (HCV), West Nile virus (WNV) or Dengue virus, human

Immunodeficiency virus (HIV), poxvirus and Vaccinia virus (W), HCMV, influenza A, human papilloma viral (HPV) venereal papillomata, viral warts such as, for example, molluscum contagiosum, leukoplakia,

- papular dermatoses such as, for example, lichen planus,

- skin cancer such as, for example, basal-cell carcinomas, melanomas or cutaneous T-cell lymphomas,

- localized benign epidermal tumors such as, for example, keratoderma, epidermal naevi,

- chilblains;

- high blood pressure,

- polycystic ovary syndrome (PCOS),

- asthma,

- cystic fibrosis,

- osteoarthritis,

- lupus erythematosus (LE) or inflammatory rheumatic disorders such as, for example rheumatoid arthritis,

- vasculitis,

- wasting (cachexia),

- gout,

- ischemia/reperfusion syndrome,

- acute respiratory distress syndrome (ARDS)

- viral diseases and infections

- lipodystrophy and lipodystrophic conditions, also for treating adverse drug effect;

- myophathies and lipid myopathis (such as carnitine palmitoyltransferase I or II deficiency);

H. formation of muscles and a lean body or muscle mass formation.

The dose range of the compounds of general formula (I) applicable per day is usually from 0.001 to 10 mg, for example from 0.01 to 8 mg per kg body weight of the patient. Each dosage unit may conveniently contain from 0.1 to 1000 mg, for example 0.5 to 500 mg.

The actual therapeutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age and weight of the patient, route of administration and severity of disease. In any case the combination will be administered at dosages and in a manner which allows a therapeutically effective amount to be delivered based upon patient's unique condition.

Pharmaceutical Compositions

Suitable preparations for administering the compounds of formula (I) will be apparent to those with ordinary skill in the art and include for example tablets, pills, capsules, suppositories, lozenges, troches, solutions, syrups, elixirs, sachets, injectables, inhalatives and powders etc. The content of the pharmaceutically active compound(s) is advantageously in the range from 0.1 to 90 wt.-%, for example from 1 to 70 wt.-% of the composition as a whole.

Suitable tablets may be obtained, for example, by mixing one or more compounds according to formula (I) with known excipients, for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants. The tablets may also consist of several layers.

Combination Therapy

The compounds of the invention may further be combined with one or more, preferably one additional therapeutic agent. According to one embodiment the additional therapeutic agent is selected from the group of therapeutic agents useful in the treatment of diseases or conditions associated with metabolic diseases or conditions such as for example diabetes mellitus, obesity, diabetic complications, hypertension, hyperlipidemia.

Therefore a compound of the invention may be combined with one or more additional therapeutic agents selected from the group consisting of anti-obesity agents

(including appetite suppressants), agents which lower blood glucose, anti-diabetic agents, agents for treating dyslipidemias, such as lipid lowering agents, antihypertensive agents, antiatherosclerotic agents, anti-inflammatory active ingredients, agents for the treatment of malignant tumors, antithrombotic agents, agents for the treatment of heart failure and agents for the treatment of complications caused by diabetes or associated with diabetes. Suitable anti-obesity agents include 1 1 beta-hydroxy steroid dehydrogenase-1 (1 1 beta-HSD type 1 ) inhibitors, stearoyl-CoA desaturase-1 (SCD-1 ) inhibitors, MCR- 4 agonists, cholecystokinin-A (CCK-A) agonists, monoamine reuptake inhibitors, sympathomimetic agents, beta3 adrenergic agonists, dopamine agonists,

melanocyte-stimulating hormone analogs, 5HT2c agonists, melanin concentrating hormone antagonists, leptin (the OB protein), leptin analogs, leptin agonists, galanin antagonists, lipase inhibitors, anorectic agents, neuropeptide-Y antagonists (e.g., NPY Y5 antagonists), ΡΥγ3-3β (including analogs thereof), thyromimetic agents, dehydroepiandrosterone or an analog thereof, glucocorticoid agonists or antagonists, orexin antagonists, glucagon-like peptide-1 agonists, ciliary neurotrophic factors, human agouti-related protein (AGRP) inhibitors, ghrelin antagonists, GOAT (Ghrelin O-Acyltransferase) inhibitors, histamine 3 antagonists or inverse agonists,

neuromedin U agonists, MTP/ApoB inhibitors (e.g., gut-selective MTP inhibitors), opioid antagonists, orexin antagonists, and the like.

Preferred anti-obesity agents for use in the combination aspects of the present invention include gut-selective MTP inhibitors CCKa agonists, 5HT2c agonists, MCR4 agonists, lipase inhibitors, opioid antagonists, oleoyl-estrone, obinepitide, pramlintide (Symlin®), tesofensine (NS2330), leptin, liraglutide, bromocriptine, orlistat, exenatide (Byetta®), AOD-9604 (CAS No. 221231 -10-3) and sibutramine.

Suitable anti-diabetic agents include sodium-glucose co-transporter (SGLT) inhibitors, 1 1 beta-hydroxy steroid dehydrogenase-1 (1 1 beta-HSD type 1 ) inhibitors, phosphodiesterase (PDE) 10 inhibitors, diacylglycerol acyltransferase (DGAT) 1 or 2 inhibitors, sulfonylureas (e.g., acetohexamide, chlorpropamide, diabinese,

glibenclamide, glipizide, glyburide, glimepiride, gliclazide, glipentide, gliquidone, glisolamide, tolazamide, and tolbutamide), meglitinides, alpha-amylase inhibitors (e.g., tendamistat, trestatin and AL-3688), alpha-glucoside hydrolase inhibitors (e.g., acarbose), alpha-glucosidase inhibitors (e.g., adiposine, camiglibose, emiglitate, miglitol, voglibose, pradimicin-Q, and salbostatin), PPAR gamma agonists

(e.g.,balaglitazone, ciglitazone, darglitazone, englitazone, isaglitazone, pioglitazone, rosiglitazone and troglitazone), PPAR alpha/ gamma agonists (e.g., CLX-0940, GW- 1536, GW-20 1929, GW-2433, KRP-297, L-796449, LR-90, MK-0767 and SB- 219994), biguanides (e.g., metformin), GLP-1 derivatives, glucagon-like peptide 1 (GLP-1 ) agonists (e.g., Byetta™, exendin-3 and exendin-4), GLP-1 receptor and glucagon receptor co-agonists, glucagon receptor antagonists, GIP receptor antagonists, protein tyrosine phosphatase-1 B (PTP-1 B) inhibitors (e.g.,

trodusquemine, hyrtiosal extract), SIRT-1 activators (e.g. reservatrol), dipeptidyl peptidease IV (DPP-IV) inhibitors (e.g., sitagliptin, vildagliptin, alogliptin, linagliptin and saxagliptin), insulin secretagogues, GPR1 19 agonists, GPR40 agonists, TGR5 agonists, MNK2 inhibitors, GOAT (Ghrelin O-Acyltransferase) inhibitors, fatty acid oxidation inhibitors, A2 antagonists, c-jun amino-terminal kinase (JNK) inhibitors, insulins, insulin derivatives, fast acting insulins, inhalable insulins, oral insulins, insulin mimetics, glycogen phosphorylase inhibitors, VPAC2 receptor agonists and glucokinase activators.

Preferred anti-diabetic agents are metformin, a glucagon-like peptide 1 (GLP-1 ) agonists (e.g., ByettaTM), GLP-1 receptor and glucagon receptor co-agonists, sodium-glucose co-transporter (SGLT) inhibitors, 1 1 beta-hydroxy steroid

dehydrogenase-1 (1 1 beta-HSD type 1 ) inhibitors and DPP-IV inhibitors (e.g.

sitagliptin, vildagliptin, alogliptin, linagliptin and saxagliptin).

Preferably, compounds of the present invention and/or pharmaceutical compositions comprising a compound of the present invention optionally in combination with one or more additional therapeutic agents are administered in conjunction with exercise and/or a diet.

Therefore, in another aspect, this invention relates to the use of a compound according to the invention in combination with one or more additional therapeutic agents described hereinbefore and hereinafter for the treatment or prevention of diseases or conditions which may be affected or which are mediated by the inhibition of the enzyme(s) acetyl-CoA carboxylase, in particular ACC2, in particular diseases or conditions as described hereinbefore and hereinafter.

In yet another aspect the present invention relates a method for treating, including preventing a disease or condition mediated by the inhibition of acetyl-CoA

carboxylase enzyme(s) in a patient that includes the step of administering to the patient, preferably a human, in need of such treatment a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of one or more additional therapeutic agents described in

hereinbefore and hereinafter,

The use of the compound according to the invention in combination with the additional therapeutic agent may take place simultaneously or at staggered times.

The compound according to the invention and the one or more additional therapeutic agents may both be present together in one formulation, for example a tablet or capsule, or separately in two identical or different formulations, for example as a so- called kit-of-parts.

Consequently, in another aspect, this invention relates to a pharmaceutical composition which comprises a compound according to the invention and one or more additional therapeutic agents described hereinbefore and hereinafter, optionally together with one or more inert carriers and/or diluents.

Further aspects of the invention include the use of a compound according to the invention or a salt thereof as a crop protection agent to combat and/or prevent fungal infestations, or to control other pests such as weeds, insects, or acarids that are harmful to crops. Another aspect of the invention relates to the use of a compound according to the invention or a salt thereof for controlling and/or preventing plant pathogenic microorganisms, for example plant pathogenic fungi. Therefore one aspect of the invention is a compound according to the formula (I) or a salt thereof for use as a fungicide, insecticide, acaricide and/or herbicide. Another aspect of the invention relates to an agricultural composition comprising a compound of the present invention together with one or more suitable carriers. Another aspect of the invention relates to an agricultural composition comprising a compound of the present invention in combination with at least one additional fungicide and/or systemically acquired resistance inducer together with one or more suitable carriers.

Examples The Examples that follow are intended to illustrate the present invention without restricting it. The terms "ambient temperature" and "room temperature" are used interchangeably and designate a temperature of about 20 °C.

Preliminary remarks:

As a rule, 1 H-NMR and/or mass spectra have been obtained for the compounds prepared. The R _f values are determined using Merck silica gel 60 F ₂ 5 ₄ plates and UV light at 254 nm.

Experimental Part

The following abbreviations are used above and hereinafter:

aq. aqueous

ACN acetonitrile

AcOH acetic acid

BOC tert-butoxy-Carbonyl-

BuLi butyllithium

CDI N,N-carbonyldiimidazole

CDT N,N-carbonylditriazole

CyH cyclohexane

DBAD di-tert-butyl azodicarboxylate

DCM dichloromethane

DIAD diisopropyl azodicarboxylate

DIBAIH diisobutyl aluminium hydride

DIPE diisopropyl ether

DIPEA N,N-diisopropylethylamine

DMAP 4-dimethylaminopyridine

DMF N,N-dimethylformamide

DMSO dimethyl sulfoxide

EtOAc ethyl acetate

EtOH ethanol

Ex example

FA formic acid

HATU 2-(1 H-7-azabenzotriazol-1 -yl)-1 , 1 ,3,3-tetramethyluronium hexafluorophosphate

HOBt hydroxybenzotriazole

LAH lithium aluminium hydride

MeOH methanol

m.p. melting point

MsCI methanesulfonyl chloride

n.d. not determined

NMP N-methyl-2-pyrrolidone

Pd/C palladium on activated carbon

PE petroleum ether

PG protecting group

r.t. room temperature (about 20°C)

sat. saturated

TBME fe/f-butyl methyl ether

TEA triethylamine

TF / TFA trifluoroacetic acid

THF tetrahydrofuran

TBAF tetrabutylammonium fluoride

TBTU 2-(1 H-benzotriazol-1 -yl)-1 , 1 ,3,3-tetramethyluronium

tetrafluoroborat

Analytical methods

1. HPLC

Method A

Analytical column: Sunfire C18 (Waters); 2.5 pm; 2.1 x 50 mm; column temperature: 60°C; flow: 1.5 mL/min; detection 210-500 nm. Method B

Analytical column: X-terra' ^M MS C18 (Waters); 2.5 pm; 4.6 x 30 mm; column temperature: r.t.; flow: 1 .0 mL/min; detection 210-420 nm.

Method C

Analytical column: XBridge C18 (Waters); 1.7 pm; 2.1 x 50 mm; column temperature: 60°C; flow: 1.3 mL/min; detection 210-500 nm.

Method D

Analytical column: XBridge C18 (Waters); 3.5 pm; 4.6 x 50 mm; column temperature: 40°C; flow: 1.5 mL/min; detection 210-500 nm.

(incl. 0.2% NH ₄ OH) (incl. 3% water)

0.0 95 5

0.2 95 5

2.2 5 95

2.3 5 95

2.4 0 100

2.6 0 100

Analytical column: XBridge C18 (Waters); 2.5 pm; 3.0 x 30 mm; column temperature: 40°C; flow: 1 .3 mL/min;

Method F

Analytical column: StableBond C18 (Agilent); 3.5 pm; 4.6 x 75 mm; column temperature: r.t.; flow: 1 .6 mL/min; detection 230-254 nm.

Method G

Analytical column: Zorbax StableBond C18 (Agilent); 3.5 pm; 4.6 x 75 mm;

column temperature: r.t.; flow: 1 .6 mL/min; detection 230-254 nm.

Method H

time (min) Vol% water Vol% acetonitrile (incl. 0.13% TFA)

0.18 95 5

2.00 2 98

2.20 2 98

2.30 95 5

Analytical column: Microsorb 100-3 C18 (Varian); 3.0 m; 4.6 x 30 mm;

column temperature: r.t.; flow: 3.5 mL/min; detection 210-380 nm.

Method I

Analytical column: Zorbax StableBond C18 (Agilent); 3.5 pm; 4.6 x 75 mm;

column temperature: r.t.; flow: 0.8 mL/min; detection 230-254 nm.

Method J

Analytical column: XTerra C18 (Waters); 4.6x50mm; 3.5pm; column temperature: 40°C; flow: 1 .0 mL/min; detection 230-254 nm.

Method K

Vol% water

time (min) Vol% methanol

(incl. 0.1 % TFA) 0.0 95 5

1 .3 0 100

2.5 0 100

2.6 95 5

Analytical column: Sunfire C18 (Waters); 3.5 pm; 4.6 x 50 mm; column temperature: 40°C; flow: 1.5 mL/min; detection 210-500 nm.

Method L

Analytical column: XBridge C18 (Waters); 1 .7 pm; 2.1 x 50 mm; column temperature: 60°C; flow: 1.0 mL/min; detection 210-500 nm.

Method M

Analytical column: Sunfire C18 (Waters); 3.5 pm; 4.6 x 50 mm; column temperature: 40°C; flow: 1.5 mL/min; detection 210-500 nm.

Method N

Vol% water Vol% acetonitrile

time (min)

(incl. 0.1 % TFA) (incl. 0.08% TFA

0.0 95 5

2.0 0 100 2.5 0 100

2.6 95 5

Analytical column: Sunfire C18 (Waters); 3.5 pm; 4.6 x 50 mm; column temperature: 40°C; flow: 1 .5 mL/min; detection 210-500 nm.

Method O

Analytical column: XBridge C18 (Waters); 2.5 pm; 3.0 x 30 mm; column temperature: 40°C; flow: 1 .3 mL/min;

Method P

Analytical column: Sunfire C18 (Waters); 3.5 pm; 4.6 x 50 mm; column temperature: 40°C; flow: 1.5 mL/min; detection 210-500 nm.

Method Q

Vol% water Vol% methanol

time (min)

(incl. 0.1 % FA) (incl. 0.1 % FA)

0.0 90 10

2.5 2 98

6.0 2 98 Analytical column: XBridge C18 (Waters); 3.5 pm; 2.1 x 50 mm; column temperature: 35°C; flow: 0.8 mL/min; detection 220-320 nm.

Method R

Analytical column: XBridge C18 (Waters); 3.5 pm; 2.1 x 50 mm; column temperature: 25°C; flow: 1.0 mL/min; detection 220-320 nm.

Method S

Analytical column: XBridge C18 (Waters); 3.5 pm; 2.1 x 30 mm; column temperature: 35°C; flow: 1.0 mL/min; detection 220-320 nm.

Method T

Analytical column: Sunfire C18 (Waters); 3.5 pm; 4.6 x 50 mm; column temperature: 40°C; flow: 1.5 mL/min; detection 210-500 nm.

Method U Vol% water Vol% methanol time (min)

(incl. 0.2% FA) (incl. 3% water)

0.0 95 5

0.2 95 5

2.2 5 95

2.3 5 95

2.4 0 100

2.6 0 100

Analytical column: Zorbax StableBond C18 (Agi ent); 1 .8 pm; 3.0 x 30 mm;

column temperature: 40°C; flow: 1.3 mL/min;

Method V

Analytical column: Sunfire C18 (Waters); 3.5 pm; 4.6 x 50 mm; column temperature: 40°C; flow: 1 .5 mL/min; detection 210-500 nm.

Method W

Analytical column: Sunfire C18 (Waters); 3.5 pm; 4.6 x 50 mm; column temperature: 40°C; flow: 1 .5 mL/min; detection 210-500 nm.

Method X Vol% water Vol% methanol time (min)

(incl. 0.2% FA) (incl. 3% water)

0.0 95 5

1 .0 10 90

2.2 10 90

2.3 0 100

2.5 0 100

Analytical column: Zorbax StableBond C18 (Agilent); 1 .8 pm; 3.0 x 30 mm;

column temperature: 40°C; flow: 1.3 mL/min;

Method Y

Analytical column: XTerra C18 (Waters); 4.6x50mm; 3.5pm; column temperature: r.t. ; flow: 1 .0 mL/min; detection 210-420 nm.

Method Z

Analytical column: Zorbax StableBond C18 (Agilent); 1 .8 pm; 3.0 x 30 mm;

column temperature: r.t.; flow: 1 .6 mL/min; Method AA

Analytical column: Sunfire C18 (Waters); 3.5 m; 4.6 x 50 mm; column temperature: 60°C; flow: 2 mUmin;

Method AB

Analytical column: Gemini C18 (Phenomenex); 2.5 pm; 3.0 x 30 mm;

column temperature: 40°C; flow: 1 .3 mL/min

Method AC

Analytical column: XBridge C18 (Waters); 3.0 pm; 4.6 x 20 mm;

column temperature: r.t.; flow: 3.5 mL/min; Method AD

Analytical column: XBhdge C18 (Waters); 2.5 pm; 3.0 x 30 mm;

column temperature: 60°C; flow: 1.3 mL/min;

Method AE

Analytical column: Zorbax 300SB-C8 (Agilent); 3.5 pm; 4.6 x 150 mm; column temperature: 35°C; flow: 1.0 mL/min;

Method AF

Analytical column: XBhdge C18 (Waters) 2.5 pm; 3.0 x 30 mm; column temperature: r.t.; flow: 1 .6 ml/min. 2. GC

Method A

Analytical column: SLB-5MS 15 m, ID 100 μΜ, df 0.10 μΜ.

Average velocity 45 cm/s, carrier gas : He, split ratio: 300 : 1 , injector temp: 250 °C, injection volume: 1 μΙ_.

Initial temp: 60 °C, initial time: 1 .0 min , solvent delay: 0.6 min , rate: 50 °C/min, final temp: 250 °C, final time: 1.0 min.

Preparation of Starting Compounds

Intermediate 1

4-lodo-1 H-pyridin-2-one

To 10.0 g (41 .8 mmol) 2-chloro-4-iodopyridine in 100 mL AcOH are added 17.1 g (208 mmol) NaOAc and the reaction mixture is heated at 180°C for 2 h in a microwave oven. DCM and water are added to the reaction mixture and the layers are seperated. The organic layer is washed with water, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The crude product is triturated with TBME.

C ₅ H ₄ INO (M= 221 .0 g/mol),

ESI-MS: 222 [M+H] ⁺

R _f (TLC): 0.3 (silica gel DCM/MeOH 9/1 )

Intermediate 2

Example 12.1 (general route)

4-lodo-/V- ropyl-2-pyridone

To 2.0 g (9.05 mmol) 4-iodo-2-pyridone in 10 mL DMF are added 1 .00 mL (10.9 mmol) 1 -bromopropane and 3.13 g (22.6 mmol) K ₂ CO ₃ . The reaction mixture is stirred at r.t. over night. The reaction is quenched by the addition of water. The resulting mixture is extracted with EtOAc. The organic layer is washed with aq. NaHC0 ₃ solution, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The residue is purified by column chromatography (silica gel, heptane/EtOAc . 70/30 - 50/50)

C ₈ HiolNO (M= 263.1 g/mol)

ESI-MS: 264 [M+H] ⁺

R _t (HPLC): 1 .51 min (method E)

The following compounds are prepared analogously to example 12.1

Intermediate 3

5-lsopropoxypicolinaldehyde

I3a Methyl 5-isopropoxypicolinate

To 2.7 g (17.6 mmol) methyl 5-hydroxypicolinate in 20 mL ACN and 5 mL DMF are added 6.09 g (44.1 mmol) K2CO3 and 5.0 mL (52.9 mmol) 2-bromopropane. The reaction mixture is stirred at reflux for 5 h and at r.t. over night. The mixture is filtered and the solvent is removed under vacuo. The residue is partitioned between EtOAc and water. The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo.

C10H13NO3 (M= 195.2 g/mol) ESI-MS: 196 [M+H] ⁺

Rt (HPLC): 3.34 min (method F)

I3b 5-lsopropoxypicolinaldehyde

1 .3 g (6.56 mmol) methyl 5-isopropoxypicolinate are added to 10 mL toluene and cooled down to -70°C. Then 9.84 mL (9.84 mmol) DIBAIH (1 mol/l in toluene) are added and stirring is continued for 1 h at -70°C. The reaction is quenched by the addition of a pH7 buffer solution and extracted with TBME. The organic layer is washed with water, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo.

C9H11 NO2 (M= 165.2 g/mol)

ESI-MS: 166 [M+H] ⁺

Rf (TLC): 0.79 (silica gel; PE/EtOAc = 1/1 )

Intermediate 4

Example 14.1 (general route)

2-Eth nyl-5-isopropoxypyridine

To 1 .00 g (6.05 mmol) 5-isopropoxypicolinaldehyde in 20 mL methanol are added 1 .67 g (12.1 mmol) K ₂ C0 ₃ followed by 1 .4 g (7.26 mmol) dimethyl 1 -diazo-2- oxopropylphosphonate. After stirring at r.t. over the weekend the reaction mixture is diluted with EtOAc and washed consecutively with NaHC0 ₃ solution and water. The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo.

C10H11 NO (M= 161 .2 g/mol)

ESI-MS: 162 [M+H] ⁺

Rf (TLC): 0.28 (silica gel, PE/EtOAc 8/2)

The following compounds are prepared analogously to example 14.1

For example I4.2 the reaction conditions are 4 h at r.t.

For examples I4.3 and I4.4 the reaction conditions are 16 h at r.t. Mass TLC retention

Ex. Starting material Product structure spec factor

result (method)

0.28

162 (silica gel,

14.1

[M+H] ⁺ PE/EtOAc

8/2)

0.75

196 (silica gel,

I4.2

[M+H] ⁺ PE/EtOAc

6/4)

0.45

160 (silica gel,

I4.3

[M] ⁺ PE/EtOAc

8/2)

160

I4.4 n.d.

[M] ⁺

Intermediate 5

Example 15.1 (general route)

5-tert-Butyl-2-iodobenzonitrile

To 1 .0 g (5.74 mmol) 2-amino-5-tert-butylbenzonitrile in 7.5 mL 4 M aq. HCI at 0°C is added 0.4 g (5.80 mmol) sodium nitrite in 2 mL water followed by 1 .60 g (9.64 mmol) Kl in 2 mL water. The reaction mixture is warmed to r.t. and extracted with EtOAc. The organic layer is washed with 10% aq. Na ₂ S ₂ 0 ₅ solution and sat. NaCI solution, dried with MgS0 ₄ and the solvent is removed in vacuo. The crude product is purified by column chromatography (silica gel, CyH/EtOAc 100/0 -»90/10).

C11 H12IN (M= 285.1 g/mol)

ESI-MS: 286 [M+H] ⁺ Rt (HPLC): 1 .77 min (method H)

The following compounds are prepared analogously to example 15.1

Intermediate 6

Example 16.1 (general route)

2-Ethox -4-iodopyridine

2.0 g (8.35 mmol) 2-chloro-4-iodopyridine and 3.4 mL (9.19 mmol) sodium ethoxide are added to 15 mL ethanol and stirred at reflux over night. The solvent is evaporated in vacuo and the residue is partitioned between water and DCM. The organic layer is dried (Na ₂ S0 ₄ ) and the solvent is removed in vacuo. The crude product is purified by column chromatography (silica gel, DCM/MeOH 100/0 96/4).

C ₇ H ₈ INO (M= 249.1 g/mol)

ESI-MS: 250 [M+H] ⁺

Rt (HPLC): 3.43 (method B)

The following compounds are prepared analogously to example 16.1

For example I6.3 the reaction mixture is stirred at r.t. over night.

For example I6.4 tBuOH is used as solvent and KOtBu is used for deprotonation of the benzylic alcohol. The reaction conditions are 16 h at 50 °C.

Intermediate 7

4-lodo-2- ropoxy-pyridine

0.58 g (25.06 mmol) sodium are carefully added to 40 mL n-propanol by several portions. The mixture is stirred until the metal is dissolved completely (ca. 45min).

Then 6.00 g (25.1 mmol) 2-chloro-4-iodo-pyridine are slowly added to the mixture.

The mixture is stirred at reflux for 3 h. The reaction is quenched by the addition of some water. The solvent is removed in vacuo and to the residue are added 20 mL

DMF/MeOH. The mixture is filtrated and the filtrate is purified by HPLC

(MeOH/H ₂ 0/NH ₃ ).

C ₈ HiolNO (M= 263.1 g/mol)

ESI-MS: 264 [M+H] ⁺

R _t (HPLC): 2.15 min (method E) Intermediate 8

4-lodo-2-(2-methoxy-ethox -pyridine

2.00 g (8.35 mmol) 3-iodo-l -chloropyridine are added to 5.00 mL (63.3 mmol) anhydrous 2-methoxyethanol. Then 316 mg (12.5 mmol) sodium hydride are added carefully. The reaction mixture is stirred at reflux over night. The mixture is allowed to cool to r.t, quenched with water and extracted with DCM.The organic layer is dried with Na ₂ S0 ₄ and the solvent is evaporated in vacuo. The crude product is purified by column chromatography (silica gel; DCM /MeOH 100/0 -»90/10).

C ₈ HiolN0 ₂ (M= 279.1 g/mol)

ESI-MS: 280 [M+H] ⁺

R _f (TLC): 0.9 (silica gel, DCM/MeOH 9/1 )

Intermediate 9

Example 19.1 (general route)

-Bromo-2-(2-methoxyethoxy)pyridine

0.25 mL 2-methoxyethanol (3.17 mmol) are added to a mixture of 80 mg (3.17 mmol) sodium hydride in 5 mL THF. The reaction mixture is stirred at r.t. for 10 min before 500 mg (2.1 1 mmol) 2,5-dibromopyridine are added. After 5 h at 75°C the reaction mixture is diluted with half sat.aq. NaHC0 ₃ solution and extracted with EtOAc. The organic layer is dried with MgS0 ₄ and the solvent is removed in vacuo. The crude product is purified by column chromatography (silica gel, PE/EtOAc 85/15).

C ₈ Hi ₀ BrNO ₂ (M= 232.1 g/mol)

ESI-MS: 232 [M+H] ⁺

R _t (HPLC): 1 .72 min (method E)

The following compounds are prepared analogously to example 19.1

For examples I9.2-5 the reaction mixture is is stirred at 50 °C over night.

For example I9.4 and I9.5 DMF is used as solvent.

Intermediate 10

4-lodo-2-isopropoxy-pyridine

To 2.30 g (10.4 mmol) 4-iodo-1 H-pyridin-2-one in 130 ml_ DCM are added 0.88 ml_ (1 1 .4 mmol) 2-propanol and 3.00 (1 1 .4 mmol) triphenylphosphine. After cooling down to 0 °C 2.23 ml_ (1 1 .4 mmol) DIAD are added dropwise. After 5 min the cooling is removed and the mixture is stirred at r.t. for 2 h.The reaction mixture is washed with water and brine, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The crude product is purified by column chromatography (silica gel, heptane/EtOAc 90/10). C ₈ HiolNO (M= 263.1 g/mol)

ESI-MS: 264 [M+H] ⁺

R _t (HPLC): 3.72 (method Q)

Intermediate 11 Example 11 1 .1 (general route)

2-Bromo-5-ethoxy-pyridine

2.51 g (22.99 mmol) 1 -bromoethane and 1 .99 g (14.37 mmol) K ₂ C0 ₃ are added to a mixture of 1 .0 g (5.75 mmol) 2-bromo-5-hydroxypyridine in 100 mL ACN. The mixture is stirred at reflux over night. Then the reaction mixture is poured onto water and extracted with TBME. The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed under vacuo. The residue is purified by column chromatography (silica gel, PE/EtOAC 1 /1 ).

C ₇ H ₈ BrNO (M= 202.1 g/mol)

ESI-MS: 202 [M+H] ⁺

Rt (HPLC): 1 .7 min (method AB)

The following compounds are prepared analogously to example 11 1 .1

For example 11 1 .4 DMF is used as solvent and the reaction mixture is stirred at

140 °C for 16 h.

Intermediate 12

5-Hydroxy-pyrimidine

a)

10.0 g (63.0 mmol) 5-bromopyridine, 6.80 g (125 mmol) sodium methoxide and 200 ml_ MeOH are stirred in a sealed tube at 1 10°C over night. The reaction mixture is allowed to cool to r.t. and the solvent is removed in vacuo. The residue is dissolved in water and extracted with DCM. The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed under reduced pressure. The crude product is used without further purification.

C ₅ H ₆ N ₂ 0 (M= 1 10.1 g/mol)

ESI-MS: 1 1 1 [M+H] ⁺

R _t (HPLC): 0.32 min (method AC) b)

An autoclave is charged with 13.1 g (1 19 mmol) 5-methoxy-pyrimidine and 250 ml Methanol. 66.8 g (1 .19 mol) KOH are added and the mixture is stirred at 125 °C over night. After this the mixture is neutralized with AcOH to pH 6-7 and then concentrated under vacuo. The residue is triturated four times with hot MeCN and the combined extracts are concentrated under vacuum. The resulting crude product is purified by flash chromatography (EtOAc 100%).

C H ₄ N ₂ O (M= 96.09 g/mol)

ESI-MS: 95 [M-H]-

Intermediate 13

5-(4-Hydroxy-phenoxy)-pyrimidine

a)

To 1 .00 g (4.99 mmol) 4-(benzyloxy)phenol and 794 mg (4.99 mmol) 5-bromo- pyrimidine in 5 mL DMF are added 3.25 g (9.99 mmol) CS2CO3 and the reaction mixture is stirred at 120°C for 6 h in a microwave oven. Then the reaction mixture is diluted with water and extracted with EtOAc. The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The residue is purified by HPLC

(MeOH/H ₂ 0/NH ₃ ).

Ci ₇ Hi ₄ N ₂ 0 ₂ (M= 278.3 g/mol)

ESI-MS: 279 [M+H] ⁺

R _t (HPLC): 2.02 min (method E) b)

A mixture of 250 mg (0.898 mmol) 5-(4-benzyloxy-phenoxy)-pyrimidine and 20 mL

THF is charged with 20 mg Pd/C and stirred under an atmosphere of hydrogen (5 bar) at 25°C for 5.5 h. Then the reaction m ixture is filtrated, and the solvent is removed in vacuo. The crude product is used without further purification.

CioH ₈ N ₂ 0 ₂ (M= 188.2 g/mol)

ESI-MS: 189 [M+H] ⁺

R _t (HPLC): 1 .16 min (method E)

Intermediate 14

Example 114.1 (general route)

5-Bromo-2-cyclopentyloxy-pyrimidine

36.3 μΙ_ (0.40 mmol) cyclopentanol and 38.7 mg (0.20 mmol) 5-bromo-2-chloro- pyrimidine are added to 1 .5 mL dioxane and cooled down to 0 °C. Then the reaction mixture is charged with 24.0 mg NaH. After removing of the cooling bath the reaction mixture is stirred at r.t. over night. The reaction is quenched by the addition of water. The solvent is removed under vacuo and the residue is dissolved in DCM, washed with water and dried with MgS04. The solvent is removed under reduced pressure. The crude product is used without further purification.

C ₉ HnBrN ₂ 0 (M= 243.1 g/mol)

ESI-MS: 243 [M+H] ⁺

R _f (TLC): 2.07 (method AA)

The following compounds are prepared analogously to example 114.1

For example 114.3 the crude product is purified by column chromatography (silica gel,

PE/EtOAc 9/1 );

For examples 114.4-7 THF is used as solvent and the product is purified by column chromatography.

Intermediate 15

Example 115.1 (general route)

-(5-lodopyridin-2-yloxy)pyrimidine

A mixture of 550 mg (2.18 mmol) 5-(5-bromopyridin-2-yloxy)pyrimidine and 2.5 ml_ 1 ,4-dioxane is charged with 42 mg (0.22 mmol) Cul, 650 mg (4.36 mmol) Nal and 50 μΙ (0.44 mmo) Ν, Ν-dimethylethylendiamine. The reaction mixture is stirred at 1 10°C over night. The mixture is allowed to cool down to r.t. and diluted with EtOAc. The mixture is washed with 5% aq. ammonia solution and water. The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo to yield the desired product without further purification.

C ₉ H ₆ IN ₃ 0 (M= 299.1 g/mol)

ESI-MS: 300 [M+H] ⁺

Rt (HPLC): 1 .63 min (method E)

The following compounds are prepared analogously to example 115.1

Mass HPLC

Ex. Starting material Product structure spec retention

result time

e use ary- rom e can e syn esze accor ngy o

Intermediate 16

Example 116.1 (general route)

1 -lodo-4-isobutoxybenzene

3.0 g (13.64 mmol) 4-iodophenol, 1 .6 mL (15.00 mmol) 1 -bromo-2-methylpropane and 7.5 g (54.54 mmol) K ₂ C0 ₃ are added to 30 mL DMF and stirred at 80°C for 4 h. Afterwards the reaction mixture is diluted with water and extracted with EtOAc. The organic layer is washed with diluted aq. NaOH (2x) and water (2x), dried with MgSO ₄ and the solvent is removed in vacuo. The crude product is used without further purification.

C10H13IO (M= 276.1 g/mol)

ESI-MS: 276 [M*] ⁺

Rt (HPLC): 1 .39 min (method X)

The following compounds are prepared analogously to example 116.1

For example 116.2 the reaction conditions are 2 d at 120 °C.

For example 116.9 the reaction time is 24 h.

Intermediate 17

-(Pyrimidin-5-yloxy)-phenyl trifluoromethanesulfonate

A mixture of 620 mg (3.30 mmol) of the phenol and 1 .29 g (3.62 mmol) N- phenyltrifluoromethanesulfonimide in 10 mL DCM is cooled down to 0°C. 502 μΙ (3.62 mmol) TEA are added dropwise and stirring is continued for 1 h at constant temperature. Then the cooling is removed and the reaction mixture is stirred at r.t. over night. The reaction is quenched by the addition of water and extracted with DCM. The organic layer is washed with sat. aq. NaHC03 solution, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The crude product is purified by flash chromatography (silica gel, CyH/EtOAc 70/30 60/40).

Cii H ₇ F ₃ N ₂ 0 ₄ S (M= 320.3 g/mol)

ESI-MS: 321 [M+H] ⁺ R _t (HPLC): 1 .88 min (method E)

Intermediate 18

Example 118.1 (general route)

2-lodo-5- 4-methoxyphenyl)pyrazine

To 5.00 g (28.7 mmol) 5-bromo-pyrazine-2-ylamine in 150 mL dioxane and 50 mL MeOH are added 4.58 g (30.2 mmol) 4-methoxyphenyl boronic acid, 0.13 g (0.17 mmol) PdCI ₂ (dppf)xCH ₂ CI ₂ and 28.7 mL (57.5 mmol) aq. 2N Na ₂ C0 ₃ solution and the reaction mixture is stirred under reflux for 7 h. The amount of solvent is reduced to some extent and EtOAc and water are added and the layers are separated. The org. layer is washed with aq. NaHC0 ₃ solution, dried with MgS0 ₄ and the solvent is removed in vacuo. The residue is triturated with TBME.

b)

In a light protected flask, 4.10 g (20.4 mmol) 5-(4-methoxyphenyl)-pyrazin-2 -amine are added to 140 mL carbon tetrachloride. After cooling down to 0 °C 4.12 mL (34.6 mmol) tert-butyl nitrite and 6.72 g (26.5 mmol) iodine are added sequently. Then cooling is removed and the reaction mixture is stirred at ambient temperature over night. The reaction mixture is diluted with DCM and washed sequently with aq.

Na ₂ S ₂ 0 ₅ solution and water. The organic layer is dried with MgS0 ₄ and the solvent is removed in vacuo. The residue is triturated with TBME and purified by column chromatography (silica gel, PE/EtOAc 6/4).

CiiH ₉ IN ₂ 0 (M= 312.1 g/mol)

ESI-MS: 313 [M+H] ⁺

Rt (HPLC): 3.10 min (method G)

The following compounds are prepared analogously to example 118.1

Intermediate 19

Example 119.1 (general route)

1 -lodo-2-methyl-4-propoxybenzene

3.44 mL (45.8 mmol) 1 -propanol is added to an ice cold mixture of 3.42 g (30.5 mmol) KOtBu in 18 mL DMF. After stirring the mixture for 10 min 1 .80 g (7.63 mmol) 4-fluoro-1 -iodo-2-methylbenzene are added and the reaction mixture is stirred at 80°C for 3 h. The reaction is quenched by the addition of a sat. aq. NH ₄ CI solution and extracted with EtOAc (2x). The combined organic layers are washed with sat. aq. NH ₄ CI solution and brine, dried with Na ₂ SO ₄ and the solvent is removed in vacuo. The crude product is purified by column chromatography (silica gel, heptane/ EtOAc 9/1 ).

C10H13IO (M= 276.1 g/mol)

EI-MS: 276 [M] ⁺

Rt (GC): 4.31 min (method A)

The following compounds are prepared analogously to example 119.1

For example 116.2 the reaction mixture is stirred at r.t. for 3 h.

Intermediate 20

1 -lodo-2-methoxy-4- ropoxybenzene

a)

To 1 .50 g (7.39 mmol) 4-bromo-3-methoxy-phenol and 1.36 g (1 1 .1 mmol) 1 -bromo- propane in 10 mL DMF are added 2.04 g (14.8 mmol) K2CO3 and the reaction mixture is stirred at 80°C over night. The reaction mixture is diluted with water and extracted with DCM. The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo.

Ci ₀ Hi ₃ BrO (M= 245.1 g/mol)

ESI-MS: 245 [M+H]+.

R _t (HPLC): 2.12 (method E) b)

A mixture of 3.64 g (14.9 mmol) 1 -bromo-2-methoxy-4-propoxybenzene and 100 mL THF is cooled down to -78 °C. 1 1 .1 mL (17.8 mmol) BuLi (1 .6M solution in hexane) are added via a syringe. The mixture is stirred for 5 min at constant temperature. Then a mixture of 5.65 g (22.3 mmol) l ₂ in 10 mL THF is added via a syringe until a yellow color persisted. The mixture is allowed to reach r.t. he solvent is removed in vacuo and the residue is purified by column chromatography (silica heptane/EtOAc 1/1 ).

C10H13IO2 (M= 292.1 g/mol)

EI-MS: 292 [M] ⁺ .

Rt (GC): 4.64 (method A)

Intermediate 21

2-lodo-5-propoxy-benzamide

a)

2.97 ml_ 32.7 mmol) 1 -bromopropane and 299 mg (1 .80 mmol) Kl are added to a mixture of 3.39 g (24.5 mmol) K2CO3 and 200 ml_ acetone. The mixture is stirred for 30 min under reflux. Then 5.00 g (18.0 mmol) methyl-5-hydroxy-2-iodobenzoate are added and the resulting mixture is refluxed for 2 h. One more equivalent of 1 - bromopropane and K2CO3 is added and refluxing is continued over night. The reaction is quenched by the addition of water and extracted with EtOAc. The organic layer is dried with Na ₂ SO ₄ and the solvent is removed in vacuo. The crude product is purified by column chromatography (silica gel, heptane/EtOAc 100/0 - 60/40).

The product is used without further characterization,

b)

A mixture of 4.12 g (12.9 mmol) methyl-5-propoxy-2-iodobenzoate and 60 ml_ MeOH is charged with 129 ml_ (258 mmol) 2N aq. NaOH solution. The resulting mixture is stirred at 50 °C for 3 h. Then the mixture was acidified to pH5 with 1 M aq. HCI and extracted with EtOAc (2x). The combined organic layers are washed with water and brine, dried with Na ₂ SO ₄ and the solvent is removed in vacuo.

The crude product from the previous saponification is added to 30 ml_ THF, charged with 2.04 g (12.6 mmol) CDI and stirred at r.t. for 1 h. More 0.5 eq CDI are added and stirring is continued for 20 min. To this mixture are added dropwise 20 ml_ of 35% ammonia in water and the resulting reaction mixture is stirred at r.t. for 5 min. The solvent is partly removed in vacuo until precipitation of a white solid occurs. The product is filtered and dried at 40 °C in vacuo. C10H12NIO2 (M= 305.1 g/mol)

ESI-MS: 306 [M+H] ⁺

Rt (HPLC): 2.98 (method Q)

Intermediate 22

1 -lodo-2-cyano-4-propoxy-benzene

To 1 .40 g (4.59 mmol) 2-iodo-5-propoxy-benzamide in 40 mL DMF are added 1 .67 mL (22.9 mmol) SOCI2 and the reaction mixture is stirred at 1 15 °C for 1 h. The reaction is quenched by the the addition of water and extracted with EtOAc (3x). The combined organic layers are washed with water and brine, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The crude product is purified by column chromatography (silica gel, heptane/EtOAc 100/0 60/40).

C10H10INO (M= 287.1 g/mol)

EI-MS: 287 [M] ⁺

R _t (GC): 4.84 (method A)

Intermediate 23

Example 123.1 (general route)

2- 4-Methoxyphenyl)-5-((trimethylsilyl)ethynyl)pyrazine

A mixture of 2.30 g (7.37 mmol) 2-iodo-5-(4-methoxyphenyl)pyrazine and 1 .56 mL (1 1 .1 mmol) ethynyltrimethylsilane in 30 mL THF is charged with 0.12 g (0.15 mmol) bis(triphenylphosphine)dichloropalladium, 0.03 g (15.0 mmol) Cul and 3.01 mL (22.1 mmol) TEA. After stirring at r.t. for 4h the reaction mixture is diluted with DCM and washed with 50 mL aq. 5% ammonia solution (1x) and 50 mL water (1x). The organic layer is dried with MgS0 ₄ and the solvent is removed in vacuo. The residue is treated with PE/EtOAc (8/2), filtered through a plug of silica gel and the solvent is again removed in vacuo. The product is used without further purification.

Ci ₆ Hi ₈ N ₂ OSi (M= 282.4 g/mol)

ESI-MS: 283 [M+H] ⁺

Rf (TLC): 0.6 (silica gel; PE/EtOAc 8/2)

The following compounds are prepared analogously to example 123.1

For examples I23.2, I23.3 and I23.7 PdCI ₂ (dppf)xCH ₂ CI ₂ is used as catalyst.

For example I23.4 -6 and I23.8 the silane is added under cooling.

For examples I23.5 and I23.8 purification by flash chromatography is necessary.

^* the used aryl-bromide can be synthesized accordingly to WO2008/148867 * ^* the used aryl-iodide can be synthesized accordingly to WO2004/039780

Intermediate 24

Example 124.1 (general route)

2-((tert-Butyldimethylsilyl)ethynyl)-5-p-tolylpyridine

4.6 g (15.00 mmol) 5-bromo-2-((tert-butyldimethylsilyl)ethynyl)pyridine are added to 12 mL methanol and 50 mL 1 ,4-dioxane. Then the mixture is charged with 2.40 g (17.3mmol) p-tolyl-boronic acid, 0.1 g (0.15 mmol) bis(triphenyphosphine)dichloro- palladium and 16.5 mL (33.0 mmol) of a 2N aq. Na ₂ C0 ₃ solution. The reaction mixture is stirred at reflux for 2 h. Then the solvent is removed in vacuo to some extent and the residue is diluted with EtOAc and water. The organic layer is sequently washed with 50mL half sat. Na ₂ C0 ₃ solution (1x) and 50 mL water (1x). The organic layer is dried with MgS0 ₄ and the solvent is removed in vacuo. The residue is treated with DIPE and PE to receive a precipitate which is filtered and dried to yield the desired product. C20H25NS1 (M= 307.5 g/mol)

ESI-MS: 308 [M+H] ⁺

Rf (TLC): 0.4 (silica gel, PE/DCM 1/1 )

The following compounds are prepared analogously to example 124.1

For examples I24.2 and I24.3 Pd(dppf)Cl2 is used as catalyst

Intermediate 25

Example 125.1 (general route)

-Ethynyl-5-(4-methoxyphenyl)pyrazine

To 2.00 g (7.08 mmol) 2-(4-methoxyphenyl)-5-((trimethylsilyl)ethynyl)pyrazine in 50 mL DCM are added 2.08 g (7.44 mmol) TBAF ^* H ₂ 0 and the reaction mixture is stirred at r.t. for 30 min. The mixture is washed with 50 mL water (3x) and the organic layer is dried with MgS0 ₄ and the solvent is removed in vacuo. The crude product is purified by column chromatography (silica gel, PE/EtOAc 100/0 - 80/20).

C13H10N2O (M= 210.2 g/mol) ESI-MS: 21 1 [M+H] ⁺

Rf (TLC): 0.3 (silica gel, PE/EtOAc 8/2)

The following compounds are prepared analogously to example 125.1 For example I25.7 TBAF*3H ₂ 0 is added at 0 °C and stirred at r.t. for 1 h. For examples I25.6 and I25.8 THF is used as solvent.

Intermediate 26

Example 126.1 (general route)

4-Eth nyl-benzoic acid methyl ester

18.1 g (77.9 mmol) 4-trimethylsilanylethynyl-benzoic acid methyl ester are are added to 400 ml_ MeOH, cooled down to 0 °C and charged with 3.24 g (23.4 mmol) K ₂ C0 ₃ . The reaction mixture is stirred for 3 h, then the solvent is removed in vacuo and the resulting residue is purified by column chromatography (silica gel, hexane/TBME 10/1 ).

CioH ₈ 0 ₂ (M= 160.2 g/mol)

EI-MS: 160 [M] ⁺

R _f (TLC): 0.7 (silica gel, CyH/EtOAc 2/1 )

The following compounds are prepared analogously to example 126.1

For example I26.2 2N NaOH solution is used instead of K2CO3 and an aq. work up is done before column chromatography.

TLC

Mass

retention

Ex. Starting material Product structure spec

factor result

(method)

0.7

160 (silica gel,

126.1

[M] ⁺ CyH /EtOAc

/ /

2/1)

Intermediate 27

3-Biphenyl-4-yl-2,3-dibromo-propionic acid

0.81 mL (15.7 mmol) bromine are added dropwise to a mixture of 3.20 g (14.3 mmol) 3-biphenyl-4-yl-acrylic acid and 100 mL tetrachloro-methane. After finishing the addition the reaction mixture is stirred at r.t. for additional 3 h. Afterwards the solvent is removed in vacuo and the crude product is crystalized from PE.

Ci5H ₁₂ Br ₂ 02 (M= 384.1 g/mol)

m.p.: 200-203 °C

Rf (TLC): 0.4 (silica gel, DCM/MeOH/AcOH 9/1/0.01 )

Intermediate 28

Bi henyl-4-yl-propynoic acid

5.00 g (13.0 mmol) 3-biphenyl-4-yl-2,3-dibromo-propionic acid are added to 40 mL tBuOH. Over a period of 25 min 5.80 g (52.1 mmol) KOtBu are added in several portions while keeping the temperature below 35 °C. Then the reaction mixture is stirred at 40°C for 2 h. Again 1 .40 g (12.5 mmol) potassium tert-butoxide are added and the mixture is stirred for additional 2h at 40°C. Then the mixture is allowed to cool to r.t. and poured onto icewater / concentrated HCI. The precipitate is filtered and partitioned between EtOAc and water. The organic layer is washed with water, dried and the solvent is removed in vacuo. The crude product is triturated with PE, filtered and dried at 80°C in vacuo. C15H10O2 (M= 222.2 g/mol)

ESI-MS: 223 [M+H] ⁺

R _f (TLC): 0.4 (silica gel, DCM/MeOH/AcOH 5/1/0.01 )

Intermediate 29

Example 129.1 (general route)

1 -(4-Bromophenyl)propane-2-amine

A mixture of 25.0 g (0.12 mol) 4-bromophenylacetone and 400 mL 7N ammonia in MeOH is charged with 1 .20 g Raney nickel. The mixture is stirred in an hydrogen atmosphere (15 psi) at r.t. over night. Again 0.6 g Raney nickel are added and the mixture is stirred again for 3.5 h. After complete reaction, the mixture is filtrated. The residue is washed with MeOH and the solvent of the filtrate is removed in vacuo. The crude product is used without further purification.

C ₉ Hi ₂ BrN (M= 214.1 g/mol)

ESI-MS: 214 [M+H] ⁺

Rf (TLC): 0.3 (silica gel, DCM/MeOH 9/1 )

The following compounds are prepared analogously to example 129.1

TLC

Mass

retention

Ex. Starting material Product structure spec

factor result

(method)

0.3

214 (silica gel;

129.1

[M+H] ⁺ DCM/MeOH

9/1)

0.2

(silica gel;

152

I29.2 DCM/MeOH/

[M+H] ⁺

NH ₃

9/1/0.02)

Intermediate 30

2- 4-Bromo-phenyl)-propionitrile

An autoclave is charged with 25.0 g (128 mmol) 4-bromobenzylcyanide, 190 mL dimethylcarbonate and 0.900 g (6.51 mmol) K ₂ C0 ₃ and stirred for 16 h at 180°C. Then the reaction mixture is allowed to cool to r.t., the mixture is diluted with EtOAc and washed with water (1x), aq. 10% Na ₂ S ₂ 0 ₃ solution (1x) and brine (1x). The organic layer is dried with MgS0 ₄ and and the solvent is removed in vacuo. The residue is purified by destination (bath temperature 204°C, head temperature 153°C). C ₉ H ₈ BrN (M= 210.1 g/mol)

R _f (TLC): 0.25 (silica gel, CyH/EtOAc 9/1 )

Intermediate 31

2- 4-Bromo-phenyl)-propylamine

A mixture of 3.00 g (14.3 mmol) 2-(4-bromo-phenyl)-propionitrile and 40 mL ammonia solution (7N in methanol) is charged with 0.30 g Raney nickel. The mixture is stirred under an atmosphere of hydrogen (50 psi) at r.t. for 34 h. The mixture is filtered and the solvent is removed in vacuo. The crude product is used without further purification.

C ₉ Hi ₂ BrN (M= 214.1 g/mol)

ESI-MS: 214 [M+H] ⁺

R _t (HPLC): 1 .63 min (method E) Intermediate 32

2-(6-Chloropyridin-3-yl)-acetamide

To 10.0 g (58.3 mmol) (2-chloropyridyl)-5-acetic acid in 150 mL THF are added 9.45 g (58.3 mmol) CDI and the mixture is stirred at 45°C for 1 h. Then 28.0 g (291 mmol) NH4CO3 are added and the mixture is stirred at r.t. over night. The reaction mixture is poured onto water and extracted with EtOAc. The organic layer is dried with MgS0 ₄ and the solvent is removed in vacuo. The residue is triturated with TBME and recrystalized from EtOH.

C7H7CIN2O (M= 170.6 g/mol)

ESI-MS: 171 M+H] ⁺

Rf (TLC): 0.45 (silica gel, DCM/MeOH 9/1 )

Intermediate 33

2-(6-Chloropyridin-3-yl)-ethanamine

To 2.00 g (1 1 .7 mmol) 2-(6-chloropyridin-3-yl)-acetamide in 50 mL THF at 0 °C are added 12.9 ml LAH (c=1 mol/l in THF) by a dropping funnel. Cooling is removed and the reaction mixture is stirred for 1 h at r.t., then 8 ml LAH (c=1 mol/l in THF) are added and the reaction mixture is stirred at r.t. over night. The reaction is carefully quenched by the addition of 2 ml of an aq. NaHC0 ₃ solution (10%). The mixture is filtrated and and the solvent is removed under reduced pressure. The crude product is used without further purification.

C7H9CIN2 (M= 156.6 g/mol)

ESI-MS: 157 [M+H] ⁺

R _t (HPLC): 1 .12 min (method AB) Intermediate 34

N-(1 , 1 -Dimethyl-2-phenyl-ethyl)-formamide

1 1 .3 g (230 mmol) NaCN are added to 60 mL AcOH. A combination of 30 mL AcOH and 60 mL concentrated sulfuric acid is carefully dropped into the NaCN/AcOH mixture while maintaining the temperature below 20 °C. Then 30 mL (195 mmol) 2- methyl-1 -phenyl-2-propanol, in 30 mL acetic acid, are added dropwise to the reaction mixture, again keeping the temperature below 20 °C. After having finished the addition, the reaction mixture is stirred for an additional hour at r.t., poured onto ice water and is finally neutralised with an aq. Na ₂ C03 solution. The resulting mixture is extracted with diethylether. The organic layer is dried with MgS0 ₄ , filtered and the solvent is removed under reduced pressure. The crude product is used without further purification.

C11 H15NO (M= 177.2 g/mol)

ESI-MS: 178 [M+H] ⁺

R _f (TLC): 0.62 (silica gel, DCM/MeOH 9/1 )

Intermediate 35

N-[2-(4-Bromo-phenyl)-1 , 1 -dimethyl-ethyl]-formamide

1 .00 g (5.64 mmol) N-(1 ,1 -dimethyl-2-phenyl-ethyl)-formamide (I34) is added to 8 mL DCM and cooled down to -5 °C. Then 1 .50 g (1 1 .3 mmol) aluminium chloride is added by several portions, stirred for 5 min, before 0.9 g (5.64) bromine is added over a period of 1 min. Having finished the addition, the mixture is stirred for two more minutes at 0 °C, poured onto ice water and extracted with DCM. The organic layer is dried with MgS0 ₄ and the solvent is removed in vacuo.

CnHuBrNO (M= 256.1 g/mol)

ESI-MS: 256 [M+H] ⁺ Rf (TLC): 0.62 (silica gel, DCM/MeOH 9/1 )

Intermediate 36

-(4-Bromo-phenyl)-1 , 1 -dimethyl-ethyl

28.0 g (109 mmol) N-[2-(4-bromo-phenyl)-1 , 1 -dimethyl-ethyl]-formamide (I35) are added to 102 ml_ water and 101 ml_ (1218 mmol) cone. HCI and stirred at reflux for 8 h. Then heating is stopped and the mixture is stirred at r.t. over night. The precipitate is filtered, washed with TBME and dried in vacuo.

CioH _u BrN ^* HCI (M= 264.6 g/mol)

ESI-MS: 228/300 [M+H] ⁺

R _f (TLC): 0.30 (silica gel, DCM/MeOH/NH ₃ 9/1/0.1 )

Intermediate 37

4-(2-(1 -Phenylethylamino)-propyl)phenol

A mixture of 15.0 g (100 mmol) 4-hydroxyphenylaceton and 15.0 ml_ (120 mmol) S- (-)-alpha-methylbenzylamine in 400 ml_ EtOH is charged with 3.00 g Raney nickel. The mixture is stirred in a hydrogen atmosphere (50 psi) at r.t. for 2 days. Then the mixture is filtrated and the solvent is removed in vacuo. The residue is purified by column chromatography (silica gel, DCM/MeOH/NH ₃ 9/1/0.01 ). The resulting product is recrystalized from PE. Then the product is dissolved in a 1/1 mixture of EtOAc and diethylether and cooled down to 0 °C. HCI (solution in diethylether) is added and the precipitate is filtered, washed with diethylether and dried at 70°C in vacuo.

Ci ₇ H ₂ iNO ^* HCI (M= 291 .8 g/mol)

ESI-MS: 256 [M+H] ⁺

R _t (HPLC) : 1 .83 min (method B) Intermediate 38

4-(2-Amino-propyl)-phenol

5.80 g (20.0 mmol) 4-[2-(1 -phenyl-ethylamino)-propyl]-phenol (I37) are added to 300 ml_ MeOH and charged with 0.60 g palladiumhydroxide (20%) on activated carbon. The mixture is stirred in a hydrogen atmosphere (50 psi) at 50°C for 1 h 15 min. Then the mixture is filtrated, the solvent is removed in vacuo and the residue is triturated diethylether. The residue is dried at 80°C in vacuo.

C ₉ Hi ₃ NO ^* HCI (M= 187.7 g/mol)

ESI-MS: 152 [M+H] ⁺

R _f (TLC): 0.1 (silica gel, DCM/MeOH/NH ₃ 9/1/0.01 )

Intermediate 39

-(4-lodophenyl)-butane-2-one

A mixture of 15.1 g (57.6 mmol) 2-(4-iodophenyl)-acetic acid, 8.43 g (86.0 mmol) Ν,Ο-dimethylhydroxylamine, 12.1 g (63.3 mmol) EDC and 1 .57 g (1 1 .5 mmol) 1 - hydroxy-7-azabenzotriazole in 140 ml_ DMF is cooled down to 0 °C. 30.2 ml_ (173 mmol) DIPEA are added slowly and after removing of the ice bath the reaction mixture is stirred at r.t. over night. It is poured onto 1 N aq. HCI and the solids are filtered off and dried in vacuo.

1 1 .7 g (36 mmol) of the above mentioned product are added to 180 ml_ THF and cooled down to 0 °C. 180 ml_ (1 80 mmol) ethylmagnesium bromide (1 mol/l) are added dropwise and the reaction is stirred at 0 °C for 1 h. The reaction is quenched by the addition of a sat. aq. NH ₄ CI solution and extracted with EtOAc. The combined organic layers are washed with brine and dried with Na ₂ S0 ₄ . The solvent is removed in vacuo and the crude product is purified by column chromatography (silica gel, heptane/EtOAc 100/0 -» 95/5).

C10H11 IO (M= 274.1 g/mol)

EI-MS: 274 [M] ⁺

Intermediate 40

1 - 4-lodobenzyl)-propylamine

5.95 g (21 .7 mmol) 1 -(4-iodophenyl)-butane-2-one (I39) are added to 150 mL 2- propanol and transferred into an autoclav. 25.1 g (326 mmol) NH ₄ OAc and 4.09 g (65.1 mmol) NaCNBH ₃ are added and the mixture is stirred at 90 °C over night. The reaction is quenched by the addition of sat. aq. NaHC0 ₃ solution and extracted with EtOAc (3x). The combined organic layers are washed with brine, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The compound is used without further purification.

C10H14IN (M= 275.1 g/mol)

ESI-MS: 276 [M+H] ⁺

Intermediate 41

2-Amino-3- 4-iodophenyl)-propan-1 -ol

A mixture of 28.5 g (75.0 mmol) 2-amino-3-(4-iodophenyl)propanoate hydrochloride in 300 mL ethanol and 300 mL water is added to a mixture of 14.2 g (375 mmol) NaBH ₄ and 600 mL water (gas evolution!) and the resulting mixture is stirred at reflux for 2 h. The ethanol is evaporated in vacuo and the remaining aq. Phase is extracted with DCM (4x). The combined organic layers are dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The compound is used without further purification.

C9H12INO (M= 277.1 g/mol) ESI-MS: 278 [M+H] ⁺

Rt (HPLC): 2.40 (method AD)

Intermediate 42

2- 4-lodophenyl)-1 -methoxymethyl-ethylamine

A mixture of 12.0 g (43.3 mmol) 2-amino-3-(4-iodophenyl)-propan-1 -ol (141 ) and 350 mL THF is cooled down to 0 °C. 3.81 g (95 mmol) NAH (60% in min. oil) are carefully added and the mixture is stirred at 0 °C for 30 min. 3.25 mL (52.0 mmol)

iodomethane are added and cooling is removed. The reaction mixture is stirred at r.t. for 1 h. The mixture is poured onto water and extracted with EtOAc (2x). The combined organic layers are washed with brine, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The compound is used without further purification.

C9H12INO (M= 291 .1 g/mol)

ESI-MS: 292 [M+H] ⁺

Intermediate 43

1 - 4-lodobenzyl)pyrrolidin-2-one

To 140 μΙ (1 .68 mmol) 2-pyrrolidone in 5 mL DMF are added 1 10 mg (2.53 mmol) sodium hydride. Then 500 mg (1 .68 mmol) 4-iodobenzyl bromide are added by several portions and the resulting mixture is stirred at r.t. over night. The solvent is removed in vacuo and the residue is resolved in DCM and water. The layers are separated and the organic layer is dried with Na ₂ S0 ₄ , filtrated and the solvent is removed in vacuo. The crude product is purified by HPLC.

C11 H12INO (M= 301 .1 g/mol)

ESI-MS: 302 [M+H] ⁺ R _f (TLC): 0.6 (silica gel, DCM/MeOH 9/1 )

Intermediate 44

Example 144.1 (general route)

N-(1 -(4-Bromophenyl)propan-2-yl)acetamide

Method I:

A mixture of 24.7 g (1 15 mmol) 1 -(4-bromophenyl)propane-2-amine and 24.2 ml (174 mmol) TEA in 250 m l_ DCM are cooled down to 0 °C. 12.4 m l (1 74 mmol) acetyl chloride are dropped in slowly and the m ixture is stirred for 1 5 m in at constant temperature. The reaction mixture is allowed to warm up to r.t. and stirred for additional 2.5 h. The reaction mixture is washed with water, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The crude product is triturated with diethylether, filtered and dried at 45°C in vacuo.

Cn HuBrNO (M= 256.1 g/mol)

ESI-MS: 256 [M+H] ⁺

Rt (HPLC): 2.60 min (method B)

Method II:

17.0 ml_ (179.7 mmol) acetic anhydride are added to a mixture of 24.2 g (1 13.03 mmol) 1 -(4-bromophenyl)propane-2-amine and 20 ml_ AcOH and the reaction mixture is stirred at r.t. over night. The solvent is evaporated in vacuo, and the residue partitonated between TBME and a saturated aq. NaHC03 solution. The layers are separated and the organic layer is washed with water, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The crude product is triturated with DIPE.

The following compounds are prepared analogously to example 144.1 .

For examples I44.6 and I44.9 and 144.10 DIPEA is used as base.

For example 144.1 1 dimethylcarbamyl chloride is used as acylating agent. For examples 144.12and 144.13 Acetic anhydride is used as acylating agent and the crude products are purified by column chromatography (silica gel, heptane/EtOAc). For examples 144.14 and 144.15 no amine base is used and the reaction is stirred at r.t. over night.

Intermediate 45

Methyl 1 -(4-iodophenyl)propan-2-ylcarbamate

0.53 ml (6.89 mmol) methyl chloroform ate are added to a mixture of 1 .50g (5.75 mmol) 1 -(4-iodophenyl)propane-2-amine and 1 .16 ml pyridine (14.3 mmol) in 30 ml DCM at 0 °C and the reaction mixture is stirred for 1 h at constant temperature. Further DCM is added and the organic solution is consecutivly washed with aq. HCI- solution (0.5 mol/l) and water, dried with MgS0 ₄ and the solvent is removed under reduced pressure. The crude product is used without further purification.

Cii HulN0 ₂ (M= 319.1 g/mol)

ESI-MS: 320 [M+H]+

Rt (HPLC): 1 .96 min (method E) Intermediate 46

lodo-phenyl)-1 -methyl-eth l]-1 , 1 -dimethyl-urea

2.70 g (10.3 mmol) 2-(4-iodo-phenyl)-1 -methyl-ethylamine and 1 .82 mL (12.9 mmol) TEA are added to 40 mL DCM and cooled down to 0°C. The mixture is charged with 1 .78 g (10.9 mmol) CDT stirred at 0-5°C for 15 min. 1 .40 g (31 .0 mmol) dimethyl- amine (gas cylinder) are added and the mixture is stirred at r.t. over night. The mixture is diluted with DCM, washed with a 1 N aq. KHS0 ₄ (2x) solution and water (1x). The organic layer is dried with MgS0 ₄ and the solvent is removed in vacuo. C12H17IN2O (M= 332.18 g/mol)

ESI-MS: 333 [M+H] ⁺

Rt (HPLC): 1 .88 min (method E)

Intermediate 47

Example 147.1 (general route)

-(4-iodophenethyl)acetamide

3.00 g (12.1 mmol) 4-iodophenethylamine and 0.37 g (3.03 mmol) DMAP in 50 mL THF are cooled down to 0 °C. 4.95 g (48.5 mmol) acetic anhydride are added and, after removing of the cooling bath, the reaction mixture is stirred for 5 h at r.t.. The reaction mixture is quenched in ice cold water and extracted with EtOAc. The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The crude product is purified by column chromatography (silica gel, DCM/MeOH 98.5/1 .5).

C10H12INO (M= 289.1 g/mol)

ESI-MS: 290 [M+H] ⁺

Rt (HPLC): 1 .75 min (method E) The following compounds are prepared analogously to example 147.1

Intermediate 48

Example 148.1 (general route)

N-[2-(5-Bromo-pyridin-2-yl)-ethyl]

A mixture of 200 mg (1 .00 mmol) 2-(5-bromopyridin-2-yl)ethanamine, 86.6 μΙ_ (1 .09 mmol) pyridine and 2 mL DCM is charged with 103 μΙ_ (1 .09 mmol) acetic anhydride and stirred at r.t. over night. The mixture is treated with saturated aq. NaHC03 solution and extracted with DCM. The organic layer is dried with Na ₂ S0 ₄ and the solvent is evaporated in vacuo.

C9H11 BrN ₂ 0 (M= 243.1 g/mol)

ESI-MS: 243 [M+H] ⁺

Rt (HPLC): 1 .25 min (method E)

The following compounds are prepared analogously to example 148.1

For example I48.2 pyridine and acetic anhydride are added at 0°C and the crude product is purified by HPLC (MeOH/H ₂ 0/NH ₃ ).

Mass HPLC

Ex. Starting material Product structure spec retention result time

Intermediate 49

N-[2-(4-Hydroxy-phenyl)-1 -methyl-ethyl]-acetamide

1 .88 g (10.0 mmol) 4-(2-amino-propyl)-phenol*HCI and 1 .80 g (21 .0 mmol) NaHC0 ₃ are combined in 50 mL water and cooled down to 0°C. 0.95 mL (10.0 mmol) acetic anhydride, dissolved in 50 mL ACN, are dropped into the mixture over a period of 1 .5 h. The reaction mixture is stirred at r.t. for 72 h. The ACN is evaporated in vacuo and the aq. residue is acidified with HCI (1 N). The mixture is extracted several times with EtOAc. The organic layers are combined, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The crude product is purified by column chromatography (silica gel, DCM/MeOH 95/5).

C11 H15 NO 2 (M= 193.2 g/mol)

ESI-MS: 194 [M+H] ⁺

Rt (HPLC): 1 .85 min (method B)

Intermediate 50

Example 150.1 (general route)

tert-Butyl 1 -(4-bromophenyl)propan-2-ylcarbamate To 25.0 g (1 17 mmol) 1 -(4-bromophenyl)propan-2-amine in 500 mL DCM are added 73 mL of a 2N aq. Na ₂ C0 ₃ solution followed by 26.9 g (123 mmol) di-tert-butyl dicarbonate (in 50 mL DCM) and the resulting mixture is stirred at r.t. for 2 h. 250 mL water are added and the layers are separated. The organic layer is washed with water (2x), dried with MgS0 ₄ and the solvent is removed in vacuo. The crude product is triturated with DIPE and PE.

Ci ₄ H ₂ oBrN0 ₂ (M= 314.2 g/mol)

ESI-MS: 314 [M+H] ⁺

Rt (HPLC): 1 .64 min (method O)

The following compounds are prepared analogously to example 150.1

For example I50.2 and I50.4 TEA is used as base.

Intermediate 51

N-(1 -(4-Bromophenyl)-1 -methyl-ethyl)-acetamide

a) 2-(4-Bromophenyl)-propan-2-ol

20.0 g (100 mmol) 4-bromoacetophenone are added to 300 mL diethylether and cooled down to 0 °C. 35.2 mL MeMgBr (3M in diethylether) are added by a dropping funnel. Cooling is removed and the mixture is stirred at r.t. over night. The reaction quenched by careful addition of 150 mL sat. aq. NH ₄ CI solution and 150 mL water. The resulting mixture is stirred for 20 min. The layers are separated and the org. layer is washed with water (2x), dried with MgS0 ₄ and the solvent is removed in vacuo.

CgHnBrO (M= 215.1 g/mol)

EI-MS: 214 [M+H] ⁺

R _f (TLC): 0.5 min (silica gel, DCM) b) N-(1 -(4-Bromophenyl)-1 -methyl-ethyl)-acetamide

To 21 .0 g (97.6 mmol) 2-(4-bromophenyl)-propan-2-ol in 1 L ACN are added 16.1 mL cone. H ₂ S0 ₄ dropwise while keeping the temperature at 20 °C. The resulting mixture is stirred at r.t. over night. The solvent is removed in vacuo and the residue is partitioned between water and diethylether. The organic layer is washed with water (2x), sat. aq. NaHCOs solution (2x) and water again (1x). The solution is dried with MgS0 ₄ and the solvent is removed in vacuo. The crude product is triturated with PE. CnHuBrNO (M= 256.1 g/mol)

EI-MS: 256 [M+H] ⁺

Rt (HPLC): 1 .08 min (method O)

Intermediate 52

Example 152.1 (general route)

N-(1 -(4-iodophenyl)propan-2-yl)acetamide To 6.00 g (23.4 mmol) N-(1 -(4-bromophenyl)propan-2-yl)acetamide (144.1 ) in 65 mL dioxan are added 0.45 g (2.34 mmol) Cul, 0.50 mL (4.70 mmol) Ν, Ν ^' -dimethyl- ethylendiamine and 7.02 g (46.9 mmol) Nal. The reaction mixture is stirred at 120°C for 70 h. The mixture is allowed to cool to r.t. and half of the solvent is removed in vacuo. EtOAc and diluted aq. ammonia solution are added and the layers are separated. The aq. layer is once more extracted with EtOAc. The organic layers are combined, dried with Na ₂ SO ₄ and the solvent is removed in vacuo. The crude product is triturated with diethylether and dried at 50°C in vacuo.

Cn HuINO (M= 303.1 g/mol)

ESI-MS: 304 [M+H]+

Rt (HPLC): 2.69 min (method Y)

The following compounds are prepared analogously to example 152.1

For the examples I52.5, I52.7 and I52.9 the crude product is purified by column chromatography. For example I52.5 the reaction time is 5 h at 1 10 °C.

For examples 152.10-1 1 the reaction time is 16 h at 120 °C.

HPLC

Mass

retention

Ex. Starting material Product structure spec

time result

(method)

304

152.1 2.69 (Y)

[M+H] ⁺

Chiral Chiral

316

I52.2 1.82 (E)

[M+H] ⁺

330

I52.3 3.38 (B)

[M+H] ⁺

318

I52.4 2.17 (E)

[M+H] ⁺

Intermediate 53

Example 153.1 (general route)

Tnfluoromethanesulfonic acid 4-(2-acetylamino-propyl)-phenyl ester

To 1 .00 g (5.18 mmol) N-[2-(4-hydroxy-phenyl)-1 -methyl-ethyl]-acetamide (I49) and 1 .88 g (5.25 mmol) N-phenyltrifluoromethanesulfonimide in 50 mL DCM are added 0.76 mL (5.50 mmol) TEA at 0°C. The reaction mixture is stirred at 0°C for 1 h and at r.t. for 6 h. Further 0.1 g (0.280 mmol) N-phenyltrifluoromethanesulfonimide are added and the mixture is stirred at r.t. over night. The mixture is washed with water and sat. aq. NaHC0 ₃ solution, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The residue is purified by column chromatography (silica gel, EtOAc 100%) and the resulting product is further crystalized from PE and dried at 45°C in vacuo. Ci ₂ Hu F ₃ N0 S (M= 325.3 g/mol)

ESI-MS: 326 [M+H] ⁺

Rt (HPLC): 2.75 min (method B)

The following compounds are prepared analogously to example 153.1

Intermediate 54

2-(4-lodo-phenyl)-1 -methyl-ethyl

Method I:

9.00 g (29.69 mmol) N-[2-(4-iodo-phenyl)-1 -methyl-ethyl]-acetamide (152.1 ) are added to 150 ml_ HCI (4N) and the reaction mixture is stirred at reflux over night. Then the mixture is diluted with soda lye and extracted with EtOAc. The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo.

C9H12IN (M= 261 .1 g/mol)

ESI-MS: 262 [M+H] ⁺

R _t (HPLC): 1 .44 (method AA)

Method II:

To 6 g (16.6 mmol) [2-(4-iodo-phenyl)-1 -methyl-ethyl]-carbamic acid tert-butyl ester (I52.5) in 40 ml DCM are added 46.5 ml HCI (1 .25mol/l in EtOH) and the solution is stirred at 70 °C over night. The solvent is removed in vacuo and the residue is resolved in water and washed with DCM. The aqueous layer is basified with 4N aq. NaOH solution and extracted two times with DCM. The org. layers are combined, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo.

Intermediate 55

-(4-lodo-phenyl)-1 , 1 -dimethyl-ethylamine

To 1 .10 g (2.93 mmol) [2-(4-iodophenyl)-1 , 1 -dimethyl-ethyl]-carbamic acid tert-butyl ester (I52.9) in 8 ml methanol are added 7.04 ml HCI (1.25 mol/l in MeOH) and the solution is stirred at 50 °C for 3 h. The solvent is removed under reduced pressure and the resulting crude product is purified by HPLC (H ₂ 0/MeOH/NH ₃ ).

CioHulN (M= 275.1 g/mol)

ESI-MS: 276 [M+H] ⁺

Rt (HPLC): 1 .77 (method E)

Intermediate 56

Example 156.1 (general route)

N- 4-((tert-Butyldimethylsilyl)ethynyl)phenethyl)acetamide

To 2.40 g (8.30 mmol) of the iodide I47.1 in 50 ml of THF are added 1 .28 g (9.15 mmol) ethynyl-tert-butyldimethylsilane and 2.33 ml (16.6 mmol) diisopropylamine. After cooling down to 0 °C 0.58 g (0.83 mmol) bis(triphenyl-phosphine)dichloro- palladium and 158 mg (0.83 mmol) Cul are added and the solution is stirred at r.t. over night. The reaction mixture is filtrated and the solvent is removed in vacuo. The residue is resolved in EtOAc and washed with water. The organic layer is dried with MgS04, filtrated and solvent is removed in vacuo. The residue is purified by column chromatography (silica gel, DCM/MeOH 10/0 20/1 ).

Ci ₈ H ₂₇ NOSi (M= 301 .5 g/mol)

ESI-MS: 302 [M+H]+

R _t (HPLC): 2.32 min (method E)

The following compounds are prepared analogously to example 156.1

For example I56.8 the acetylene is added on latest stage and the reaction time is 1 h at r.t. For example I56.5 the reaction time 1 h at 0 °C.

HPLC

Mass

Starting retention

Ex. Product structure spec

material time

result

(method)

Intermediate 57

N-(2-{4-[(tert-Butyldimethylsilanyl)-ethynyl]-phenyl}-1 -methyl-ethyl)-acetam

To 2.40 g (7.38 mmol) trifluoromethanesulfonic acid 4-(2-acetylamino-propyl)-phenyl ester (153.1 ), 1 .52 mL (8.12 mmol) (tert-butyldimethylsilyl)acetylene and 2.56 mL (18.4 mmol) diisopropylamine in 25 mL ACN are added 72.3 mg (0.089 mmol)

[1 , 1 ^' bis(diphenylphosphino)ferrocene]dichloropalladium(ll), complex with dichloro- methane and 17.2 mg (0.09 mmol) Cul, and the mixture is stirred at r.t. for 24 h. Again 0.69 mL (3.69 mmol) (tert-butyldimethyl-silyl)acetylene are added and stirring is continued for additional 24 h. The mixture is poured onto aq. ammonia solution (5%), diluted with EtOAc and the organic layer is separated. The organic layer is washed with diluted aq. ammonia solution (1x) and water (1x), dried with MgS0 ₄ and the solvent is removed in vacuo. The residue is purified by column chromatography (silica gel; PE/EtOAc 2/8).

Ci ₉ H ₂₉ NOSi (M= 315.5 g/mol)

ESI-MS: 316 [M+H] ⁺

R _f (TLC): 0.4 (silica gel, PE/EtOAc 2/8)

Intermediate 58

Example 158.1 (general route)

N-(4-Ethynylphenethyl)acetamide

To 2.20 g (7.30 mmol) N-(4-((tert-butyldimethylsilyl)ethynyl)phenethyl)acetamide (156.1 ) in 30 ml_ DCM are added 2.24 g (8.03 mmol) TBAF*H ₂ 0 and the mixture is stirred at r.t. over night. The mixture is washed with water (2x). The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The crude product is purified by column chromatography (silica gel, DCM/MeOH 10/0 - 20/1 ).

C12H13NO (M= 187.2 g/mol)

ESI-MS: 188 [M+H] ⁺

Rt (HPLC): 1 .48 min (method E)

The following compounds are prepared analogously to example 158.1

For examples I58.4-9 TBAF*3H ₂ 0 is added at 0°C. The reaction times are 1 h at r.t.. For examples 158.10 and 158.1 1 the desilylation is done with K2CO3 (0.1 eq) in MeOH. The reaction conditions are 3 h at r.t..

Intermediate 59

Example 159.1 (general route)

N- -(4-Ethynylphenyl)propan-2-yl)cyclopropanecarboxamide

To 900 mg (2.73 mmol) N-(1 -(4-iodophenyl)propan-2-yl)cyclopropanecarboxamide (I52.3) and 0.56 mL (3.01 mmol) (tert-butyldimethylsilyl) acetylene in 5 mL THF at 0 °C are added 0.77 mL (5.48 mmol) DIPEA, 96.1 mg (0.14 mmol) bis(triphenyl- phosphine)dichloropalladium and 53.1 mg (0.28 mmol) Cul, and the reaction mixture is stirred at r.t. over night. The mixture is diluted with water and extracted with DCM (2x). The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The residue is purified by column chromatography (silica gel, DCM/MeOH 98/2) to yield the silylated compound. To this substance in DCM are added 949 mg (3.01 mmol) TBAF*3H ₂ 0 and the mixture is stirred at r.t. for 3 h. The mixture is diluted with water and extracted with DCM. The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The crude product is purified by column

chromatography (silica gel, DCM/MeOH 98/2).

C15H17NO (M= 227.3 g/mol)

ESI-MS: 228 [M+H] ⁺

Rt (HPLC): 3.41 min (method B)

The following compounds are prepared analogously to example 159.1

Intermediate 60

{2-[4-(4-Ethoxy-phenylethynyl)-phenyl]-1 -methyl-ethyl}-carbamic acid tert-butyl ester

To 5.00 g (13.8 mmol) [2-(4-iodo-phenyl)-1 -methyl-ethyl]-carbamic acid tert-butyl ester (I52.5) and 2.02 g (13.8 mmol) 4-ethoxyphenylacetylene in 80 ml_ ACN are added 4.46 ml_ (32.2 mmol) TEA, 135.6 mg (0.17 mmol) [1 , 1 ^' -bis(diphenyl- phosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane and 32.3 mg (0.17 mmol) Cul, and the reaction mixture is stirred at r.t. over night. The precipitate is filtered and washed with ACN. The resulting crude product is purified by column chromatography (CyH/EtOAc 100/0 90/10).

C24H29NO3 (M= 379.5 g/mol)

ESI-MS: 380 [M+H] ⁺

Rt (HPLC): 1 .47 min (method E)

Intermediate 61

Example 161 .1 (general route)

{ -[4-(4-Propoxy-phenylethynyl)-phenyl]-propyl}-carbamic acid tert-butyl ester

To 1 .00 g (2.77 mmol) [2-(4-iodo-phenyl)-propyl]-carbamic acid tert-butyl ester (I52.8) and 0.44 g (2.77 mmol) 1 -ethinyl-4-propoxybenzene in 25 ml_ THF are added 0.78 ml_ (5.54 mmol) DIPEA, 40.5 mg (0.06 mmol) [1 , 1 ^' -bis(diphenylphosphino)ferrocene] dichloropalladium(ll) and 10.6 mg (0.055 mmol) Cul. The reaction mixture is stirred at r.t. for 3 h. EtOAc is added and the mixture is washed with diluted aq. ammonia solution (1 x) and water (1 x), dried with MgS0 ₄ and the solvent is removed in vacuo. The crude product is purified by column chromatography (silica gel, PE/EtOAc 9/1 ). C25H31 NO3 (M= 393.5 g/mol)

ESI-MS: 394 [M+H] ⁺

Rt (HPLC): 2.40 min (method E)

The following compounds are prepared analogously to example 161 .1

For example 161 .2 diisopropylamine is used as base.

Mass HPLC

Starting

Ex. Product structure spec retention material(s)

result time

Intermediate 62

1 -[4-(4-Ethoxy-phenylethynyl)-phenyl]-ethyl}-carbamic acid tert-butylester

24.6 g (168 mmol) 1 -ethoxy-4-ethynyl-benzene, 52.8 g (176 mmol) [1 -(4-Bromo- phenyl)-ethyl]-carbamic acid tert-butyl ester (50.2) and 42.6 mL (307 mmol) TEA are added to 400 mL ACN. The mixture is warmed to 65°C. 8.84 g (7.65 mmol)

Pd(PPh ₃ ) ₄ and 2.91 g (15.3 mmol) Cul are added and the reaction mixture is stirred at reflux for 2 h. The mixture is cooled to r.t. and the solvent is removed in vacuo. The crude product is purified by column chromatography (hexane/EtOAC 9: 1 - 3: 1 ). C23H27NO3 (M= 365.5 g/mol)

ESI-MS: 388 [M+Na] ⁺

Rt (HPLC): 2.30 min (method S)

Intermediate 63

1 -(4-((4-Ethoxyphenyl)ethynyl)phenyl)ethanam ine

To 25.0 g (62.90 mmol) tert-butyl 1 -(4-((4-ethoxyphenyl)ethynyl)phenyl)ethyl- carbamate (I62) in 375 mL EtOAc are added 79 mL (315 mmol) HCI (4M in dioxane). The mixture is stirred at r.t. over night, filtered and the obtained precipitate is dried. The crude product is suspended in DCM and sat. NaHC0 ₃ is added until a clear solution is obtained. The layers are separated and the aqueous layer is extracted two more times with DCM. The organic layers are combined, washed with brine (1x), dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The residue is purified by column chromatography (silica gel, heptane/EtOAc/TEA 75/25/1 0/100/1 ).

Ci ₈ Hi ₉ NO (M= 265.4 g/mol)

ESI-MS: 249 [M+H-NH ₃ ] ⁺

R _t (HPLC): 3.14 min (method Q)

Intermediate 64

1 -(4-((4-Ethoxyphenyl)ethynyl)phenyl)propan-2-amine hydrochloride

To 3.30 g (8.70 mmol) tert-butyl 1 -(4-((4-ethoxyphenyl)ethynyl)phenyl)propan-2-yl- carbamate (I60) in 40 mL MeOH are added 20 mL (25 mmol) HCI (1.25M in MeOH).

The mixture is stirred at 70 °C for 7 h. The solvent is removed in vacuo and the crude product is triturated with DIPE and dried in normal atmosphere.

Ci ₈ Hi ₉ NO ^* HCI (M= 315.9 g/mol)

ESI-MS: 280 [M+H] ⁺

Rt (HPLC): 2.00 min (method M)

Intermediate 65

2-(4-((4-Propoxyphenyl)ethynyl)phenyl)propan-1 -amine

To 0.70 g (1.78 mmol) tert-butyl 2-(4-((4-propoxyphenyl)ethynyl)phenyl)propyl- carbamate (161 .1 ) in 5 mL MeOH are added 4.27 mL (5.34 mmol) HCI (1 .25M in MeOH). The mixture is stirred at r.t. over night. The solvent is removed in vacuo and the crude product is treated with aq. NaHCO ₃ solution. The precipitate is filtered, washed with water and dried at 50 °C in vacuo.

Ci ₈ Hi ₉ NO ^* HCI (M= 293.4 g/mol)

ESI-MS: 294 [M+H] ⁺

Rt (HPLC): 2.26 min (method E)

Intermediate 66

2- 4-((2-Cyclobutoxy-pyrimidin-5-ylethynyl)-phenyl]-propylamine

To 0.90 g (2.21 mmol) 2-(4-((2-cyclobutoxy-pyrimidin-5-ylethynyl)-phenyl]-propyl carbamic acid tert-butyl ester (161 .2) in 5 mL dioxane are added 5.30 mL (6.63 mmol) HCI (1 .25M in dioxane). The mixture is stirred at r.t. for 2 h. The mixture is basified with 1 M aq. NaOH solution and extracted with DCM (2x). The org. layers are combined, washed with water (1x), dried with MgSO ₄ and the solvent is removed in vacuo.

C19H21 N3O (M= 307.4 g/mol)

ESI-MS: 308 [M+H] ⁺

R _t (HPLC): 2.15 min (method E) Intermediate 67

2- 4-((2-Methoxy-pyrimidin-5-ylethynyl)-phenyl]-propylamine

To 0.14 g (0.34 mmol) 2-(4-((2-cyclobutoxy-pyrimidin-5-yl-ethynyl)-phenyl]-propyl carbamic acid tert-butyl ester (161 .2) in 1 mL MeOH are added 0.82 mL (1 .03 mmol) HCI (1 .25M in MeOH). The mixture is stirred at r.t. over night and 2 h at 40 °C. Then additional 0.82 mL (1 .03 mmol) HCI (1 .25M in MeOH) are added and the reaction mixture is again stirred for 2 h at 40 °C. The solvent is removed in vacuo and the residue is purified by HPLC (MeOH/H ₂ O/NH ₃ ).

Ci ₆ Hi ₇ N ₃ O (M= 267.3 g/mol)

ESI-MS: 268 [M+H] ⁺

Rt (HPLC): 1 .06 min (method O)

Intermediate 68

-(4-lodophenyl)-1 , 1 -dimethyl-ethylamine

To 1 .10 g (2.93 mmol) 2-(4-iodophenyl)-1 , 1 -dimethyl-ethyl-carbamic acid tert-butyl ester (I52.9) in 10 mL MeOH are added 7.04 mL (8.80 mmol) HCI (1.25M in MeOH).

The mixture is stirred at 50 °C for 3 h. The solvent is removed in vacuo and the residue is purified by HPLC (MeOH/H ₂ O/NH ₃ ).

C9H12IN (M= 275.1 g/mol)

ESI-MS: 276 [M+H] ⁺

R _t (HPLC): 1 .77 min (method E)

Intermediate 69 Example 169.1 (general route)

N-(1 -(4-((2-Chloropyrimidin-5-yl)ethynyl)phenyl)propan-2-yl)acet amide

To 1 .20 g (5.96 mmol) N-(1 -(4-ethynylphenyl)propan-2-yl)acetamide(l58.3) in 10 mL

THF are added 1 .43 g (5.96 mmol) 2-chloro-5-iodopyrimidine, 418 mg (0.60 mmol) bis(triphenylphosphine)dichloropalladium, 56.8 mg (0.30 mmol) Cul and 2.03 mL

(1 1 .9 mmol) DIPEA. The reaction mixture is stirred at r.t. for 4 h. The solvent is removed in vacuo and the residue is purified by column chromatography (silica gel,

DCM/MeOH 98/2).

Ci ₇ Hi ₆ CIN ₃ 0 (M= 313.8 g/mol)

ESI-MS: 314 [M+H] ⁺

R _t (HPLC): 2.12 min (method AA)

The following compounds are prepared analogously to example 169.1

For examples I69.3 and I69.4 additional purification by prep. HPLC is necessary.

For examples I69.5 and I69.6 the reaction mixture is stirred at r.t. over night.

Intermediate 70

N- 1 -(4-((2-Chloropyrimidin-5-yl)ethynyl)phenyl)propan-2-yl)acet ami

To 3.30 g (16.4 mmol) N-(1 -(4-ethynylphenyl)propan-2-yl)acetamide (I58.3) in 40 mL THF are added 2.44 g (16.4 mmol) 2,4-dichloropyrimidine, 57.5 mg (82.0 pmol) bis- (triphenyphosphine)dichloropalladium and 9.10 mL (65.7 mmol) TEA. The reaction mixture is stirred under reflux for 4 h and at r.t. over night. The reaction mixture is filtrated and the solvent is removed in vacuo. The residue is triturated with water and afterwards with diethylether.

Ci ₇ Hi ₆ CIN ₃ 0 (M= 313.8 g/mol)

ESI-MS: 314 [M+H] ⁺

R _t (HPLC): 2.1 1 min (method M)

Intermediate 71

Example 171 .1 (general route)

-((4-(2-acetamidopropyl)phenyl)ethynyl)benzoate

To 10.0 g (63.4 mmol) methyl 3-ethynylbenzoate (J. Org. Chem 1981 , 46, 2280-6) and 7.00 g (23.1 mmol) N-(1 -(4-iodo-phenyl)propan-2-yl)acetamide (152.1 ) in 80 mL DMF are added 100 ml_ TEA, 250 mg (1 .31 mmol) Cul and 1 ,20 g (1 .71 mmol) bis- (triphenylphosphine)-palladium (II) chloride. After stirring over night r.t. the solvents are removed under reduced pressure. The residue is partitioned between EtOAc and diluted aq. NH ₄ CI solution. The organic layer is separated and the aq. layer is extracted with EtOAc (2x).The org. layers are combined, washed with brine, dried with Na ₂ SO ₄ and the solvent is removed in vacuo. The residue is purified by column chromatography (silica gel, EtOAc 100%).

Ci ₇ Hi ₆ CIN ₃ O M= 313.8 g/mol)

R _t (HPLC): 8.75min (method AE)

The following compounds are prepared analogously to example 171 .1

Intermediate 72

Example 172.1 (general route)

-((4-(2-Acetamidopropyl)phenyl)ethynyl)benzoic acid

To a mixture of 6.00 g (17,9 mmol) methyl 3-((4-(2-acetamido-propyl)phenyl)ethynyl)- benzoate (171 .1 ) in 150 ml_ MeOH are added at 0 °C 18 ml_ LiOH solution (3 M in water). The reaction mixture is stirred at r.t. over night. The MeOH is removed in vacuo and the desired product is precipitated by acidification with 2N aq. HCI. The resulting solid is filtered, washed with pentane and dried in vacuo.

C17H16CIN3O M= 313.8 g/mol

ESI-MS: 322 [M+H] ⁺

R _t (HPLC): 7.01 min (method AE)

The following compounds are prepared analogously to example 172.1

Intermediate 73

N- 2-[4-(2-Methanesulfinyl-pyrimidin-4-ylethynyl)-phenyl]-1 -methyl-ethyl}-acetamide

A mixture of 0.30 g (0.922 mmol) N-{1 -methyl-2-[4-(2-methylsulfanyl-pyrimidin-4- ylethynyl)-phenyl]-ethyl}-acetamide (example 14.1 ) in 9 mL DCM is cooled down to 0 °C and charged with 0.27 g (1 .10 mmol; 70% purity) 3-chloroperoxybenzoic acid. The mixture is stirred for 30 min at constant temperature. The mixture is poured onto sat. aq. NaHC0 ₃ solution. The organic layer is separated, dried with Na ₂ S0 ₄ and filtered. The resulting mixture can be used directly used in the following reaction. C18H19N3O2 S (M= 341 .4 g/mol)

ESI-MS: 342 [M+H] ⁺

Rt (HPLC): 2.20 min (method B) Intermediate 74

Example 174.1 (general route)

N-(1 -(4-((4-hydroxyphenyl)ethynyl)phenyl)propan-2-yl)acetamide

4.00 g (19.9 mmol) of N-(1 -(4-ethynylphenyl)propan-2-yl)acetamide (I58.3) and 5,25 g (23,9 mmol) 4-iodophenol are added to 125 ml of a 1 : 1 mixture of DMF and TEA. After cooling down to 0 °C 189 mg (0.99 mmol) Cul and 976 mg (1 ,39 mmol) Pd(PPh ₃ ) ₄ are added. After stirring over night at r.t. the mixture is treated with EtOAc and sat. NH ₄ CI solution. The organic layer is washed with brine, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The residue is purified by column

chromatography (silica gel, EtOAc).

C19H19NO2 (M= 293.4 g/mol)

ESI-MS: 294 [M+H] ⁺

Rt (HPLC): 1 .27 m in (Method U)

The following compounds are prepared analogously to example 174.1

Intermediate 75

2-Oxo-pyrrolidine-3-carboxylic acid

To 0.50 g (3.18 mmol) 2-oxo-pyrollidine-carboxylic acid ethyl ester in 10 mL EtOH are added 5 mL aq. NaOH (1 M) solution. The reaction mixture is stirred at r.t. for 3 h. The EtOH is removed in vacuo and the residue is diluted with water and acidified with aq. HCI (2M) solution. The resulting precipitate is filtered and dried.

C5H7NO3 (M= 129.1 g/mol)

ESI-MS: 130 [M+H] ⁺

Intermediate 76

Thiazole-5-carbox lic acid (2-(4-iodophenyl)-1 -methylethyl)-amide

To 109 mg (0.84 mmol) thiazole-5-carboxylic acid (I54) in 10 mL DMF are added

267 μί (1 .53 mmo.) DIPEA and 246 mg (0.77 mmol) TBTU. After stirring at r.t. for

10 min 200 mg (0.77mmol) of intermediate 54 are added and stirring is continued for

5 h. The reaction mixture is purified directly by HPLC (MeOH/H ₂ O/TFA).

C13H13IN2O3S (M= 372.2 g/mol)

ESI-MS: 373 [M+H] ⁺

R _t (HPLC): 2.14 min (method AA)

Intermediate 77

Example 177.1 (general route)

(4-Ethynylphenyl)-morpholin-4-yl-methanone

To 3.50 g (23.9 mmol) 4-ethynylphenyl benzoic acid in 20 mL THF are added 3.88 g (23.9 mmol) CDI. The mixture is stirred at 60 °C for 30 min and then charged with 2, 1 1 mL (23.9 mmol) morpholine. The complete mixture is stirred under reflux for 5 h and at r.t. for 24 h. The solvent is removed in vacuo and the residue is purified by column chromatography (silica gel, EtOAc 100%).

C13H13NO2 (M= 215.2 g/mol)

ESI-MS: 216 [M+H] ⁺

The following compounds are prepared analogously to example 177.1

For example I77.4 the crude product is purifed by HPLC and the resulting product is isolated as TFA salt.

Preparation of Final Compounds

Example 1

Example 1 .1 (general route)

N-(1 -(4-((4-Chlorophenyl)ethynyl)phenyl)propan-2-yl)acetamide

To 45.5 mg (0.15 mmol) N-(1 -(4-iodophenyl)propan-2-yl)acetamide (152.1 ) and 27.3 mg (0.20 mmol) 1 -chloro-4-ethynylbenzene in 750 μΙ sec-butylamine are added 14.3 (0.02 mmol) bis(triphenyphosphine)dichloropalladium (in 400 μΙ sec-butylamine) followed by 1 .0 mL water.The reaction mixture is stirred at r.t. overnight. The solvent is removed in vacuo and the residue is purified by HPLC (ACN/H ₂ 0/TFA).

Ci ₆ Hi ₈ CINO (M= 31 1.1 g/mol)

ESI-MS: 312 [M+H] ⁺

R _t (HPLC): 1 .35 min (method B)

The following compounds are prepared analogously to example 1 .1

152.1 373

1.25 (A) I25.4 [M+H] ⁺

152.1 369

1.30 (A) I25.5 [M+H] ⁺

152.1 389

1.10 (A) I26.2 [M+H] ⁺

321

152.1 1.24 (A)

[M+H] ⁺

152.1 337

1.15 (A) 15.1 [M+H] ⁺

306

152.1 1.43 (A)

[M+H] ⁺

320

152.1 1.51 (A)

[M+H] ⁺

320

152.1 1.11 (A)

[M+H] ⁺

374

152.1 1.39 (A)

[M+H] ⁺

F

152.1 361

1.02 (A) I25.8 [M+H] ⁺

Example 2

Example 2.1 (general route)

N-(1 -(4-((4-(1 H-Pyrrol-1 -yl)phenyl)ethynyl)phenyl)propan-2-yl)acetamide

To 40.4 mg (0.15 mmol) 1 -(4-iodophenyl)-H-pyrrole and 40.3 mg (0.20 mmol) N-(1 - (4-ethynylphenyl)propan-2-yl)acetamide (I58.3) in 750 μΙ sec-butylamine are added 14.3 mg (0.02 mmol) bis(triphenylphosphine)dichloropalladium (in 400 μΙ sec-butylamine) followed by 1 .0 mL water.The reaction mixture is stirred at r.t. for 72 h. The solvent is removed in vacuo and the residue is purified by HPLC (ACN/H ₂ 0/TFA). C23H22N2O (M= 342.1 g/mol)

ESI-MS: 343 [M+H] ⁺

Rt (HPLC): 1 .35 min (method C)

The following compounds are prepared analogously to example 2.1

For example 2.32 additional purification by column chromatography (silica gel,

DCM/MeOH 10/0 8/2) is necessary.

For examples 2.43-100 the alkyne is dissolved in THF before use. Reaction conditions 5 h at 80 °C (alkyne/aryliodide-ratio = 1 /1 ).

349 2.21

I59.4

[M+H] ⁺ (AA)

336 2.15 9.4**

[M+H] ⁺ (AA)

306 2.01

I59.4

[M+H] ⁺ (AA)

306 2.23

I59.4

[M+H] ⁺ (AA)

I59.4 322

2.12(AA) 116.4 [M+H] ⁺

I59.4 336 2.22 116.1 [M+H] ⁺ (AA)

I59.4 322 2.16 116.6 [M+H] ⁺ (AA)

323 2.12

I59.4

[M+H] ⁺ (AA)

I59.4 352 2.12 I20 [M+H] ⁺ (AA)

I59.4 348 2.23 116.8 [M+H] ⁺ (AA)

I59.4 334 2.19 116.2 [M+H] ⁺ (AA) I59.4 323 2.13 115.3 [M+H] ⁺ (AA)

320 2.11 9.4**

[M+H] ⁺ (AA)

334 2.12

159.1

[M+H] ⁺ (AA)

346 2.27

159.1

[M+H] ⁺ (AA)

366 1.97

159.1

[M+H] ⁺ (AA)

370 2.09

159.1

[M+H] ⁺ (AA)

159.1 349 2.13 16.1 [M+H] ⁺ (AA) o

376 2.24 9.1**

[M+H] ⁺ (AA)

346 2.12

159.1

" [M+H] ⁺ (AA) 346 2.29

159.1

[M+H] ⁺ (AA)

335 2.09

159.1

[M+H] ⁺ (AA)

363 2.20

159.1

[M+H] ⁺ (AA)

389 2.28

159.1

[M+H] ⁺ (AA)

345 1.80

159.1

[M+H] ⁺ (AA)

159.1 392 2.19 I20 [M+H] ⁺ (AA)

159.1 335 2.07 I9.2 [M+H] ⁺ (AA)

159.1 363 2.21 115.3 [M+H] ⁺ (AA)

364 2.01

159.1

[M+H] ⁺ (AA) 329 1.97 8.3**

[M+H] ⁺ (AA)

363 2.08

I58.3

[M+H] ⁺ (AA)

329 1.60 8.3**

[M+H] ⁺ (AA)

350 2.18 8.3**

[M+H] ⁺ (AA)

332 1.96

I58.3

[M+H] ⁺ (AA)

I58.3 372 1.87 114.6 [M+H] ⁺ (AA)

I58.3 386 2.11 114.8 [M+H] ⁺ (AA)

Ci 344 2.04

I58.3

[M+H] ⁺ (AA)

319 1.71

I58.3

[M+H] ⁺ (AA) 314 1.81

2.99 I58.3

[M+H] ⁺ (AA)

334 2.20

2.100 I58.3**

[M+H] ⁺ (AA)

310 2.11

2.101 I59.4

[M+H] ⁺ (AA)

I59.4 309 2.03

2.102

19.1 [M+H] ⁺ (AA)

370 2.19

2.103 I59.4

[M+H] ⁺ (AA)

294 2.00

2.104 I59.4

[M+H] ⁺ (AA)

344 1.89

2.105 I59.4

[M+H] ⁺ (AA)

297

2.106 I58.3 1.04 (P)

[M+H] ⁺

282

2.107 I58.3 0.83 (P)

[M+H] ⁺

358

2.108 I58.3 1.14 (P)

[M+H] ⁺

322 2.03

2.109 I58.3**

[M+H] ⁺ (AA)

^* the used aryl-iodide can be synthesized accordingly to WO2005/103032 for these examples the appropriate aryl-bromide is used

Example 3

Example 3.1 (general route)

N-(1 -(4-((2.4-Dimethoxyphenyl)eth nyl)phenyl)propan-2-yl)acetamide

A mixture of 36.2 mg (0.18 mmol) N-(1 -(4-ethynylphenyl)propan-2-yl)acetamide (I58.3) and 300 μΙ acetone is added to 50.6 mg (0.15 mmol) 1 -bromo-2.4-dimethoxy- benzene followed by a suspension of 14.3 (0.02 mmol) bis(triphenylphosphine)- dichloropalladium in 300 μΙ acetone and 600 μΙ water. After addition of 22.4 mg (0.20 mmol) piperidine the mixture is stirred in a sealed tube for 1 .5 h at 60°C. The solvent is removed in vacuo and the residue is purified by HPLC (ACN/H ₂ 0/TFA).

C21 H23NO3 (M= 337.4 g/mol)

ESI-MS: 338 [M+H] ⁺

Rt (HPLC): 2.56 min (Method D)

The following compounds are prepared analogously to example 3.1

HPLC

Mass

Starting retention

Ex. Structure spec

material(s) time

result

(method)

338

3.1 I58.3 2.56 (D)

[M+H] ⁺

326

3.2 I58.3 2.77 (D)

-0— [M+H] ⁺ 333

3.12 I58.3 2.52 (D)

[M+H] ⁺

322

3.13 I58.3 2.55 (D)

[M+H] ⁺

336

3.14 I58.3 2.60 (D)

[M+H] ⁺

342

3.15 I58.3 3.58 (B)

[M+H] ⁺

285

3.16 I58.3 2.34 (P)

[M+H] ⁺

326

3.17 I58.3 2.47 (P)

[M+H] ⁺

Example 4

Example 4.1 (general route)

N-(1 -(4-((4-ethoxyphenyl)ethynyl)phenyl)propan-2-yl)butyramide

8.41 mg (0.10 mmol) butanoic acid are dissolved in 300 μΙ_ DMF together with 32.1 mg (0.10 mmol) TBTU and 50.0 μΙ_ (0.30 mmol) DIPEA and the mixture is stirred at r.t. for 5 min. 27.9 mg (0.10 mmol) 1 -(4-((4-ethoxyphenyl)ethynyl)phenyl)propan-2- amine (I64) are added and the reaction mixture is stirred at 40°C over night. The mixture is filtered through a plug of alox, eluted with DMF/MeOH (9/1 ) and the solvent is removed in vacuo. The residue is purified by HPLC.

C23H27NO2 (M= 349.5 g/mol)

ESI-MS: 350 [M+H] ⁺

Rt (HPLC): 1 .43 min (Method C)

The following compounds are prepared analogously to example 4.1

For examples 4.27, 4.29, 4.34 and 4.74 the BOC protected amino acid is used for the coupling and the PG is removed afterwards by stirring the compound either in 0.5 mL HCI (1 .25 M in MeOH) at r.t. for 30 min (4.27,4.29 and 4.34) or in a 1 /1 mixture of TFA/DCM at r.t. for 2 h (4.74).

For examples 4.76-80, the reaction mixture is stirred at r.t.

HPLC

Starting Mass

retention

Ex. material Structure spec

time (s) result

(method)

350

4.1 I64 1.43 (C)

[M+H] ⁺

350

4.2 I64 1.43 (C)

[M+H] ⁺

348

4.3 I64 1.40 (C)

[M+H] ⁺

348

4.4 I64 1.40 (C)

[M+H] ⁺

O OH

352

4.5 I64 1.28 (C)

[M+H] ⁺

352

4.6 I64 1.37 (C)

[M+H] ⁺

340

4.31 I64 1.36 (C)

[M+H] ⁺

391

4.32 I64 1.18 (C)

[M+H] ⁺

378

4.33 I64 1.33 (C)

[M+H] ⁺

363

4.34 I64 1.49 (C)

[M+H] ⁺

362

4.35 I64 1.47 (C)

[M+H] ⁺

392

4.36 I64 1.38 (C)

[M+H] ⁺

378

4.37 I64 1.41 (C)

[M+H] ⁺

375

4.38 I64 1.18 (C)

[M+H] ⁺

320

4.39 I63 2.40 (K)

[M+H] ⁺

H

338

4.40 I63 2.36 (K)

[M+H] ⁺

334

4.41 I63 2.39 (K)

[M+H] ⁺

334

4.42 I63 2.37 (K)

[M+H] ⁺

Example 5

Example 5.1 (general route)

N-(1 -(4-((4-ethoxyphenethynyl)phenyl)propan-2-yl)cyclopropanesul fonamide

To 27.9 mg (0.10 mmol) 1 -(4-(4-ethoxyphenethynyl)phenyl)propan-2-amine (I64) in 2 ml_ DCM are added 67.0 μΙ_ (0.48 mmol) TEA followed by 16.9 mg (0.12 mmol) cyclopropanesulfonyl chloride. The reaction mixture is stirred at r.t. over night.

Additional 8.50 mg (0.06 mmol) sulfonyl chloride and 34 μΙ_ (0.24 mmol) TEA are added and stirring is continued for 4 h. The solvent is removed in vacuo and the residue is purified by HPLC (MeOH/H ₂ 0/TFA).

C22H29NO3S (M= 387.5 g/mol) ESI-MS: 388 [M+H] ⁺

R _t (HPLC): 2.44 m in (Method N)

The following compounds are prepared analogously to example 5.1

Example 6

Example 6.1 (general route)

1 - 4-(Dimethylamino)phenyl)-3-(1 -(4-((4-ethoxyphenyl)ethynyl)phenyl)ethyl)urea

To 26.5 mg (0.10 mmol) 1 -(4-((4-ethoxyphenyl)ethynyl)phenyl)ethanamine (I63) in 2 mL DMF are consecutively added 65.0 μΙ_ (0.40 mmol) DIPEA and 24.3 mg (0.15 mmol) 4-(dimethylamino)phenyl isocyanate. The reaction mixture is stirred at r.t. over night and purified by HPLC. C27H29N3O2 (M= 427.5 g/mol)

ESI-MS: 428 [M+H] ⁺

Rt (HPLC): 1 .89 min (method N)

The following compounds are prepared analogously to example 6.1

For example 6.4 the ethyl-protected carboxylic acid is used. For the saponification, the compound is dissolved in 1 .5 mL ethanol, charged with 1 M NaOH and stirred at r.t. for 3 h. the solvent is removed in vacuo and the residue is washed with DMF.

Example 7

Example 7.1 (general route)

3-(1 -(4-((4-Ethoxyphenyl)ethynyl)phenyl)ethyl)-1 , 1 -dimethylurea

To 26.5 mg (0.10 mmol) 1 -(4-((4-ethoxyphenyl)ethynyl)phenyl)ethanamine (I63) and

27.7 μΙ_ (0.20 mmol) TEA in 1 .5 mL DCM are added 1 1 .0 μΙ (0.12 mmol) dimethyl- carbamyl chloride at 0 °C. The reaction mixture is stirred at r.t. over night and directly purified by HPLC (MeOH/H ₂ 0/NH ₃ ).

C21 H24N2O2 (M= 336.4 g/mol)

ESI-MS: 337 [M+H] ⁺

Rt (HPLC): 2.37 min (method N)

The following compounds are prepared analogously to example 7.1 .

Example 8

Example 8.1 (general route)

N-(1 -(4-((4-(piperidine-1 -carbonyl)phenyl)ethynyl)phenyl)propan-2-yl)acetamide

To 30 mg (0.10 mmol) 4-((4-(2-acetamidopropyl)phenyl)ethynyl)benzoic acid (I72.2) in 1 mL DMF are added 20.0 μΙ (0.10 mmol) TEA and 50 mg (0.15 mmol) TBTU. The mixture is stirred at r.t. for 5 min before it is added to 10 mg (0.12 mmol) piperidine in

500 μΙ DMF. After stirring at r.t. for 72 h the mixture is purified by HPLC

(MeOH/H ₂ 0/NH ₃ ).

C25H28N2O2 (M= 388.5 g/mol)

ESI-MS: 389 [M+H] ⁺

Rt (HPLC): 1 .91 min (method L)

The following compounds are prepared analogously to example 8.1

For examples 8.43-8.48 TEA is used as base and the reaction mixture is filtrated through a plug of alox before purification.

361

8.15 I72.2 1.74 (L)

[M+H] ⁺

417

8.16 I72.2 2.02 (L)

[M+H] ⁺

349

8.17 I72.2 1.70 (L)

[M+H] ⁺

403

8.18 172.1 1.80 (L)

[M+H] ⁺

411

8.19 I72.2 1.90 (L)

[M+H] ⁺

363

8.20 I72.2 1.77 (L)

[M+H] ⁺

375

8.21 I72.2 1.81 (L)

[M+H] ⁺

379

8.22 172.1 1.59 (L)

[M+H] ⁺

412

8.23 172.1 1.74 (L)

[M+H] ⁺ 437

8.51 172.1 2.26 (N)

[M+H] ⁺

365

8.52 172.1 1.77 (N)

[M+H] ⁺

426

8.53 172.1 1.60 (N)

[M+H] ⁺

404

8.54 172.1 1.51 (N)

[M+H] ⁺

Example 9

Example 9.1 (general route)

N- 1 -(4-((4-(pentan-3yloxy)phenyl)ethynyl)phenyl)propan-2-yl)ace tamide

14.7 μΙ (0.14 mmol) 3-pentanol, 40 mg (0.14 mmol) N-(1 -(4-((4-hydroxyphenyl)- ethynyl)phenyl)propan-2-yl)acetamide (174.1 ) and 69.8 mg (0.21 mmol) polymer bound triphenylphosphine (~3mmol/g) are added to 1 mL THF followed by 31.4 mg (0.14 mmol) DBAD. After stirring the mixture for 2 h at r.t. further 7.5 μΙ (0.07 mmol) 3-pentanol and 16 mg (0.07 mmol) DBAD are added and stirring is continued for 72 h. The reaction mixture is filtered and the filtrate is purified by HPLC

(MeOH/H ₂ 0/TFA). C24H29NO2 (M= 363.5 g/mol)

ESI-MS: 364 [M+H] ⁺

Rt (HPLC): 2.46 min (method M)

The following compounds are prepared analogously to example 9.1

For example 9.10 the boc-protected azetidine is used in the mitsonobu reaction. For deprotection, the compound is dissolved in a 2/1 mixture of MeOH and HCI (1.25 mol/l in MeOH) and stirred at 70 °C for 2 h. Purification by HPLC.

For examples 9.13-42 1 .5 eq. alcohol, tpp and DBAD are used and after 16 h one more equivalent DBAD is added and stirring is continued for another 24 h.

Example 10

Example 10.1 (general route) N- 1 -(4-((4-(Pyrimidin-5-yloxy)phenyl)ethynyl)phenyl)propan-2-yl )acetam

28.1 mg (0.14 mmol) 5-iodopyrimidine, 40.0 mg (0.14 mmol) N-(1 -(4-((4-hydroxy- phenyl)ethynyl)phenyl)propan-2-yl)acetamide (176.1 ), 1 .30 mg (0.07 mmol) Cul, 1 .9 mg (0.14 mmol) Ν, Ν-dimethylglycine hydrochloride and 58.7 mg (0.18 mmol) CS2CO3 are added to 1 ml_ dioxane. The reaction mixture is stirred at 90°C for 2 h then filtered through a plug of silica gel and washed with DMF. The filtrate is purified by HPLC (MeOH/H ₂ 0/TFA).

C23H21 N3O2 (M= 371 .4 g/mol)

ESI-MS: 372 [M+H] ⁺

Rt (HPLC): 2.22 min (method M)

The following compounds are prepared analogously to example 10.1

In case of 10.3 the reaction mixture is stirred at 120°C over night.

372

10.3 I76.2 2.24 (M)

[M+H]+

Example 11

Example 1 1 .1 (general route)

N-(1 -(4-((2-((2-Methoxyethyl)(methyl)amino)pyrimidin-4-yl)ethyny l)phenyl)propan-2- l)acetamide

To 31 .4 mg (0.10 mmol) N-(1 -(4-((2-chloropyrimidin-4-yl)ethynyl)phenyl)propan-2-yl)- acetamide (I70) and 25.8 μΙ (0.15 mmol) DIPEA in 1 mL NMP are added 26.7 mg (0.30 mmol) N-(2-methoxyethyl)methylamine. The reaction mixture is stirred in a sealed tube at 120°C over night and purified byHPLC (MeOH/H ₂ 0/TFA).

C21 H26N4O2 (M= 366.5 g/mol)

ESI-MS: 367 [M+H] ⁺

Rt (HPLC): 2.19 min (method K)

The following compounds are prepared analogously to example 1 1 .1

For example 1 1 .49 4 eq. of the amine are used and the reaction conditions are 3h at

100 °C.

Start, Mass HPLC

Ex. mateStructure spec ret. time rial result method

367

1 1.1 I70 2.19 (K)

[M+H] ⁺

H

Example 12

Example 12.1 (general route)

N-(1 -(4-((2-ethoxypyrimidin-4-yl)ethynyl)phenyl)propan-2-yl)acet amide

25 mg (0.08 mmol) N-(1 -(4-((2-chloropyrimidin-4-yl)ethynyl)phenyl)propan-2- yl)acetamide (I70) in 1 .0 mL dioxane are added to 9.3 μΙ (0.16 mmol) ethanol in 0.5 ml dioxane and cooled down to 0 °C. 10 mg (0.24 mmol) NaH are added and the mixture is stirred at r.t. over night. The reaction is quenched with water and the solvent is evaporated in vacuo. The residue is purified by HPLC (MeOH/H ₂ 0/TFA). C19H21 N3O2 (M= 351 .5 g/mol)

ESI-MS: 353 [M+H] ⁺

Rt (HPLC): 1 .99 min (method K)

The following compounds are prepared analogously to example 12.1

For example 12.19 the reaction mixture is stirred at 80 °C for 5 h.

For examples 12.58-68 the reaction mixture is stirred at r.t. for 3 h.

For example 12.66 the commercially available sodium alkoxide is used.

Example 13

Example 13.1 (general route)

N-(1 -(4-((2-((2-Methoxyethyl)(methyl)amino)pyrimidin-5-yl)ethyny l)phenyl)propan-2- l)acetamide

28.2 mg (0.09 mmol) N-(1 -(4-((2-chloropyrimidin-5-yl)ethynyl)phenyl)propan-2-yl)- acetamide (169.1 ) in 1 .5 mL DMSO are added to 12.0 mg (0.14 mmol) N-(2-methoxy- ethyl)-methylamine followed by 21 .8 μΙ (0.14 mmol) DIPEA. The reaction mixture is stirred at r.t. over night and is directly purified by HPLC (MeOH/H ₂ 0/TFA).

C21 H26N4O2 (M= 366.5 g/mol)

ESI-MS: 367 [M+H] ⁺

Rt (HPLC): 2.06 min (method K)

The following compounds are prepared analogously to example 13.1

For examples 13.88-91 DMF is used as solvent and the reaction time is 3 h at r.t.

Chiral

375

13.93 I69.6 2.19 (E)

[M+H] ⁺

H \ ^χ

Π O

Chiral

377

13.94 I69.6 1.95 (E)

[M+H] ⁺

H \ ^χ

π O

Chiral

309

13.95 I69.6 1.72 (E)

[M+H] ⁺

H ⁿ \ ^χ o

Example 14

Example 14.1 (general route)

N-{1 -Methyl-2-[4-(2-methylsulfanyl-pyrimidin-4-ylethynyl)-phenyl ]-ethyl}acetamide

To 0.52 g (2.58 mmol) N-[2-(4-ethynyl-phenyl)-1 -methyl-ethyl]-acetamide (I58.3) and 0.50 g (1 .98 mmol) 4-iodo-2-(methylthio)pyrimidine in 3 mL sec-butylamine and 3 mL water are added 0.14 g (0.20 mmol) bis(triphenylphosphine)dichloro-palladium and the mixture is stirred at r.t. over night. The reaction mixture is diluted with water and extracted with DCM. The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The residue is purified by column chromatography (silica gel, DCM/MeOH 96/4). The resulting product is triturated with diethylether.

Ci ₈ Hi ₉ N ₃ OS (M= 325.4 g/mol)

ESI-MS: 651 [2M+H] ⁺

Rt (HPLC): 2.80 min (method B)

The following compounds are prepared analogously to example 14.1

Example 15

N- 1 -(4-((2-(sec-Butylamino)pyrimidin-5-yl)ethynyl)phenyl)propan -2-yl)acetamide

2.50 g (12.4 mmol) N-(1 -(4-ethynylphenyl)propan-2-yl)acetamide (I58.3), 3.0 g (12.42 mmol) 2-chloro-5-iodopyrimidine and 872 mg (1 .24 mmol) bis(triphenylphosphine)- dichloropalladium in 10 mL water and 10 mL sec-butylamine are stirred at r.t. over night. The reaction mixture is diluted with water and extracted with DCM. The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The residue is purified by column chromatography (silica gel, DCM/MeOH 98/2).

C ₂ iH ₂₆ N 0 (M= 350.5 g/mol)

ESI-MS: 351 [M+H] ⁺

Rt (HPLC): 2.07 (method E)

Example 16

Example 16.1 (general route)

N-(4-((4-Ethoxyphenyl)ethynyl)phenethyl)propionamide

150 mg (1 .03 mmol) 1 -ethoxy-4-ethynylbenzene, 327 mg (1 .08 mmol) N-(4-iodophen- ethyl)propionamide (I47.2) and 36 mg (0.05 mmol) bis(triphenylphosphine)dichloro- palladium in 2.0 mL water and 1 .5 mL sec-butylamine are stirred at r.t. over night and for additional 4 h at 30°C. The reaction mixture is partitioned between DCM and water. The solvent of the organic layer is evaporated in vacuo and the residue is purified by HPLC (MeOH/H ₂ 0/NH ₃ ).

C21 H23NO2 (M= 321 .4 g/mol)

ESI-MS: 322 [M+H] ⁺

Rt (HPLC): 2.16 min (method E)

The following compounds are prepared analogously to example 16.1

Example 17

N-(1 -(4-((6-Ethoxypyrimidin-4-yl)ethynyl)phenyl)propan-2-yl)acet amide

To 290 mg (1 .44 mmol)(N-{2-[4-(6-ethoxy-pyrimidin-4-ylethynyl)-phenyl]-1 -methyl- ethyl}-acetamide (I58.3), 370 mg (1 .46 mmol) 4-ethoxy-6-iodo-pyrimidine (I6.3) and 0.60 ml triethylamin in 8 ml_ THF are added 0.05 g (0.07 mmol) bis-(triphenyl- phosphin)-palladium(ll)-chloride and 0.03 g (0.16 mmol) Cul. The reaction mixture is stirred at r.t. for 1 h. The reaction is poured onto icewater and EtOAC and afterwards neutralized with citric acid (10% in water). The organic layer is separated, dried with Na ₂ SO ₄ and the solvent is evaporated in vacuo. The residue is purified by column chromatography (silica gel, DCM/MeOH 91 /9). The resulting product is triturated with diethylether and dried at 80°C in vacuo.

C19H21 N3O2 (M = 323.4 g/mol)

ESI-MS: 324 [M+H] ⁺

Rt (HPLC): 3.00 min (method B)

Example 18

Example 18.1 (general route)

N- 2-[4-(4-Ethoxy-phenylethynyl)-phenyl]-1 -methyl-ethyl}-N-methyl-acetamide

32.1 mg (100 pmol) N-{2-[4-(4-ethoxy-phenylethynyl)-phenyl]-1 -methyl-ethyl}- acetamide are added to an ice cooled mixture of 40.0 mg (1 .00 mmol) sodium NaH and 2.50 ml_ THF. The reaction mixture is stirred at 0 °C for 10 min. Then 25.0 μΙ_ (0.40 mmol) methyliodide are added dropwise and the mixture is stirred at r.t. for 2 h. The reaction is quenched by the addition of water and sat. NH ₄ CI solution, and is extracted with DCM. The organic layer is separated and the solvent is removed in vacuo. The residue is lyophilised from ACN/water.

C22H25NO2 (M = 335.4 g/mol)

ESI-MS: 336 [M+H] ⁺

Rt (HPLC): 2.34 min (method M)

The following compounds are prepared analogously to example 18.1

For example 18.2 the crude product was purified by HPLC

Example 19

1 - 2-[4-(4-Ethoxy-phenylethynyl)-phenyl]-1 -methyl-ethyl}-3,3-dimethyl-azetidin-2-one

To 33.5 mg (120 pmol) 2-[4-(4-ethoxy-phenylethynyl)-phenyl]-1 -methyl-ethylamine (I64) in 2.0 mL ACN are added 166 mg (1 .20 mmol) K ₂ C0 ₃ , a few crystals DMAP and finally 23.5 μί (0.18 mmol) 3-chloropivaloyl chloride (in 1 .0 mL ACN). The reaction mixture is stirred at reflux for 6 h. The solvent is removed in vacuo and the residue is resolved EtOAc and washed with water (1 x), sat. aq. NaHC03 solution (2x) and again with water. The organic layer is dried with Na ₂ S0 ₄ and the solvent is evaporated in vacuo. The residue is purified by HPLC (MeOH/H ₂ 0/TFA). C24H27NO2 (M = 361 .5 g/mol)

ESI-MS: 362 [M+H] ⁺

Rt (HPLC): 2.41 min (method M)

Example 20

Example 20.1 (general route)

N-(2-{4-[2-(2-Methoxy-ethoxy)-pyridin-4-ylethynyl]-phenyl}-1 -methyl-ethyl)- acetamide;compound with trifluoro-acetic acid

To 435 mg (1 .56 mmol) 2-(2-methoxy-ethoxy)-pyridine (I8) and 0.45 g (1 .56 mmol) N- [2-(4-ethynyl-phenyl)-1 -methyl-ethyl]-acetamide (I58.3) in 5.0 mL DMF and 0.66 mL (4.68 mmol) TEA are added 6.87 mg (0.01 mmol) [1 , 1 ^' -bis(diphenylphosphino)- ferrocene]-dichloropalladium(ll), complex with dichlormethane (1 : 1 ) and 14.8 mg (0.08 mmol) Cul.The mixture is stirred at r.t. for 3 h. The reaction is quenched by the addition of water and extracted with DCM. The organic layer is dried with MgS0 ₄ , filtrated and the solvent is removed in vacuo. The residue is purified by HPLC

(ACN/MeOH/TFA).

C2i H ₂₄ N ₂ 03 x C2HF3O2 (M= 466.5 g/mol)

ESI-MS: 353 [M+H] ⁺

Rt (HPLC): 2.80 min (method B)

The following compounds are prepared analogously to example 20.1

HPLC

Mass

Starting retention

Ex. Structure spec

materials time

result

(method)

I58.3 353

20.1 2.80 (B)

I8 [M+H] ⁺

— 0

Example 21

N- 2-(4-Biphenyl-4-ylethynyl-phenyl)-1 -methyl-ethyl]-acetamide

To 0.22 g (1 .00 mmol) biphenyl-4-yl-propynoic acid (I28) and 0.26 g (1 .00 mmol) N- [2-(4-bromo-phenyl)-1 -methyl-ethyl]-acetamide (144.1 ) in 3.00 ml_ NMP are added 0.06 g (0.10 mmol) 1 , 1 ^' -bis(diphenylphosphonino)ferrocene, 1 .68 g (6.00 mmol) TBAF*H ₂ 0 and 0.05 g (0.05 mmol) tris(dibenzylidenacetone)dipalladium(0). The reaction mixture is stirred at 90 °C for 3 h. The mixture is allowed to cool to r.t. and poured onto saturated aq NH ₄ CI solution. The precipitate is filtered, washed with water und purified by column chromatographie (silica gel; DCM/MeOH 9/1 ). The resulting product is triturated with isopropanol and dried at 60°C in vacuo.

C25H23NO (M= 353.5 g/mol)

ESI-MS: 354 [M+H] ⁺

Rt (HPLC): 3.57 min (method B)

Example 22

N- 2-[4-(3,4-Dimethoxy-phenylethynyl)-phenyl]-1 -methyl-ethyl}-acetamide

To 0.40 g (1 .32 mmol) N-[2-(4-iodo-phenyl)-1 -methyl-ethyl]-acetamide (152.1 ) and 0.21 g (1 .32 mmol) 3,4-dimethoxyphenyl acetylene in 5 ml_ THF are added 0.10 g (0.13 mmol) bis-(triphenylphosphin)-palladium(ll)-chlorid, 26.0 mg (0.14 mmol) Cul and 0.56 g (1 .72 mmol) CS2CO3. The mixture is stirred in a sealed tube at r.t. over night. The reaction mixture is poured onto sat. aq. NaHC03 solution and extracted with EtOAc (2x). The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The residue is purified by HPLC (ACN/MeOH/TFA).

C21 H23NO3 (M= 337.4 g/mol)

ESI-MS: 338 [M+H] ⁺

Rt (HPLC): 2.85 min (method B)

Example 23

Example 23.1 (general route)

N-{2-[4-(2-Ethoxy-pyridin-4-ylethynyl)-phenyl]-1 -methyl-ethyl}-acetamide

Chiral

To 100 mg (0.50 mmol) N-[2-(4-ethynyl-phenyl)-1 -methyl-ethyl]-acetamide (I58.2) and 124 mg (0.50 mmol) 2-ethoxy-4-iodo-pyridine (16.1 ) in 5.00 mL ACN are added

20.3 mg (0.03 mmol) 1 , 1 ^' -bis[diphenylphosphino]ferrocenepalladium dichloride dichloromethane complex (1 : 1 ), 4.83 mg (0.03 mmol) Cul and 0.16 mL (1 .16 mmol)

TEA. The mixture is stirred at r.t. over night, then poured onto water and extracted with DCM. The organic layer is dried with MgS0 ₄ and the solvent is removed in vacuo. The residue is purified by column chromatographie (silica gel; PE/EtOAc 1/1

-» EtOAc 100% ).

C20H22N2O2 (M= 332.4 g/mol)

ESI-MS: 323 [M+H] ⁺

Rt (HPLC): 2.10 min (method E)

The following compounds are prepared analogously to example 23.1

For examples 23.1 1 , 23.14 and 23.15 TEA and ACN are replaced by

diisopropylamine and THF.

HPLC

Starting Mass

retention

Ex. material Structure spec

time

(s) result

(method) 159.1 398

23.1 1 2.10 (E)

117 [M+H] ⁺

I58.3 351

23.12 2.10 (E)

11 1.3 [M+H] ⁺

I58.3 323

23.13 1.91 (E)

11 1.1 [M+H] ⁺

I58.4 351

23.14 2.34 (E)

11 1.2 [M+H] ⁺

H

I58.5 350

23.15 2.34 (E)

115.4 [M+H] ⁺

Example 24

Example 24.1 (general route)

N- 1 -Methyl-2-[4-(4-propoxy-phenylethynyl)-phenyl]-ethyl}-acetam ide

To 0.33 g (1.00 mmol) tnfluoromethanesulfonic acid 4-(2-acetylamino-propyl)-phenyl ester (I53.2) and 0.18 g (1 .10 mmol) 1 -ethynyl-4-propoxybenzene in 3 ml_ DMF and and 0.60 ml_ (4.50 mmol) TEA are added 0.04g (0.06 mmol) bis-(triphenylphosphin)- palladiumdichlorid. The mixture is stirred in a sealed tube at 80°C for 24 h. The reaction mixture is partitioned between EtOAc and water, the organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The residue is purified by column chromatographie (silica gel, DCM/EtOAc 1/1 ). The resulting product is triturated with diethylether and dried at 80°C in vacuo.

C22H25NO2 (M= 335.4 g/mol) ESI-MS: 336 [M+H] ⁺

Rt (HPLC): 3.32 min (method B)

The following compounds are prepared analogously to example 24.1

For examples 24.2 and 24.3 the reaction is stirred at 90°C for 3 h.

Example 25

N- 2-[4-(4-tert-Butylphenylethynyl)-phenyl]-1 -methyl-ethyl}-acetamide

To 0.50 g (1.54 mmol) tnfluoro-methanesulfonic acid 4-(2-acetylamino-propyl)-phenyl ester (I53.2) and 0.32 g (2.00 mmol) 4-tert.butylphenylacetylen in 3.0 mL water and 3.0 mL sec-butylamine are added 0.10 g (0.14 mmol) bis(triphenyphosphine)dichloro- palladium and the mixture is stirred at r.t. for 4 h and at 80°C for 1 h. The reaction mixture is allowed to cool to r.t. and is then partitioned between EtOAc and citric acid (10% in water). The organic layer is dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The residue is purified twice by column chromatography (silica gel;

DCM/MeOH 9/1 and aluminium oxide DCM/EtOAc 4/1 ). The resulting product is triturated with MeOH. C23H27NO (M= 333.5 g/mol)

ESI-MS: 334 [M+H] ⁺

Rt (HPLC): 3.53 min (method B)

Example 26

-{2-[5-(4-Ethoxy-phenylethynyl)-pyridin-2-yl]-ethyl}-acetami de

0.55 mL (3.91 mmol) DIPEA is added to 190 mg (0.78 mmol) N-[2-(5-bromo-pyridin- 2-yl)-ethyl]-acetamide (148.1 ), 3.72 mg (0.02 mmol) Cul and 13.7 mg (0.02 mmol) bis(triphenylphosphin)palladium-(ll)-chloride. 171 mg (1 .17 mmol) 4-ethoxyphenyl- acetylene are added and the reaction mixture is heated for 10 min at 80°C in a microwave oven. The mixture is diluted with EtOAc and washed with water (1 x) and diluted aq. ammonia solution. The organic layer is dried with MgS0 ₄ and the solvent is removed in vacuo. The residue is purified by HPLC (MeOH/H ₂ 0/NH3).

C19H20N2O2 (M= 308.4 g/mol)

ESI-MS: 309 [M+H] ⁺

Example 27

Example 27.1 (general route)

N-{2-[4-(2-Cyclopentyloxy-pyrimidin-5-ylethynyl)-phenyl]-1 -methyl-ethyl}-acetamide

To 33.1 mg (0.17 mmol) N-[2-(4-ethynyl-phenyl)-1 -methyl-ethyl]-acetamide (I58.3) and 40.0 mg (0.17 mmol) 5-bromo-2-cyclopentyloxypyrimidine (114.1 ) in 2.0 mL THF are added 1 1 .6 mg (0.02 mmol) bis(triphenylphosphin)palladiumdichlorid, 1 .57 mg (8.00 μηιοΙ) Cul and 56.0 μί (0.33 mmol) DIPEA. The reaction mixture is stirred at r.t. over night. The solvent is removed in vacuo and the residue is purified by HPLC

(MeOH/H ₂ 0/TFA).

C22H25N3O2 (M= 363.5 g/mol)

ESI-MS: 364 [M+H] ⁺

R _t (HPLC): 2.27 min (method T)

The following compounds are prepared analogously to example 27.1

For examples 27.2 and 27.3. Pd(dppf)Cl2 is used as catalyst.

Example 28

(S)-N-(1 -(4-((1 -Methyl-1 H-pyrazol-4-yl)ethynyl)phenyl]ethyl}cyclopropane- carboxamide

To 100 mg (0.91 mmol) 1 -methyl-1 H-pyrazole-4-carbaldehyde in 1 .00 mL MeOH are added 289 mg (2.09 mmol) K ₂ CO ₃ and finally dropwise 349 mg (1 .82 mmol) dimethyldiazo-2-oxopropylphosphonat (in 2.0 mL MeOH).The reaction mixture is stirred at r.t. over night. The reaction is quenched by the addition of water and EtOAc. The organic layer is separated, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. To the residue is added 286 mg (0.91 mmol) cyclopropanecarboxylic acid [1 -(4-iodo-phenyl)-ethyl]-amide (I52.2), 63.7 mg (0.09 mmol) bis-(triphenylphosphin)- palladiumdichlorid, 2.00 mL 2-butylamine and 2.00 mL water. The reaction mixture is stirred at r.t. over night. The mixture is diluted with water and extracted with DCM. The organic layer is dried with Na ₂ S0 ₄ and the solvent is evaporated in vacuo. The residue is purified consecutively by column chromatography (silica gel, DCM/MeOH 98:2) and HPLC (MeOH/H ₂ 0/NH ₃ ).

Ci ₈ Hi ₉ N ₃ 0 (M= 293.4 g/mol)

ESI-MS: 294 [M+H] ⁺

Rt (HPLC): 1 .65 (method E)

Example 29

Example 29.1 general route

{1 -[4-(4-Ethoxy-phenylethynyl)-phenyl]-ethyl}-carbamic acid methyl ester

To 26.5 mg (0.10 mmol) 1 -[4-(4-ethoxy-phenylethynyl)-phenyl]-ethylamine(l63) in 2.00 mL acetone are added 47.7 mg (0.45 mmol) Na ₂ C0 ₃ and 10.2 μί methyl chloroformate. The reaction mixture is stirred at 40°C for 3 h. After cooling down to r.t. the reaction mixture is filtered and the solvent is removed in vacuo. The residue is purified by HPLC (MeOH/H ₂ 0/TFA).

C ₂₀ H ₂ iNO ₃ (M= 323.4 g/mol)

ESI-MS: 324 [M+H] ⁺

R _t (HPLC): 2.33 min (method T) The following compounds are prepared analogously to example 29.1

Example 30

N-(2-{4-[2-(Cyclopentyl-methyl-amino)-pyrimidin-4-ylethynyl] -phenyl}-1 -methyl-ethyl)- acetamide

The mixture from intermediate 73 is further diluted with 1 1 ml_ DCM. 0.50 ml_ (4.44 mmol) N-methylcyclopentylamine are added and the reaction mixture is stirred at r.t. for 2 days, and at 50°C for 1 day. The mixture is washed with water, the organic layer is separated, dried with Na ₂ S0 ₄ and the solvent is removed in vacuo. The residue is consecutively purified by column chromatography (silica gel, DCM/MeOH 92/8) and HPLC (MeOH/H ₂ 0/TEA).

C23H ₂₈ N ₄ 0 (M= 376.5 g/mol)

ESI-MS: 377 [M+H] ⁺

Rt (HPLC): 3.26 min (method B)

Example 31

Example 31 .1 general route

N-(1 -Methyl-2-(4-(4-(thiazol-2-ylmethoxy)-phenylethynyl)-phenyl) -ethyl)-acetamide

To 1 1 .2 mg (0.10 mmol) 1 ,3-thiazol-2-yl-methanol in 2 mL DCM are added 20.8 μΙ_ (0.15 mmol) TEA and after cooling down to 0 °C 7.79 μΙ_ (0.10 mmol) MsCI. The mixture is stirred at r.t. for 1 .5 h. The solvent is removed in vacuo and the residue added to 2 mL DMF. Then 29.3 mg (0.10 mmol) phenol 174.1 and 65.1 mg (0.20 mmol) CS2CO3 are added and the reaction mixture is stirred at 75 °C for 4 h. The reaction mixture is filtered through a plug of alox, the solvent is removed in vacuo and the residue is purified by HPLC (MeOH/H ₂ 0/TFA).

C23H22N2O2S (M= 390.5 g/mol)

ESI-MS: 391 [M+H] ⁺

R _t (HPLC): 2.23 m in (method AA)

The following compounds are prepared analogously to example 31 .1

For example 31 .2 the second part of the reaction is proceded at 100 °C over night.

Example 32

Example 32.1 general route

N-{2-[4-(4-Propoxy-phenylethynyl)-phenyl]-propyl}-acetamide

To 0.12 g (0.41 mmol) 2-[4-(4-propoxy-phenylethynyl)-phenyl]-propylamine (I65) in

5.0 mL DCM are consecutively added 0.14 mL (1 .02 mmol) TEA and 34.9 μί (0.49 mmol) acetyl chloride. The reaction mixture is stirred at r.t. for 3 h. The solvent is removed in vacuo and the residue is purified by HPLC (MeOH/H ₂ 0/NH3).

C22H25NO2 (M= 335.4 g/mol)

ESI-MS: 336 [M+H] ⁺

Rt (HPLC): 2.23 min (method E)

The following compounds are prepared analogously to example 32.1

Example 33

Example 33.1 general route

1 , 1 -Dimethyl-3-{2-[4-(4-propoxy-phenylethynyl)-phenyl]-propyl}- urea

0.14 g (0.48 mmol) 2-[4-(4-propoxy-phenylethynyl)-phenyl]-propylamine (I65) and 0.10 mL (0.72 mmol) TEA in 5.0 mL DCM are cooled down to 0°C and charged with 82.2 mg (0.50 mmol) CDT. The mixture is stirred at 0-5°C for 15 min. Additional 20.0 mg (0.12 mmol) CDT are added and stirring is continued for 15 min.. Then 0.06 g (1 .43 mmol) dimethylamine are added and the mixture is stirred at r.t. for 3 h. The solvent is removed in vacuo and the residue is purified by HPLC (MeOH/H ₂ 0/FA). C23H28N2O2 (M= 364.5 g/mol)

ESI-MS: 365 [M+H] ⁺

Rt (HPLC): 2.28 min (method E)

The following compounds are prepared analogously to example 33.1

For example 33.4 NaOMe dissolved in MeOH is added instead of an amine and the mixture is stirred at r.t. over night.

HPLC

Mass

Starting retention

Ex. Structure spec

material time

result

(method)

365

33.1 I65 2.28 (E)

[M+H] ⁺

379

33.2 I66 2.36 (E)

[M+H] ⁺

379

33.3 I66 2.40 (E)

[M+H] ⁺

Example 34

Thiazole-5-carboxylic acid (2-(4-(2-cyclobutoxy-pyrimidin-5-ylethynyl)-phenyl)-1 - methyl-ethyl)-amide

100 mg (0.27 mmol) thiazole-5-carboxylic acid (2-(4-iodophenyl)-1 -methylethyl)- amide (I76) are added to 2.0 mL THF and cooled down to 0 °C. 2.87 mg (4.00 pmol) bis(triphenylphosphine)palladium dichloride, 1 .02 mg (5.00 pmol) Cul, 90.6 μΙ_ (0.65 mmol) diisopropylamine and finally 51 .5 mg 2-cyclobutoxy-5-ethynyl-pyrimidine

(I25.7) are added and the reaction mixture is stirred at r.t. over night. The solvent is removed in vacuo and the residue is dissolved in EtOAc and washed with diluted ammonia solution (1 x) and water (2x). The organic layer is dried with MgS0 ₄ and the solvent is removed in vacuo. The crude product is purified by HPLC

(MeOH/H ₂ 0/TFA).

C23H ₂₂ N ₄ 0 ₂ S (M= 418.5 g/mol)

ESI-MS: 419 [M+H] ⁺

Rt (HPLC): 2.30 min (method AA)

Example 35

Example 35.1 general route

N-(1 , 1 -Dimethyl-2-(4-(4-propoxyphenylethynyl)-phenyl)-ethyl)-aceta mide

To 350 mg (1 .10 mmol) of intermediate I44.9 and 180 mg (1 .10 mmol) 1 -ethynyl-4- propoxy-benzene in 4 mL THF are added 18.0 mg (20.2 pmol) [1 , 1 ^' bis(diphenyl- phosphino)ferrocene]dichloropalladium(ll), complex with dichloromethane, 4.20 mg (20.2 pmol) Cul and 0.31 ml_ (2.21 mmol) diisopropylamine. The reaction mixture is stirred at r.t. for 3 h. EtOAc is added and the resulting mixture is washed with diluted aq. ammonia solution (1 x) and water (1 x), dried with MgS0 ₄ and the solvent is removed in vacuo. The crude product is purified by HPLC (MeOH/H ₂ 0/NH3).

C23H ₂ 2N 0 ₂ S (M= 349.5 g/mol)

ESI-MS: 350 [M+H] ⁺

Rt (HPLC): 2.33 min (method E)

The following compounds are prepared analogously to example 35.1

For example 35.3 ACN and TEA are used instead of THF and diisopropylamine and the reaction conditions are 10 h at 100 °C.

Examples of Formulations

The following examples of formulations, which may be obtained analogously to methods known in the art, serve to illustrate the present invention more fully without restricting it to the contents of these examples. The term "active substance" denotes one or more compounds according to the invention, including the salts thereof.

Example 1 : Tablet containing 50 mg of active substance Composition:

(1 ) Active substance 50.0 mg

(2) Lactose 98.0 mg

(3) Maize starch 50.0 mg

(4) Polyvinylpyrrolidone 15.0 mg

(5) Magnesium stearate 2.0 mg

215.0 mg

Preparation:

(1 ), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5) is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch on one side.

Diameter of the tablets: 9 mm.

Example 2: Tablet containing 350 mg of active substance

Preparation:

(1 ) Active substance 350.0 mg

(2) Lactose 136.0 mg

(3) Maize starch 80.0 mg

(4) Polyvinylpyrrolidone 30.0 mg

(5) Magnesium stearate 4.0 mg

600.0 mg

(1 ), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5) is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch on one side.

Diameter of the tablets: 12 mm.

Example 3: Capsules containing 50 mg of active substance

Composition:

(1 ) Active substance 50.0 mg

(2) Dried maize starch 58.0 mg

(3) Powdered lactose 50.0 mg

(4) Magnesium stearate 2.0 mg 160.0 mg

Preparation:

(1 ) is triturated with (3). This trituration is added to the mixture of (2) and (4) with vigorous mixing. This powder mixture is packed into size 3 hard gelatin capsules in a capsule filling machine.

Example 4: Capsules containing 350 mg of active substance

Composition:

(1 ) Active substance 350.0 mg

(2) Dried maize starch 46.0 mg

(3) Powdered lactose 30.0 mg

(4) Magnesium stearate 4.0 mg

430.0 mg

Preparation:

(1 ) is triturated with (3). This trituration is added to the mixture of (2) and (4) with vigorous mixing. This powder mixture is packed into size 0 hard gelatin capsules in a capsule filling machine.

Example 5: Dry ampoule containing 35 mg of active substance per 2 ml

Composition:

Active substance 35.0 mg

Mannitol 100.0 mg

water for injections ad 2.0 ml

Preparation:

The active substance and mannitol are dissolved in water. After packaging, the solution is freeze-dried. To produce the solution ready for use, the product is dissolved in water for injections.